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1 Executive Summary 
Introduction 
Screening for multiple cancer types in a single test has the potential to offer both cost savings and 
health gains in comparison to offering several separate type-specific programmes.  There are a large 
number of blood based biomarkers which are common to multiple cancer types.  If used individually, 
these biomarkers are generally not sufficiently sensitive or specific to be used for early detection of 
cancer, nor is their yield of cancers detected per cohort of patients screened sufficiently high to 
make them economically efficient.  It is possible that by combining several different biomarkers a 
blood based cancer screening test with sufficiently high sensitivity, specificity, and efficiency could 
be developed.  The UK Early Cancer Detection Consortium (ECDC) was formed in 2012 to develop a 
multi-marker, multi-cancer, blood based generic screening test to be used in national screening 
programmes.  The intention of the ECDC is to develop a test will both indicate the possibility of 
cancer, and provide guidance on which type of cancer is suspected.  
The objectives of this study are to develop an early economic model to evaluate an early generic 
cancer screening programme and to identify what evidence needs to be generated to allow for 
robust economic evaluation in the future.  
Methods 
A conceptual model was developed to assess the potential cost and health impacts of a new generic 
cancer screening programme which included impacts such as changes in treatment costs and 
improvements in overall survival due to earlier diagnosis.  The conceptual model highlighted the 
data required to populate an economic model.   
Literature searches and expert elicitation were undertaken to obtain data on: proposed screening 
pathways; costs (cost of treatment by stage of disease, cost of a screening test and cost of follow-
up); screening characteristics (uptake, test characteristics, completion rates, harms, positivity rate, 
and stage shift); health related quality of life (for cancer patients, decrement associated with false 
positives); cancer incidence; and survival. For reasons of feasibility the scope of literature searches 
and the economic modelling was restricted to five cancer types (bladder; breast; colorectal; lung; 
and ovarian).  The available data for each of these areas were summarised and critiqued. 
An economic model was developed using available data.  A simple structure was employed where 
the health gains from screening were based solely on stage shift (moving diagnoses from late stage 
disease to early stage).  The model was used to predict cost outcomes and resource use for one 
round of the screening programme.  The new programme was modelled as an addition rather than a 
replacement to standard care (type specific programmes for breast and colorectal cancer).  The 
model was used to conduct scenario analyses to explore the impact of model parameters on cost-
effectiveness.  
Results 
For several parameters obtained from the literature reviews available, potentially biased or of poor 
quality.  Due to the early stage of the evaluation some data were not available such as: the test 
sensitivity and specificity; the proposed generic cancer screening pathways; and the unclear rate of 
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the test.  The data available on the lifetime costs of treatment of cancer by stage at diagnosis was 
unsatisfactory for modelling; where lifetime costs were available, they were often based on old data 
or on treatment pathways which did not reflect heterogeneity in patient care.  Data on disease 
natural history were not available for all cancer types.  These data limitations meant that populating 
some model structures (such as modelling of precancerous conditions) was not possible. Due to 
these data limitations, accurate estimation of the cost-effectiveness of such a screening programme 
was not possible.   
The study highlighted the extent to which certain model parameters vary by cancer type and the 
importance of this in relation to economic modelling.  Data analysis undertaken as part of this study 
illustrated that the QALY gains from earlier diagnosis (for diagnosis in stages I/II instead of III/IV) of 
cancer varied widely by cancer type ranging from 6.1 discounted QALYs (13.7 life years) for ovarian 
cancer to 1.1 discounted QALYs (2.3 life years) for small cell lung cancer.   
ICER values were generated using the early economic model, however these values should be 
interpreted with caution, as the model structure was associated with structural limitations.  The ICER 
values from this early economic model ranged from £12,277 to £185,911 per QALY gained 
demonstrating a high degree of uncertainty.  However, it is important to note that when data and 
structural issues are addressed, the ICER could well be lower than this range.  Indeed, the health 
economic reappraisal of the NHS bowel cancer screening programme found that bowel cancer 
screening dominated no screening (i.e. cost savings and QALY gains).  The wide range of ICER values 
and the structural limitations highlight the need to improve the evidence base to support economic 
evaluations of generic cancer screening programmes.  
The study allowed the identification of key future research priorities. The literature searches 
undertaken established areas where data was associated with significant uncertainty.  The expert 
elicitation component of this study illustrated that identifying pathways for people with a positive 
test result in a generic cancer screening programme is much more difficult than for a type specific 
programme.  The exploratory modelling undertaken showed that the important drivers of cost-
effectiveness were the same as would be expected for a type specific cancer screening programme, 
i.e.: the stage shift associated with screening (which would depend on test sensitivity and specificity 
and the natural history of each cancer), the cost of the screening test, the positivity rate of the 
programme (which would depend on the sensitivity, the specificity and the prevalence) and the cost 
of follow up for false positives.  It is expected that further data to inform the majority of these 
parameters will be generated during development of a new test. 
Discussion 
The study found that there was a substantial degree of uncertainty in the health economic effects of 
a generic cancer screening programme, which was largely due to several data issues.  To address this 
limitation, future research is needed into: the lifetime treatment costs for each cancer type by stage 
at diagnosis; the natural history of multiple cancer types; the follow up pathways for false positive 
screens; and the QALY gains from earlier detection of cancer.   
The lifetime cancer treatment costs were found to be poorly understood.  A recent research study 
attempted to address this gap, however 1) costing was restricted to four cancer types, 2) the 
pathways were based on national guidelines and expert opinion so may not reflect actual use and 3) 
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some parts of the pathway were implausible to ECDC experts.  Research should be conducted to 
establish the lifetime treatment costs by stage at diagnosis and cancer type.  Two study designs are 
possible to calculate the lifetime cost: 1) using observational data on the actual pathways which 
patients follow or 2) using recommended pathways from NICE guidelines and expert opinion.  There 
may be value in comparing costing obtained using both methods. As treatment pathways for cancer 
will continue to change, regular updating of the costs (e.g. every five years) is suggested 
The natural history of each cancer type detected by a generic screening programme needs to be 
understood in order to adequately represent the benefits of screening within a model.  Natural 
history parameters include: the rate at which precancerous conditions develop; the rate of 
progression between the different precancerous; and cancerous stages of the disease and an 
understanding of symptomatic presentation rates.  An understanding of the natural history of the 
disease is also one of the criteria that the National Screening Committee uses to approve or reject 
new screening programmes.  Further research by experts in the field of cancer into the natural 
history of cancer types which would not have previously been considered for detection in a cancer 
screening programme is recommended.  
QALY gains associated with earlier detection were calculated in this study using published incidence 
and survival data.  The available data was adequate however it is essential that up to date incidence 
and survival data for all cancer types is regularly published.  This will enable accurate estimation of 
QALY gains in health economic modelling which incorporate improvements in survival over time due 
to the introduction of new treatments and technologies. 
Further research should be conducted into the follow up pathways for positive results from a generic 
cancer screening test prior to a trial of the test.  In contrast to, a type specific cancer screening 
programme it is not obvious which follow up procedure(s) a person with a positive test result should 
receive.  It is recommended that further research in this area be undertaken by experts in the field 
prior to the trial of the test.  Furthermore the model results were sensitive to the cost of diagnosing 
false positives, indicating that controlling these costs may be a key driver of the overall cost-
effectiveness of a generic cancer screening programme.   
Conclusions 
A generic cancer screening programme could potentially offer benefits over type specific 
programmes.  This study highlights future research required to test this hypothesis.  Further clinical 
research needs to be conducted before it will be possible to determine if a blood based approach 
would be a cost-effective method for screening for multiple cancer types.   
In order to allow a future economic evaluation of a generic cancer screening programme research 
funding in the following areas should be prioritised: lifetime cancer treatment costs by stage at 
diagnosis, the natural history of different cancer types and the QALY gains associated with earlier 
detection of cancer.  If these limitations in the evidence base are not addressed, then accurate 
assessment of the cost-effectiveness of early detection strategies for multiple cancer types will not 
be possible.  
Researchers developing tests suitable for a generic cancer screening programme should carefully 
consider the follow up pathways for people with positive results in order to efficiently determine if 
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the result is a false positive.  Currently for many cancers there is insufficient understanding of the 
biological and/or radiological characteristics of false positives.  This is evidenced by high false 
positive rates even within established single-tumour screening programmes.  In addition, it is 
essential to understand whether the screening test will detect precancerous conditions (and for 
which cancer types). If the test does detect pre-cancerous conditions, then using the test in a 
screening programme for the general population may alter the observed incidence of cancerous 
conditions, as early treatment may prevent cancerous tumours from developing. 
In conclusion, it is not yet possible to robustly assess the cost-effectiveness of a new generic cancer 
screening programme using only currently available evidence.   
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2 Introduction 
2.1 Background 
There are a large number of blood based biomarkers which are common to many cancer types. If 
used individually these biomarkers are not sufficiently sensitive or specific to be used for the earlier 
detection of cancer. One prominent example of this is circulating cell free DNA, which is present in 
higher concentrations in a cancer patient’s blood (1).  However cell free DNA alone is not a viable 
biomarker alone, as it is not sufficiently specific. Elevated levels of cell free DNA have been observed 
in patients with a variety of noncancerous conditions including sepsis, inflammatory conditions, 
myocardial infarction, obstructive sleep apnoea and after exercise (1)(2).  
The UK Early Cancer Detection Consortium (ECDC) was formed to develop a blood based generic 
cancer screening test which combines multiple biomarkers(3). It is proposed that by combining 
several different biomarkers a blood based generic cancer screening test with sufficiently high 
sensitivity and specificity can be developed.  The test will consist of two components: the initial test 
which will be a high sensitivity test to detect all patients with cancer and a reflex test which will be a 
high specificity test for those patients identified by the initial test. It is intended that this screening 
test will be used as part of a generic cancer screening programme. The aim of the generic cancer 
screening test is earlier diagnosis of cancer, which can lead to earlier treatment and better survival.  
The proposed generic cancer screening programme requires that a blood sample is taken, the 
samples are sent to an external laboratory for testing and the results are sent to the person in the 
screening programme and their GP. This offers the potential to conduct the generic cancer screening 
programme at the same time as any other regular health interventions that take a blood sample, for 
example the NHS health checks. Currently there are three cancer type specific screening 
programmes in the UK for colorectal (in the NHS bowel screening programme), breast and cervical 
cancers.  The generic cancer screening programme is currently not intended to replace these 
screening programmes, but to operate alongside them. 
The ECDC has undertaken systematic reviews to identify potentially useful biomarkers and the 
acceptability to patients of a blood based cancer screening programme.(4;5)  A Delphi exercise has 
also been undertaken to establish what information decision makers in the NHS may need at the 
local and national level prior to the introduction of a new blood based generic cancer screening 
programme. The Delphi exercise was undertaken between August and November 2014, 27 persons 
who were involved in research or treatment of cancer were surveyed by the ECDC (6). They found 
that at least 75% of those responding considered affordability, cost utility and implications of false 
positives/negatives to be of high or very high importance in designing a generic cancer screening 
programme.(6) 
2.2 Aims 
The aims of this project are to: 
• Develop a conceptual model to assess the potential cost and health impacts of a new cancer 
screening programme and identify data required to populate an economic model. 
• Obtain data to populate an economic model through literature searching and clinical input. 
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• Describe available data and establish any key data gaps. 
• Construct a draft economic model using available data and produce outputs to inform the 
development of the generic cancer screen. 
Section 2 describes the conceptual model and data requirements. Section 3 describes the data 
including how it was identified and data quality. Sections 4 and 5 describe the draft economic model 
and results. Conclusions are provided in section 6. 
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3 Economic model 
3.1 Conceptual Model 
A conceptual model of the health and cost impacts of a generic cancer screening programme was 
developed. The conceptual model was presented to the ECDC at a meeting in March 2014 to ensure 
that all important impacts were included. The conceptual model is shown in Figure 3.1. 
The main potential benefits of a generic cancer screening programme were lower treatment costs 
and improved survival due to earlier diagnosis of cancer. It is also possible that the screening 
programme will result in the diagnosis and treatment of non-cancer conditions which are detected 
incidentally. 
There are several potential harms and costs of the screening programme. The definitions of these 
harms are given in Table 3.1. Follow up of false positive results will incur a cost to the NHS and may 
be associated with adverse psychological impact that may impact on HRQoL. It is also possible that 
the generic cancer screening programme will lead to the treatment of false positives. Treatment of 
false positives is unnecessary but may occur if a 100% specific diagnostic test for the cancer type is 
not available (e.g. for ovarian cancer). False reassurance may occur for persons with false negative 
results who may then be less willing to present if they have symptoms. There may be increases in 
overdiagnosis which is the diagnosis of a cancer that would not have led to symptoms or mortality 
during the remaining lifetime of the patient.(7) Overdiagnosis will lead to overtreatment and hence 
people will receive unnecessary treatment.  
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Figure 3.1: A conceptual model of the health and cost impact of generic cancer screening 
programme
 
Table 3.1: Definitions used in this report 
Name  Definition 
Generic cancer screening test The test which will be used in the proposed screening programme 
Stage at diagnosis The stage of cancer at the time the patient is diagnosed 
Overdiagnosis The diagnosis of a disease in an individual through a screening 
programme, which otherwise would not have caused symptoms 
or death (7) 
Overtreatment The treatment of those patients who have been over diagnosed 
Treatment of false positives The treatment of those patients who have had a positive cancer 
screening test, but who do not have cancer 
HRQoL Health related quality of life 
 
3.2 Model Scope 
The conceptual model was simplified to form a model structure which could be used for the 
economic evaluation. Several potential impacts of the generic cancer screening programme on the 
NHS were not included in the model.  The effect of false reassurance (less willing to seek 
symptomatic diagnosis following false negative result) was excluded from the modelling due to 
insufficient data on the mechanisms of this effect in cancer screening programmes. (8) 
Blood based screening for multiple tumour 
types (reflex testing approach using multiple 
tests)
*Investment in 
laboratory infrastructure
Cost of the test 
(Technology and Staff)
Administration costs
*Long term reduction in 
investment in type 
specific screening 
programmes (bowel, 
breast and cervical
Negative resultsPositive results
True positive results False positive results
Detection of cancer 
at an earlier stage
Change in treatment 
costs
Improved survival and 
quality of life
Change in overdiagnosis 
rates
Cost of follow up pathways
Quality of life decrement due 
to adverse psychological 
events
Unnecessary treatment of 
some people without cancer
*Diagnosis and treatment of 
non-cancer conditions 
(incidental findings)
False negative results
*False reassurance: 
less willing to seek 
symptomatic 
diagnosis
*Detection of cancer 
at a later stage
*Change in treatment costs
*Reduced survival and quality 
of life
*Change in overtreatment 
rates
True negative results
* Impacts excluded 
from model scope
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The cost-effectiveness analysis follows methods guidance from the National Institute for Health and 
Care Excellence (NICE) and take an NHS and personal social services perspective (9). The initial 
investment in laboratory infrastructure was excluded as one off costs are not usually included within 
a cost-effectiveness analysis. The model compares the introduction of a generic cancer screening 
programme to current practice which includes three site specific screening programmes (bowel, 
breast and cervix). 
The generic cancer screening test is intended to detect multiple cancer types. The model scope was 
restricted to five cancer types (bladder, breast, colorectal, lung and ovarian) as it would be 
unfeasible to model all types of cancer. These five cancer types were selected by the ECDC based on 
prevalence and potential for the generic cancer screen to be beneficial and together they account 
for 45.1% of cancer incidence.  It should be noted that, type specific screening programmes exist for 
breast and colorectal cancer therefore the benefits of screening for these cancer types will be lower 
than if no type specific screening programme existed for these cancer types.  
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4 Data to inform an economic model of the generic cancer 
screen 
4.1  Data requirements 
The conceptual model illustrates the data required to estimate the cost-effectiveness of a generic 
cancer screening test. As the aim of the generic cancer screening test is to alter the distribution of 
stage at diagnosis. Data on survival and treatment costs by stage at diagnosis was required. 
Information on the proposed screening and follow-up pathways for the generic cancer screen are 
required.  
 
To summarise the following data are required: 
• Proposed screening pathways 
• Cost data: Cost of treating cancer by stage, Cost of generic cancer screening test and follow-
up 
• Screening data: uptake, test characteristics, completion rates, harms, over diagnosis, 
positivity rate, and stage shift due to screening  
• HRQoL: for cancer patients, decrement associated with false positive result 
• Cancer incidence and survival data 
 
Data was obtained via: discussion with the ECDC; elicitation from experts; and literature searches 
and is described in Sections 4.2 to 4.8 
 
4.2 Proposed Screening Pathways 
To allow the costs and health impacts of the generic cancer screen to be modelled the patient 
pathways associated with the proposed screening programme were determined. The pathways were 
established via numerous discussions with the ECDC in 2014. These pathways are described within 
this Section and are summarised in Figure 4.2.  
Persons are invited to complete a screen via an invitation letter. This is the same as the mode of 
invitation used by the existing breast, bowel and cervical screening programmes. If no response is 
received a second invitation letter will be sent. It is also possible to opt out of the screening 
programme at the invitation stage. An option to complete consent paperwork online will be 
available. Persons declining or failing to make an appointment will be re-invited at the subsequent 
screening round. 
The options for screening age range and screening intervals to consider were obtained via ECDC 
opinion (Ian Cree and Sian Taylor-Phillips). In the base case an age range of 40-72 years was 
considered with 4 yearly screening intervals.   
It was assumed that the blood sample would be taken at a GP surgery. Four options were considered 
for the mode of taking the blood sample: (1) the sample may be taken by either a practice nurse or a 
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phlebotomist; (2) the sample may be taken as part of the NHS health checks or separate to the 
health checks.  
The proposed follow-up pathways were discussed by the ECDC at a (meeting in October 2014, ECDC 
input summarised in Appendix 1) and are presented in the Figure below. A summary of the input 
given regarding the pathways are given in Appendix 1. Positive test results will receive a letter 
inviting them to attend a referral centre (secondary care) which will be followed by a cancer type 
specific diagnostic test. In addition it was assumed that all persons with a positive result would see a 
cancer nurse specialist to reduce their anxiety in the recall period. The staffing requirements to 
provide this cancer nurse specialist support were based on data from the NHS breast cancer 
screening programme. 
Persons with an unclear result following diagnosis investigations may be retested after a year. 
Persons with a negative or unclear result following diagnostic investigations may self-refer 
themselves to a GP to discuss their outcomes. Due to an absence of data on the proportion of the 
number of patients who self-refer is 40%.  This number was tested in scenario analyses. They will be 
offered a repeat test after just one year.  Those with negative results will receive a letter confirming 
this and will be re-invited at the subsequent screening round. Due to the lack of evidence, it was 
assumed that40% of patients with false positive results self-refer to a GP to discuss their results in 
the base case. 
Figure 4.2: Proposed pathways for the generic cancer screening test  
  
4.3 Cost of generic cancer screening test and follow-up 
Invitation letter sent
Person makes an 
appointment Person does not make 
an appointment
2nd letter is sentPerson 
does not 
attend Invited at next screening round
Person declines
GENERIC CANCER SCREENING PROGRAMME PATHWAYS
Person provides 
blood sample (at GP
or pharmacy, etc)
Test is negative
(patient sent results)
Invited at next 
screening round
Referral centre 
(secondary care)
Test is unclear
Re-test after one year
Test is positive
Enter cancer 
treatment 
pathway 
Diagnostic pathway of the 
suspected cancer
(Cancer type specific test)
Positive result
Patient may self-
refers to a GP for 
counselling
Generic cancer screen
Follow up
Unclear result
Negative result
Opts out of 
the screening 
programme
Tests are conducted 
(initial and reflex)
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The cost of the generic cancer screen can be split into the following four components: 
1. Cost of inviting patients to attend and communicating the results 
2. Cost of taking the blood sample (including test consumables, and transportation of sample 
to laboratory) 
3. Cost of the biomarker tests on blood sample 
4. The cost of cancer nurse specialist support 
5. Cost of follow-up pathways 
The data used to inform these costs is described here and is summarised in Tables 4.3 a, b and c.  
Cost of inviting patients to attend and communicating the results 
The cost of inviting people to the screening programme, the cost of running a helpline for the 
screening programme and the cost of communicating the results to patients and their GP were 
based on costs estimated by the Southern Hub for the Bowel cancer screening programme (10). The 
total cost of this was £2.09 per screening invitee.  
 
Cost of taking the blood sample  
It was assumed that the blood sample would be taken at a GP surgery. Two options were considered 
for the mode of taking the blood sample: 1) the sample may be taken by either a practice nurse or a 
phlebotomist; 2) the sample may be taken as part of the NHS health checks or separate to the health 
checks. It has been assumed that in the NHS health checks the blood samples will be sent to the 
laboratories at no additional cost as they will already be sent there as part of standard practice. The 
staff costs were taken from Curtis 2013 and the staff time was obtained by expert clinical opinion 
(11). The cost of taking a blood sample is given in Table 4.3a for the costs used in the model and for 
the breakdown of this cost, see Table 4.3b. As the staff time is relatively uncertain a scenario 
analysis was conducted where the staff time for nurse outside the NHS health was halved to 5 
minutes. A scenario analysis was also conducted were the blood tests were conducted within the 
health checks. In this scenario, the staff time involved was 5 minutes to ensure that the staff had 
time to ensure that the patient had consented to the generic cancer screening test.  The cost in the 
base case is therefore £6.17 per sample, assuming a phlebotomist does this as part of a health 
check. 
 
Cost of the biomarker tests on blood sample 
It is envisaged that the generic cancer screen will use tests for several different biomarkers. Blood-
based biomarkers that can be used for early identification of cancer in the general population will be 
used possibly including some of the following types of tests: adhesion and matrix proteins, auto-
antibodies and immunological markers, classical tumour markers, coagulation and angiogenic 
proteins, cytokines, chemokines and insulin-like growth factors, circulating-free DNA, hormones, 
metabolomics, micro RNA and other RNAs, novel proteins, nuclear proteins, viral proteins, volatile 
organic compounds. The test will consist of two components: the initial test which will be a high 
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sensitivity test to detect all patients with cancer and a reflex test which will be a high specificity test 
for those patients identified by the initial test.  The cost of the biomarker tests will be: 
Cost of biomarkers in initial test + (proportion of samples requiring reflex test* cost of biomarkers in 
reflex test) 
As not all samples will require reflex testing the average number of biomarker tests performed 
(including initial and reflex) will not be an integer. For example, if 75% of samples receive 1 test and 
the remaining 25% receive 3 tests then the average number of tests is 1.5. The average number of 
biomarker tests performed per sample was assumed to range from 1.5 to 3 with 2 being assumed in 
the base case. The costs of testing for 8 biomarkers were provided by Ian Cree (ECDC) (12). These 
biomarkers will not necessarily be included in the generic cancer screening test, but were instead 
used to inform the potential cost of biomarkers in the generic cancer screening test. Some of the 
values were estimates and some values were obtained from a large district general hospital 
(2011/12 financial year). The cost of all reported biomarkers is given in Table 4.3c. The average cost 
of the CA, prostate specific antigen (PSA) and Carcinoembryonic antigen (CEA) biomarkers is £33. It 
may be possible to test for all biomarkers of a certain type for a fixed cost. The cost of testing for 
multiple volatile organic compounds (VOCs) was taken to be £10 (13). This cost estimate does not 
include any consumables related to VOCs (gas, vials, pre-concentrator or nurse time). Given the 
estimate of the cost of biomarkers and the assumption on the number of biomarkers in the generic 
cancer screening test, it was assumed that the base case cost of the biomarkers in the generic cancer 
screening test was £66.  
 
The cost of cancer nurse specialist support 
It was assumed that ongoing support would be given to people identified as having cancer by cancer 
nurse specialists, as in The NHS breast screening programme. The minimum staffing level is 0.1 
whole time equivalent cancer specialist nurses per 10,000 patients screened (4% positivity rate so 
400 positives) (14).It was assumed that this staffing level was related to the positivity of the NHS 
breast screening programme hence a minimum staffing level of 0.1 whole time equivalent cancer 
specialist nurses per 400 positive people was assumed. A cancer specialist nurse is equivalent to a 
nurse advanced in the unit costs of health and social care. The yearly cost (including salary, salary on 
costs and overheads but excluding qualifications) of an average nurse advanced was £81,705 per 
year. Whether or not this service would be provided alongside a new screening programme is 
uncertain, therefore a scenario analyses excluding these costs was undertaken.  
 
Cost of follow-up pathways 
It is expected that the generic cancer screening test results will indicate the type of cancer present. It 
has been assumed that patients who have a positive generic cancer screening test result will be 
referred to an appropriate secondary care clinician. For example, a person suspected of having 
bladder cancer will be referred to an urologist or oncologist. Therefore the costs of follow up were 
assumed to be the costs of procedures used to diagnose patients in secondary care, see Section 4 of 
Table 4.3a. For people without cancer (false positives) it has been assumed that they will receive the 
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most expensive diagnostic pathway. It was assumed that people with unclear screening test results 
did not receive further follow up but were invited to receive another screening test in one year.  
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Summary 
Table 4.3a: Summary of generic cancer screening test and follow-up costs 
 
 
Table 4.3b: Component costs of taking blood sample for generic cancer screen 
 
Table 4.3c: Costs of tumour markers 
 
 
   
1.      Cost of inviting patients to attend and communicating the results
Sending invitations and reminders, processing opt-outs, sending results letters, follow-up invitations £1.51
Helpline costs per screening invitee £0.58
Total cost £2.09
2.      Cost of taking the blood sample (including test consumables, and transportation of sample to laboratory)
Assumes 10 minutes required to take sample
Nurse takes blood sample at a GP surgery (within the health checks) £9.33
Nurse takes blood sample at a GP surgery £32.33
Phlebotomist takes blood sample at a GP surgery (within the health checks) £6.17
Phlebotomist takes blood sample at a GP surgery £29.17
3.      Cost of the biomarker tests on blood sample
Cost of tumour marker tests (each, average cost) £33
Average number of tumour marker tests per person screened 2
Cost of tumour marker tests £66
4.    Cost of follow-up pathways
Cost of follow-up for true positive screens (assumed to be the cost of diagnosing cancer) See treatment 
costs Table
Cost of follow-up for false positive screens (assumed to be the maximum cost of diagnosing cancer) See treatment 
costs Table
Cost Source
Practice nurse cost per hour £44 Unit costs of health and social care 2013
Phlenotomist cost per hour £25 Unit costs of health and social care 2013
Time taken for nurse/phlebotomist to take blood sample (minutes) 10 ECDC opinion (IC)
Time taken for nurse/phlebotomist to take blood sample (minutes) 5 ECDC opinion (IC)
Within health checks: Test consumables (needles, vials, etc.) £2 ECDC opinion (IC)
Outside health checks: Cost of consumables and transporting the blood samples to the laboratory £25 ECDC opinion (IC), from Sputnik trial
Tumour marker Source
2011/12 2012/13 (Inflated using HCHS)
CA 125 £23 £24 NICE ovarian cancer guidelines
CA 125 £34 £35
CA19.9 £35 £35
CA15.3 £36 £36
PSA £34 £35
CEA £31 £31
2015
FAIMS £20 Expert opinion IC
cfDNA £50 Expert opinion IC
Mutation analysis cfDNA £200 Expert opinion IC
Costs  of tumour markers
IC personal communication. Costs were obtained from a 
large district hospital in the 2011/12 financial year
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4.4 Cost of Cancer Diagnosis and Treatment 
4.4.1 Literature searches 
A series of literature searches were conducted to obtain cost-effectiveness and costing studies which 
might contain data on the cost of treating each of the five cancer types within the model scope. The 
searches were conducted in MEDLINE and MEDLINE in PROCESS in October 2014. In addition, the 
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) journal was 
searched for publications on the treatment of each of the five cancer types. The search terms 
relating to each disease were obtained and adapted where necessary from single technology 
appraisal submissions to the National Institute for Health and Care Excellence. The Scottish 
Intercollegiate Guidelines Network (SIGN) economic search filters (15) were used and search terms 
were added to remove any potentially irrelevant materials from the searches.  The search strategies 
are presented in the Appendix.  
The following exclusion criteria were applied to all search results: 
1. It did not only include patients with the cancer type under consideration 
2. The studies only contained qualitative data 
3. Only costs to the NHS were included 
4. It was not an original study; in this case the original study referenced was included in its 
place 
5. It did not consider UK patients 
6. It did not present treatment costs specific to cancer stage 
7. It did not present a cost for all patients with the cancer type 
 
These exclusion criteria were identified so that: the study results were relevant to the UK population 
and studies which reported consistent methodologies for calculating the cost of cancer across the 
different cancer stages were identified.  
In addition to the published literature a report by Incisive Health for Cancer Research UK was 
identified in the grey literature (dated September 2014). This reports the financial implications of 
earlier diagnosis of ovarian, lung, colon and rectal cancer. (16) The Incisive Health report uses 
national pathways and British sources for unit costs to create a cost of treating a patient by stage at 
diagnosis. The national pathways were simplified and amended according to clinical input to better 
reflect the cost of treating cancer patients in the UK.  
A group of clinical experts were contacted to ensure that key studies had not been missed. Details of 
the experts contacted are provided in the Appendix. No additional studies were identified via the 
experts. 
The studies identified for each of the five cancer types are presented in Table 4.4a. Where 
appropriate prices were inflated to 2012/13 using the hospital & community health services (HCHS) 
pay and prices index(11;17).  
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Table 4.4a: Results of literature search for cancer treatment costs  
Cancer Type Studies found in 
literature search 
Included studies Included studies 
references 
Other studies 
identified 
Bladder 3 1 (18)  
Breast* 108 7 (19-26)  
Colorectal 106 1 (27) (10;16) 
Lung 58 1 (28) (16) 
Ovarian 6 0   (16) 
*, A modified set of exclusion criteria was applied 
 
4.4.2 Studies of cancer diagnosis and treatment 
 
Bladder cancer 
The search identified three potentially useful studies of which two studies were excluded: one was 
an opinion piece and one considered patients with haematuria. (29) (30) Mowatt et al. was 
published in 2010, the study assessed the clinical benefit and cost-effectiveness of different 
strategies for the detection and diagnosis of bladder cancer in the UK. (18) Unit costs of procedures 
used in treating bladder cancer were reported, however the lifetime cost of treating non muscle 
invasive bladder cancer, muscle invasive bladder cancer and metastatic bladder cancer was not 
presented.  
As no existing studies providing data on bladder cancer treatment costs in the UK were identified by 
the search, a de novo bladder cancer costing study was undertaken as part of this project. This study 
is presented in a separate Appendix. National Collaborating Centre for Cancer (NCC-C) draft clinical 
guidelines (31), expert opinion, NHS reference costs (32) and the unit costs of health and social care 
(11) were used in the bladder cancer costing study. However, due to insufficient clinical input the 
proportion of patients who followed each part of the bladder cancer treatment and diagnosis 
pathways could not be determined hence the costing study remains incomplete.  
In the absence of an estimate from the de novo costing study, it was assumed that stage specific 
costs of diagnosing and treating bladder cancer are the same as the costs of diagnosing and treating 
colorectal cancer. This assumption was made for three reasons. Firstly, both types of cancer can be 
treated during the diagnostic procedure in the very earliest stages. Secondly, both cancer types use 
surgery to treat more advanced tumours. Finally, both cancers are in similar areas of the body 
therefore the costs of surgery in these two cancers may be similar. 
 
Breast cancer 
The search identified 108 articles potentially relevant to the cost of treating breast cancer. When all 
criteria were applied only one study on the cost of treating breast cancer remained (19). There were 
concerns about the applicability of this study for the cost of treating breast cancer in the UK. 
Therefore, criteria 6 and 7 were removed from the exclusion criteria to obtain studies which 
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reported the average cost of treating breast cancer. 7 articles were included using the modified 
exclusion criteria. Of these 7 articles, two articles contained lifetime treatment costs by stage for all 
breast cancer patients (19;20) and five (21-26) articles had information on the lifetime treatment 
costs for either late or early stage breast cancer patients.   
The study by Madan et al. (20) used the costs from Johnston (33) which report the cost of treating 
breast cancer by a patient’s Nottingham prognostic index (NPI). As NPI cannot be matched to stage 
at diagnosis groups, these costs were excluded.  
Table 4.4b: Breast cancer lifetime treatment costs identified by the literature review 
Study Cost 
reported 
in the 
study 
Original 
price 
year 
Inflated 
cost 
(2012/13) 
Study Details 
Late Stage 
Remak and 
Brazil (22) 
£12,502 2000/1 £18,394 The population is women presenting with stage IV 
breast cancer. Less than 40% of patients who 
present with late stage breast cancer have a stage 
IV cancer.  
Cameron 
et al. (23) 
£11,424 2005/6 £13,710 The population is post-menopausal women with 
ER+ advanced breast cancer.  About 80% of breast 
tumours are ER positive in post-menopausal 
women (34).  
Reis et al. 
(19) 
£45,328 2009/10 £48,542 The population is those patients at an increased 
familial risk of breast cancer. Most patients in the 
UK are not at an increased risk of breast cancer 
(35). The palliative care costs were at least five 
times higher than other studies on late stage 
breast cancer.  
Fleeman et 
al. (26) 
£15,661 2008/9 £16,957 The population is those women who receive 
anastrozole as a first line treatment for metastatic 
breast cancer. This population represents less 
than 10% of patients with metastatic breast 
cancer.  
Fleeman et 
al. (26) 
£13,992 2008/9 £15,150 The population is those women who receive 
laptinib as a first line treatment for metastatic 
breast cancer only. This population represents 
less than 10% of patients with metastatic breast 
cancer. 
Early stage 
Ward et al. 
(24) 
£23,690 2005/6 £28,430 The population is those women eligible to receive 
anthracycline based chemotherapy.  Currently the 
only recommended adjuvant chemotherapy 
option by NICE includes an anthrcycline 
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(doxorubicin). This chemotherapy option is only 
recommended for patients who are node positive 
(30% of breast cancers).  
Wolowacz 
et al. (25) 
£15,587 2005/6 £18,706 The population is those women with node 
positive early breast cancer. Out of all breast 
cancers, approximately 30% are node positive.  
Reis et al. 
(19) 
£17,456 2009/10 £18,694 The population is those women at an increased 
familial risk of breast cancer. Most patients in the 
UK are not at an increased risk of breast cancer 
(35).. 
 
The costs from Cameron et al. (23) will be used for the lifetime treatment costs of late stage breast 
cancer as the study included around 80% of the late stage breast cancer population. The costs from 
Ward et al. (24) will be used for the lifetime treatment costs of early stage breast cancer. This study 
was selected as it generally uses more recent sources for the cost inputs in the model than 
Wolowcaz et al. (25), it incorporates a cost of death in the model, clearly takes into account the cost 
of recurrence and covers a similar proportion of the population with breast cancer.  Reis et al. (19) 
was not considered as relevant to the cost of treating early stage breast cancer, as it appeared to 
cover a smaller proportion of the UK population with breast cancer.  
No information was available on the cost of diagnosing breast cancer, as all studies looked at 
treatments for patients after they had been diagnosed. Therefore it was assumed that the stage 
specific cost of diagnosing breast cancer was the average of the stage specific costs of treating 
colorectal, NSCLC, SCLC and ovarian cancer.  
 
Colorectal cancer 
The search identified 106 articles potentially relevant to the cost of treating colorectal cancer.  Only 
one of these articles, by Sweet et al. (27) was deemed relevant. Further to the articles discovered in 
the search two reports were identified from grey literature: one by Incisive Health (16) and one by 
Whyte et al.(a) (36).  
Sweet et al. defined treatment costs as any costs that occurred after diagnosis. (27) They calculated 
the long term treatment costs by dividing the average lifetime treatment costs by the average life 
expectancy of patients diagnosed with CRC.  It is unclear how they calculate the initial cost, or the 
length of time that the initial cost covers. The costs are calculated from data collected by the 
department of health in the payments by results scheme.  The prices are not discounted; however it 
would be possible to use the model to calculate the lifetime treatment costs of colorectal cancer 
patients.   The costs are reported in 2007 prices, Table 4.4c reports the inflated values that would be 
used in the economic model.  
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Table 4.4c: The cost of treating and follow up of colorectal cancer in England in 2012 prices 
Dukes’ stage Initial cost  
Yearly follow up 
cost  
Stage A – Screen detected £5,928 £175 
Stage A  – not screen detected £4,564 £175 
Stage B £11,319 £175 
Stage C £19,959 £175 
Stage D £13,680 £414 
Source; Sweet et al.(27) 
 
Whyte et al.(a) (36) report the lifetime cost of diagnosing, treating, follow up and recurrence of 
colorectal cancer by stage and age diagnosis. The costs were obtained from a whole disease model 
of colorectal cancer by Tappenden (37). 
Table 4.4d: The lifetime treatment cost of colorectal cancer in the UK 
  Dukes' stage at diagnosis 
Age at diagnosis A B C D 
40-49 £8,375 £8,362 £13,862 £11,198 
50-59 £5,465 £6,712 £9,272 £8,078 
60-69 £4,423 £5,120 £6,945 £6,227 
70-79 £3,040 £3,305 £4,291 £4,176 
80-100 £1,320 £1,479 £1,493 £772 
Incidence weighted average £3,651 £3,918 £5,318 £4,574 
Source; Whyte et al.(a)(36) 
 
In the Incisive Health report, the costs for colon and rectal cancer were calculated independently 
(16). To allow for recurrence it has been assumed that all of patients with stage I, II or III cancer 
shown not to survive to 5 years after being diagnosed suffer a recurrence of their disease. Further to 
this, the incisive health report assumed that the cost of treating a recurrence of the disease was the 
same as treating a patient with stage IV cancer. The weighted average cost of diagnosing and cost of 
treatment, follow up and recurrence of colon and rectal cancer were calculated using the number of 
patients with colon and rectal cancer from a study by Maringe et al.(38) . 
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Table 4.4e: The costs of diagnosing, treating, follow up and recurrence of colorectal cancer 
 Colorectal cancer 
TNM 
stage 
Cost of 
diagnosis 
Cost of 
treatment, 
follow up 
and 
recurrences 
Total cost 
Stage I £561 £3,526 £4,088 
Stage II £561 £10,296 £10,857 
Stage III £498 £16,327 £16,825 
Stage IV £463 £11,829 £12,293 
Source; Incisive Health (16) 
   
Data from the ICBP indicates that the mean age at which patients present with colon cancer is 72 
and with rectal cancer is 70 (38). The lifetime treatment costs are generally lower in the 70-79 age 
group in Whyte et al.(a).(36)  than the Incisive Health report (16). This is likely due to the assumption 
made in the Incisive Health report that only patients with stage I-III colorectal cancer at initial 
diagnosis could suffer from a recurrence and at recurrence all cancers were stage IV colorectal 
cancer. Not all recurrences of colorectal cancer will be stage IV at recurrence, indeed ,(one clinical 
opinion suggests that stage III would be the most common stage of recurrent cancers, hence this 
assumption will likely lead to an overstatement of the cost of treating colorectal cancer in the UK 
population. The lifetime treatment costs of stage IV colorectal cancer in the incisive health report 
are generally much higher than the costs of treating stage D colorectal cancer in Whyte et al.(a)(36).  
As the costs are significantly different and it is unclear why they are so different, the costs from 
Whyte et al.(a) (36)will be used in the base case and the values from the Incisive health report will 
be included as a scenario analysis. The costs reported by Sweet et al. (27) will not be used in scenario 
analyses as it is unclear how long the initial costs should apply for. Diagnosis costs will be estimated 
from the Incisive Health report, assuming that stage I, II, III and IV colorectal cancer correspond to 
Duke’s stage A, B, C and D respectively.  
 
Lung cancer  
The search identified 58 articles potentially relevant to the cost of treating lung cancer. Only one of 
studies from the search by Fleming et al. was deemed to be relevant (28). Fleming et al. conducted a 
costing study using patient charts and prices obtained from a survey of Northern Irish hospitals. All 
patients registered with the Northern Ireland Cancer Registry in 2001 were included in the study. 
The resource use for each patient was established using hospital notes for each patient in the 12 
months after they presented with lung cancer. Unit costs were obtained from the British National 
Formulary and a survey of local service providers. The cost of diagnosis, surgery, chemotherapy, 
radiotherapy, inpatient care and total costs were calculated and expressed in 2004 prices.  
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Table 4.4f: The diagnosis and treatment costs 12 months after presentation of small cell and non-
small cell lung cancer in Northern Ireland. 
 Stage Diagnosis costs Treatment and follow up costs 
Small cell lung cancer 
Limited  (stage I and II) £1,174 £9,389 
Extensive (stage III and IV) £935 £5,578 
Un-staged £1,052 £6,225 
Overall £1,005 £6,311 
Non-small cell lung cancer 
Limited (stage I and II) £1,003 £7,646 
Advanced (stage III) £1,014 £7,131 
Extensive (stage IV)  £884 £4,802 
Un-staged £936 £6,423 
Overall £957 £6,458 
Source; Fleming et al(28)  
Data from 2004 inflated to 2012/13 prices 
  
In the Incisive health report, to allow for recurrence it has been assumed that all patients with stage 
I,II or III small cell lung cancer shown not to survive to 5 years after being diagnosed suffer a 
recurrence of their disease (16). Further to this, it has been assumed that the cost of treating a 
recurrence of the disease was the same as treating a patient with stage IV Lung cancer.  
The clinical experts had concerns that the proportion of patients receiving CT scans, spirometry and 
chemotherapy were too low in patients with stage 1-3 lung cancer. This could lead to an 
understatement of the cost of treating lung cancer in the early stages of the disease. The clinical 
experts also had concerns that too many patients with stage 3 lung cancers were receiving surgery. 
This could lead to an overstatement of the cost of treating lung cancer in the early stages of the 
disease. However it could also reflect local variations in the treatment of patients with lung cancer. 
The cost in the Incisive Health report for each stage of non-small cell lung cancer is given in Table 
4.4g 
Table 4.4g: The cost of diagnosing, treating, follow up and recurrence of non-small cell lung cancer in 
English patients in 2012/13 
TNM 
stage 
Cost of 
diagnosis 
Cost of treatment, follow 
up and recurrences 
Stage I £2,939 £6,517 
Stage II £2,939 £14,033 
Stage III £3,124 £17,885 
Stage IV £2,906 £10,172 
Incisive Health report (16) 
The cost of treating non-small cell lung cancer used in the model will be taken from the Incisive 
Health report, as this data estimates the lifetime treatment cost of small cell lung cancer rather than 
the treatment costs which occur within a year of diagnosis. In Fleming et al. (4), limited stage disease 
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refers to stage I and II tumours, advanced stage disease refers to stage III tumours and extensive 
disease refers to stage IV tumours. The cost of treating non-small cell lung cancer is generally higher 
in the Incisive Health report than Fleming et al. (4). There are two reasons why this is likely to be the 
case. Firstly, Fleming et al. (4) only follow up patients with non-small cell lung cancer for one year. As 
such, the cost of treating some recurrences will have been missed from this data set. Secondly, the 
Incisive Health report assumes that all patients who do not survive up until the fifth year suffer from 
a stage IV recurrence of their lung cancer. This likely overstates the lifetime treatment cost of non-
small cell lung cancer, as this assumption ignores the fact that a small number of lung cancer 
recurrences may be non-metastatic.  As the costs in the Incisive Health report are more recent, it is 
likely that they are a better reflection of the cost of treating non-small cell lung cancer in the UK. 
Due to the potential limitations that using the Incisive health report pose, a scenario analysis will be 
conducted where the cost of treating patients with stage 1, 2 or 3 lung cancer is increased by 10%.  
As the one year net survival of small cell lung cancer patients is less than 25%, the cost of treating 
and follow up for a small cell lung cancer patient is likely to be appropriately captured within the first 
year. For small cell lung cancer patients, the data from Fleming et al. (4) inflated to 2012/13 prices, 
will be used in the economic model.  However, it should be noted that the information presented in 
Fleming et al.(28) is now likely to be out of date.   
 
Ovarian cancer 
The search identified 6 articles potentially relevant to the cost of treating ovarian cancer. None of 
these articles were deemed to be relevant, however one article which was not published in a peer 
reviewed journal was known. The Incisive Health report (16) uses national pathways and British 
sources for unit costs to estimate the cost of treating a patient by stage at diagnosis. The national 
pathways were simplified and amended according to clinical input to better reflect the lifetime cost 
of treating ovarian cancer patients in the UK. In calculating the lifetime cost of treatment, the cost of 
diagnosing, treating and following up ovarian cancer was considered. To allow for recurrence it was 
assumed that all of patients with stage I, II or III ovarian cancer shown not to survive to 5 years after 
being diagnosed suffer a recurrence of their disease. Further to this, the incisive health report 
assumed that the cost of treating a recurrence of the disease was the same as treating a patient with 
stage IV ovarian cancer. The cost reported for each stage of ovarian cancer is given in Table 4.4h.  
Table 4.4h: The cost of treating ovarian cancer in English cancer patients in 2012/13  
FIGO Stage 
Cost of diagnosing ovarian cancer 
Cost of treatment, follow up and recurrences of 
ovarian cancer 
Stage I £462 £6,370 
Stage II £505 £18,335 
Stage III £548 £22,935 
Stage IV £361 £14,720 
Source, Incisive Health report (16)  
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Summary 
A summary of the diagnosis and treatment costs used in the economic model for each of the five 
cancer types by stage at diagnosis is presented in Table 4.4i. 
Table 4.4i: Summary of diagnosis and treatment costs 
Cancer type and Stage Diagnosis costs Lifetime treatment 
costs (excludes 
diagnosis cost) 
Source 
Bladder cancer stage I £561 £3,533 
Assumed to be the 
same as colorectal 
cancer costs 
Bladder cancer stage II £561 £3,989 
Bladder cancer stage III £498 £5,338 
Bladder cancer stage IV £463 £4,671 
Breast cancer stage 1 £1,284 £23,690 Diagnosis costs: 
assumption based 
on other cancer 
types. Treatment 
costs: stage 1&2 
Ward et al. (24), 
stage 3&4 
Cameron et al.(23) 
Breast cancer stage 2 £1,295 £23,690 
Breast cancer stage 3 £1,276 £11,725 
Breast cancer stage 4 £1,166 £11,725 
Colorectal Cancer Dukes' 
Stage A  
£561 £3,533 
Diagnosis costs: 
Incisive Health 
(16), Treatment 
costs: Whyte et 
al.(36) 
Colorectal Cancer Dukes' 
Stage B  
£561 £3,989 
Colorectal Cancer Dukes' 
Stage C  
£498 £5,338 
Colorectal Cancer Dukes' 
Stage D  
£463 £4,671 
NSC Lung cancer Stage 1 £2,939 £6,517 
Incisive Health (16) 
NSC Lung cancer Stage 2 £2,939 £14,033 
NSC Lung cancer Stage 3 £3,124 £17,885 
NSC Lung cancer Stage 4 £2,906 £10,172 
SC Lung cancer Stage 1 £1,174 £9,389 
Fleming et al.(28) 
SC Lung cancer Stage 2 £1,174 £9,389 
SC Lung cancer Stage 3 £935 £5,578 
SC Lung cancer Stage 4 £935 £5,578 
Ovarian cancer stage 1 £462 £6,370 
Incisive Health (16) 
Ovarian cancer stage 2 £505 £18,335 
Ovarian cancer stage 3 £548 £22,935 
Ovarian cancer stage 4 £361 £14,720 
NSC; non-small cell,  SC; small cell 
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4.5 Screening Data  
 
4.5.1 Uptake 
The uptake of the generic cancer screening test is unknown hence values from other screening 
programmes may be informative. The uptake in the existing NHS screening programmes is: NHS 
breast screening 74%, NHS Cervical screening 74%, NHS bowel cancer screening 55% and the uptake 
in the NHS health checks is 48.8%.(10;39-41) Based on this data a range of values between 55% and 
74% will be considered in the economic model, with 55% been used as the base case. 
 
4.5.2 Generic screening test characteristics 
 
Sensitivity and specificity 
The generic cancer screening test will utilise a combination of biomarkers to ensure that high 
sensitivity and specificity are obtained. At the time of the project the test characteristics were not 
known; however they will be estimated via a study as part of a subsequent ECDC work package. To a 
certain extent it is envisaged that it will be possible to design the generic cancer test to have the 
optimal trade-off between sensitivity and specificity. The sensitivity of the test is likely to vary by 
cancer type and cancer stage but as no data on this is available a constant sensitivity will be assumed 
for the purposes of this project. Sensitivity and specificity were not used in the economic model, as 
there was no natural history model. Consequently there was no way of estimating the prevalence of 
asymptomatic cancer in the current model structure. Without the prevalence of asymptomatic 
cancer it was not possible to apply the sensitivity and specificity in the model. 
 
Unclear result rate 
The proportion of samples which will result in an ‘unclear’ result is unknown. An unclear rate of 
0.096 was observed for the cervical screening programme in 2000-01 and this was used in the base 
case.(41) A range for the unclear rate of 0.05-0.2 was considered in the scenario analyses. 
 
Positivity rate 
Positivity is the percentage of the population who received a positive result from a screening 
programme including patients with both true positive and false positive results. The positivity 
associated with the generic cancer screening test will be dependent on the test characteristics of the 
generic cancer screening test and the prevalence of disease in the population. It is anticipated that 
positivity rates for the generic screening test will be available following ECDC work package 3. 
Positivity data was obtained for the NHS bowel, breast and cervical screening programmes; see 
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Table 4.5a. Based on the data available from other screening programmes a rate of 2% will be 
considered in the base case with a range of 1%-4% in scenario analyses. 
Table 4.5a: The positivity rates of the current NHS screening programmes 
Type of 
screening 
Positivity 
rate 
Screening 
programme 
Source 
Bowel 2.1% NHS bowel 
cancer 
screening 
programme.  
Logan et al. (42) 
Breast 4% NHS breast 
cancer 
screening 
programme. 
NHS breast cancer screening programme 
annual review 2012. (39) 
Cervical 4.2% NHS cervical 
cancer 
screening 
programme.  
Number of people screened: NHS cervical 
screening programme annual review 2012. 
(41) 
Number of people receiving follow up: 
NHS Cervical Screening Programme Statistical 
Bulletin 2012-13.(43) 
 
False positivity rate 
The false positive rate is the proportion of patients out of the whole population who receive false 
positive results. This can be obtained by multiplying the positivity rate by the complement of the 
positive predictive value (note positive predictive value (PPV) =true positives/positives). 
To inform the false positive rate data from existing UK screening programmes was considered. Data 
available from the NHS cervical cancer screening programme did not allow calculation of a false 
positive rate. (43) In the evaluation of the first million cases in the NHS bowel screening programme, 
the positivity was 2.0% and the PPV ranged from 10.1% to 58.8% depending on whether low to high 
risk cases were counted as cancers. This gives a range of false positive rate to be 0.8% to 1.8%. From 
the NHS breast cancer screening annual review, the PPV was 19.6% in women aged 50-70 in 
2010/11(39). In the model base case the positivity is 2% using this data and the data from the NHS 
breast screening programme the base case false positive rate is 1.6%. As this value is likely to be 
sensitive to the screening test used, the false positivity rate was varied between 0.8% and 1.8% 
whilst the positivity rate was 2% in the scenario analyses.  
 
4.5.3 Overdiagnosis 
Overdiagnosis is the diagnosis of a cancer that otherwise would not have caused symptoms or death 
within a patient’s remaining lifetime (7).  Overdiagnosis can occur either as a result of a screening 
programme or as an incidental finding. Treatment of precancerous conditions can prevent cases of 
cancer and thus result in QALY gains. However, overdiagnosis usually incurs costs and will harm a 
patient’s HRQoL thus reducing QALYs. 
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It would be useful to understand: 1) what the current rates of overdiagnosis are for the cancer types 
in the scope, and 2) how overdiagnosis rates will change as a result of the generic cancer screening 
programme. However, there is little data available to answer these questions.  It is unknown if the 
generic cancer screen will result in the detection of a significant number of precancerous conditions.  
In the NHS breast screening programme there are an estimated 2.3 cases of overtreatment per 1000 
people screened (44). The overtreatment rate within the NHS bowel cancer screening programme is 
not known. Overdiagnosis was excluded from the economic model for two reasons. Firstly, the 
economic model does not include a natural history component to estimate the prevalence of 
asymptomatic cancer. Therefore the rates of overdiagnosis cannot be directly estimated in the 
model results. Secondly, there was no information on a plausible range of overdiagnosed cases in a 
blood based screening programme. It is envisaged that more information on this will become 
available in future ECDC work packages. The exclusion of overdiagnosis will mean that the ICERs are 
lower bounds, as total costs will be lower bounds and total QALYs will be upper bounds. See Section 
7.5 for more details.  
 
4.5.4 Treatment of people who receive a false positive 
In screening, false positives may receive cancer treatment unnecessarily if there is no 100% specific 
diagnostic test available. For example, in the UKCTOCs trial first screening round a false positive 
treatment rate of 0.01-1.70% was observed (depending on screening arm and tumour definition 
used). So, 0.01-1.70% of persons screened received treatment for ovarian cancer (assumed to be an 
oophorectomy) but did not have ovarian cancer (45) (46;47).  In the base case, 0.87% of female 
attendees received an unnecessary operation for ovarian cancer. As the generic cancer screen will 
have a different false positive rate to the UKCTOCs trial a scenario analysis in which no patient 
receives false positive treatment will also be considered. 
For colorectal cancer colonoscopy is assumed to be 100% specific so no treatment of false positives 
will occur. For lung cancer diagnosis, a CT scan is assumed to be 100% specific so i.e. no treatment of 
false positives could occur. Clinical advice on whether treatment of false positives may be possible 
for bladder or breast cancer was not available so an assumption that no unnecessary treatment 
would occur was made. In conclusion, it was assumed that treatment of persons who receive a false 
positive result in the generic cancer screening programme is possible for ovarian cancer only.  
 
4.5.5 Stage shift due to screening 
 Stage shift was defined as the percentage of patients who in the presence of screening do not 
present with an early stage cancer (stage I or II) but would have been detected with a late stage 
(stage III or IV) cancer without screening.   
The formulae for stage shift, S, was: 
𝑆𝑆 = 1 − ( 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑃𝑃 𝑠𝑠𝑛𝑛 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠) , where P = the proportion of cancers that were detected at stage III or IV. 
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Stage shift due to the generic cancer screen was not available, so data on stage shift from other UK 
screening programmes was considered. The stage shift for the NHS breast cancer screening 
programme was obtained from a cost-effectiveness study on the extending the age range of women 
eligible to routinely participate in the NHS breast screening programme (20;48). The stage shift 
observed in the trial data underlying the cost-effectiveness study was between prognostic groups 
and not stage at diagnosis groups, this is a limitation of using this data for a stage shift in the 
economic model. The observed stage shift was that 21% of patients who would have been diagnosed 
with late stage cancer in the absence of screening were diagnosed with early stage cancer in the 
presence of screening. After adjusting for the uptake of the screening programme, the observed 
stage shift was 31% in those patients who attended the screening programme.  
Data was obtained on the stage distribution of cancers observed in the NHS bowel screening 
programme from the evaluation of the screening pilot (49). Data on the stage distribution prior to 
the UK bowel screening programme was obtained from the incidence data available from Oxford, 
Northern and Yorkshire and Eastern regions in 2004-6 used by Whyte et al (50).The calculated stage 
shift from this data was 57%. This may be an overestimate of the stage shift as the screening pilot 
only includes those cancers at screening and not interval cancers.  
The base case stage shift used in the economic modelling was assumed to be 31% in the base case. 
This value was the stage shift observed for breast cancer, adjusted for the stage shift in the NHS 
breast cancer screening programme. A range of other values were considered in scenario analyses. 
Table 4.5b: The stage shift associated with UK cancer screening 
 Screened population Unscreened population 
Stage Number Percentage Number Percentage 
Bowel cancer 
Stage A/B 345 72.3% 11991 35.8% 
Stage C/D 132 27.7% 21519 64.2% 
Stage Shift  56.9%   
Breast cancer 
DCIS/Excellent/Good 184 39.2% 183 23.5% 
Poor/Moderate 285 60.8% 595 76.5% 
Stage Shift  21%   
Sources; Evaluation of the UK Colorectal Cancer Screening Pilot 
Final Report (49),Whyte et al. (50) and Madan et al.(51) 
 
4.6 Cancer incidence and survival data 
The main benefit of the proposed generic screening programme is improved survival and increased 
QALYs as a result of earlier diagnosis. Hence data on cancer incidence and survival by stage at 
diagnosis for each of the five cancer types included in the model scope was required. 
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The international cancer benchmarking partnership (ICBP) has published a series of papers 
comparing international differences in survival between countries in breast, colorectal, lung and 
ovarian cancers. The UK is one of the countries included in these comparisons. 
In addition to the ICBP data the following sources were searched for data on cancer incidence and 
survival by age and stage: National Lung Cancer Audit, the lead Knowledge and Intelligence Team for 
each cancer, ICBP, Cancer Research UK, references mentioned in the NICE bladder cancer draft 
guidelines (52). A summary of incidence and survival information is presented in Tables 4.6a and b 
respectively.  
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Table 4.6a: Summary of cancer incidence data available 
Cancer 
Type 
Incidence data available Sources and references 
Bladder by stage at diagnosis:  
in England in 2012 
 
National Collaborating Centre for Cancer 
(NCC-C) draft clinical guidelines (31) 
by age at diagnosis:  
in England in 2012 
 
National Collaborating Centre for Cancer 
(NCC-C) draft clinical guidelines (31) 
no data by age and stage obtained  
Breast by stage at diagnosis : 
in England, Wales and Northern 
Ireland in 2000-7 
 
In the West Midlands 1980-2002 
 
 
Walters et al. (53)  
 
 
Woods et al. (54) 
 
by age at diagnosis:  
in UK  in 2009-11 
 
In the West Midlands 1980-2002 
 
Cancer Research UK  
 
Woods et al. (54) 
no data by age and stage obtained  
Colorectal by age at diagnosis:  
in England and Northern Ireland in 
2000-7 
 
Maringe et al. (38) 
 
by stage at diagnosis:  
in England and Wales in 2012 
 
Cancer Research UK  
by age and stage at diagnosis: in 
England 
 
Whyte et al. (10) 
Lung by stage at diagnosis:  
in England and Northern Ireland in 
2004-7 
 
 
Walters et al. (55) 
 
by age at diagnosis:  
in UK in 2013 
 
National Lung Cancer Audit (LUCADA) (56) 
no data by age and stage obtained  
Ovarian by stage at diagnosis in England and 
Northern Ireland in 2004-7 
Maringe et al. (57) 
 
by age at diagnosis:  
in England in 2009 
 
in UK in 2009-11 
 
Trent Cancer registry (58)  
 
Cancer Research UK  
no data by age and stage obtained  
 
  
30 
 
Table 4.6b: Summary of cancer survival data available 
Cancer 
Type 
Survival data available Sources and references 
Bladder by stage at diagnosis: 
 in England in 2012 
National Collaborating Centre for 
Cancer (NCC-C) draft clinical guidelines 
(31) 
by age at diagnosis:  
in England in 2012 
National Collaborating Centre for 
Cancer (NCC-C) draft clinical guidelines 
(31) 
No data was obtained by age 
and stage at diagnosis 
 
Breast By stage and age at diagnosis: 
in England, Wales and 
Northern Ireland in 2000-7 
 
Walters et al. (53)  
 
By stage at diagnosis in 
Former Anglia Cancer Network 
in 2006-10 
Cancer Research UK (52) 
Colorectal By stage and age at diagnosis: 
in England and Northern 
Ireland in 2000-7 
 
Maringe et al. (38) 
 
Lung By stage and age at diagnosis: 
in England and Northern 
Ireland in 2004-7 
 
Walters et al. (55) 
 
Ovarian By stage and age at diagnosis: 
in England and Northern 
Ireland in 2004-7 
 
Maringe et al. (57) 
 
By stage at diagnosis in 
Former Anglia Cancer Network 
in 2006-10 
Cancer Research UK (52) 
 
4.7 Health related quality of life data 
4.7.1 Cancer HRQoL data 
A literature search was conducted (in November 2014) using the ScHARR health utilities database for 
each of the five cancer types within the scope. These searches identified 28 studies. Studies were 
excluded if 1) there were no British patients, 2) it did not consider all patients with a stage at 
diagnosis, 3) the treatments under consideration were not available in the UK, 4) it was not specific 
to a cancer type or 5) the HRQoL was higher than the utility used for people without cancer. Full 
details are provided in the Appendix.  After exclusions there was one relevant study which was on 
the utility of advanced lung cancer patients. (59)  
 
Chouaid et al. (59) consider the utility of patients with advanced non-small cell lung cancer (Stage 
IIIb or Stage IV). The study was a cross sectional study of the utility of adult patients with advanced 
non-small cell lung cancer across nine countries, one of which is the UK. One of the ways in which 
utility was estimated was using the EQ-5D-3L questionnaire and EQ-5D preference weights on the 
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preferences of the UK population for different EQ-5D health states (60).  A utility value of 0.66 (95% 
CI 0.62-0.69) was reported.  
 
In addition to cancer specific studies, generic HRQoL values for patients with and without cancer are 
available from a study by Ara and Brazier (61).  Ara and Brazier pool the data from four consecutive 
health surveys for England. These surveys contain information on whether an individual has one of 
several health conditions, including cancer, and their HRQoL measured using the EQ-5D 
questionnaire. When completing an EQ-5D questionnaire patients assign themselves to one health 
state. These health states are valued using a study on the preferences of the UK population for 
different EQ-5D health states (60). A HRQoL of 0.697 (95% CI 0.657-0.736) for persons with cancer 
and 0.798 (95% CI 0.755-0.839) for persons without cancer was reported.  
 
A brief search for systematic reviews of HRQoL data also found one additional study, a meta-analysis 
for lung cancer patients HRQoL. (62) The systematic review included any article which: had a 
previously unpublished HRQoL for lung cancer, reported the elicitation technique and noted who 
had provided the HRQoL value. A hierarchal linear model was used to estimate the HRQOL for 
patients with different types of lung cancer. Using the results of the hierarchal linear model, the 
HRQoL for lung cancer patients with the patient as a respondent, an EQ-5D valuation of health 
states, and death to perfect health as bounds to the scale was calculated. The HRQoLs obtained from 
Sturza (62) are given in Table 4.7. No country specific criteria were applied to the study by Sturza 
(62).  
Table 4.7: The health state utility values of lung cancer patients 
Stage Small cell lung cancer Non-small cell lung cancer 
Non metastatic 0.494 0.716 
Mixed/not specified 0.443 0.665 
Metastatic 0.244 0.466 
Source; Sturza (62) 
 
The HRQoLs from Sturza (62) will be used for patients with lung cancer and the values from Ara and 
Brazier will be used for all other cancers. The values from Chouaid et al. (59) will not be used, as they 
would not be consistent with the utility values used for other patients with lung cancer. 
 
4.7.2 Psychological impact of false positive screening test results 
It is hypothesised that a false positive screening test result may cause harm to an individual’s HRQoL 
through increased anxiety. A brief search was conducted using Google scholar to obtain the 
psychological and clinical literature on the impact of a false positive screening test result. Several 
economic models of screening were assessed to determine what approach, if any, had been taken to 
address the psychological impact of a false positive screening test result. 
 
These searches identified very little literature supporting an impact of false positives on QALYs. In 
one potentially relevant study by Collins et al. (63) conducted a meta-analysis of 12 randomized 
controlled trials of screening interventions, 6 of trials included in the meta-analysis were trials of 
cancer screening programmes. The results of this study suggest that there is no detectable impact of 
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false positive screening test results on a patient’s anxiety, depression and mental quality of life after 
4 weeks. Therefore, it was assumed that any impact of false positive screening test results on HRQOL 
values lasted for less than four weeks.   
 
Madan et al. (20) explore the effect of the psychological impact of a false positive screening test 
result on the cost-effectiveness of an extension of the NHS breast screening programme. QALY 
decrements of 0, 0.01, 0.02, 0.03 and 0.04 (0, 3.5, 7, 10.5 and 14 days in a year spent in a health 
state equivalent to death) per false positive were applied.   
 
Based on the Madan et al study a range of 0-0.04 will be considered in the model to reflect ‘no QALY 
decrement due to false positive’ and ‘the maximum plausible QALY decrement (0.04 = HRQOL of 0.5 
for 4 weeks)’. In the base case no utility decrement was assumed.  
 
4.8 Summary of data availability and quality  
 
Proposed screening pathways 
The proposed screening pathways were elicited from the ECDC. There was uncertainty in several 
areas of the pathways. For example, who would take the blood sample and whether or not it would 
be taken as part of the health checks. In addition there was uncertainty and discussion around the 
follow-up pathways for unclear results. Establishing these is important as they are likely to be a key 
determinant of costs. 
 
Cost of treating cancer by stage 
An extensive literature search was undertaken to obtain treatment and diagnosis costs for the five 
cancers in the scope by stage at diagnosis. Published literature in this area is very limited indeed. 
One unpublished study by Incisive health contained useful estimates but the study may not be of 
high quality. Clinical opinion suggested that some of the assumptions and values used in the Incisive 
study may not be reliable. No data was available for bladder cancer treatment. Therefore, it was 
assumed that the cost of treating and diagnosing bladder cancer was the same as the cost of treating 
and diagnosing colorectal cancer.  
 
Cost of generic cancer screening test and follow-up 
As the generic cancer screening test is still in development, costs were not available. Costs for 
several aspects of the screening test were taken from other NHS screening programs. Costs of follow 
up were estimated using NHS reference costs for procedures and consultations. There was 
considerable uncertainty surrounding the costs of the biomarkers tested for as part of the screen. 
 
Screening data 
Data on uptake rates, completions rates, and rates of over diagnosis were estimated based on other 
NHS screening programmes. There was no data available on the test characteristics of the proposed 
generic cancer screen as it is still in development. A range of acceptable values for sensitivity and 
specificity was available from the Delphi exercise so this could be used to inform scenario analyses. It 
is anticipated that further data will be available to inform the full model in later work packages. 
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HRQoL 
Literature searches were undertaken for HRQoL values relating to the five cancer types within the 
model scope. Limited cancer type specific values were identified. However, general cancer utility 
values were available which were suitable for use in the economic model. One study which provided 
a HRQoL decrement value for a false positive screening test result was identified. 
 
Cancer incidence and survival data  
Data on cancer incidence and survival by stage at diagnosis was available for each of the five cancer 
types. Incidence data by age and stage was available for colorectal cancer only.  Incidence data by 
age and incidence data by stage was available separately for each of the other four cancer types. The 
proportion of cancer cases which were unstaged in the data sets available ranged from 25.3% 
(breast cancer to 65% (bladder cancer). Survival data was available by stage at 1 year for all 5 cancer 
types, at 3 years for breast and colorectal cancer and at 5 years for bladder cancer. Generally the 
cancer incidence and survival data was satisfactory for the economic modelling.  
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5 Draft economic model: methods 
5.1 Modelling assumptions 
Cohort modelled 
The cohort modelled was the 2015 population of England and Wales who would be eligible for 
screening in a generic cancer screening programme. The two comparisons of interest are: 
• Generic cancer screening programme in addition to the type specific cancer screening 
programmes (breast, bowel and cervical). 
• Generic cancer screening programme as a replacement to the type specific cancer screening 
programmes (breast, bowel and cervical). 
This analysis considers the first comparison in which the new generic cancer screening programme is 
additional. 
The model represents the lifetime impact of one cohort being screened once. However, a screening 
programme may reduce the incidence of cancer in later screening rounds, as some of the cancers 
have been detected earlier. Also, any interaction between the generic cancer screening programme 
and the type specific screening programmes in terms of reducing future incidence of cancer is not 
included in the model. As there is no current example of two concurrent screening programmes, 
estimating these effects would be exceptionally difficult. The approach taken of excluding these 
effects and using incidence and survival data from after the introduction of the NHS breast and 
bowel cancer screening programmes provides the best available estimate of the benefits of a new 
screening programme without clinical data.  
Cancer types 
The modelling is restricted to five cancer types for reasons of feasibility. The included types consist 
of 45.1% of the incidence of all cancers in the UK.(64) This means that the benefits of screening on 
QALYs (due to earlier detection) will be underestimated; hence the incremental cost-effectiveness 
ratio (ICER) evaluated here provides an upper bound on the ICER for all cancer types. 
Precancerous conditions 
The intention is that the generic cancer screening test is designed to detect cancer and not 
precancerous conditions. Hence the economic modelling excludes precancerous conditions. If 
following development of the generic cancer screening test it is found that precancerous conditions 
are detected then this will have significant impacts on the health economics and a more complex 
model will be required to capture these effects. 
Treating precancerous conditions may result in a QALY gain where cases of cancer are prevented. 
Treating precancerous conditions can also cause a QALY decrement where cancer would never have 
presented symptomatically within a person’s lifetime as unnecessary treatment can be harmful to 
HRQoL. These two effects will influence the ICER in different ways; if treating precancerous 
conditions prevents cases of cancer then the ICER will be an upper bound. If treating precancerous 
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conditions harms patients, then the ICER will be a lower bound. Hence the impact may well vary 
between cancer types and is difficult to predict.  
 
5.2 Predicted outcomes of screening 
A common approach to screening modelling is to develop a disease natural history model which 
estimates the number of persons with precancerous disease and cancer at any given time point. This 
can then be used in combination with data on the sensitivity and specificity of a cancer screening 
test to generate predicted screening outcomes. Screening outcomes, such as incidence by stage, can 
be used to determine predicted outcomes in terms of life years gained and QALYs. 
As the draft economic model is being constructed ahead of any estimates of screening test 
sensitivity and specificity being available a different approach to modelling predicted screening 
outcomes was taken. A parameter, the stage shift of cancer incidence, was used to describe the 
impact of the cancer screen on the stage distribution of cancer incidence.  In addition to this 
parameters for positivity rates and false positivity were included.  
The definition of early stage is not always precisely known and varies by cancer type. References 
were identified which suggest that for ovarian cancer stages 1 and 2 are early (45) and for SCLC early 
is TNM stages I and II (55). Definitions for colon and bladder cancer classify into 
early/intermediate/late with stage 1 being early. (38) (31) No information was found for NSCLC, 
rectal or breast cancer.  
For this analysis it was assumed that cancer diagnosed in stage 3 or 4 were late stage and those 
diagnosed in stage 1 or 2 are referred to as early stage.(45;47) For persons attending screening the 
stage shift is defined to be the proportion of late stage incidence which is picked up at an early stage 
as a result of the screen. 
 
5.3 Estimating the incidence of cancer 
The future incidence of each cancer type by age was estimated using ONS population projections 
and the age specific incidence rates for each cancer type (65). Details on the sources for the age 
specific incidence rates are given in the Appendix. Data on the total incidence of cancer in 2012 was 
taken from the ONS and the Welsh cancer intelligence and surveillance unit (66;67). This data was 
compared to the modelled incidence in a 2012 cohort.  
To test the modelling approach the model predicted incidence and observed incidence was 
compared for the incidence of cancer in the 2012 population in England and Wales, see Table 5.3. 
The age-specific incidence data used varies in the countries and years included as shown in the 
Appendix. These differences are expected to be responsible for the differences in observed and 
modelled incidence seen. 
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Table 5.3: Comparison of modelled and observed incidence 
 Cancer type 
 Bladder Breast Colorectal Lung Ovarian 
Observed incidence in England and Wales in 2012 9,660 44,718 36,497 38,240 6,225 
Model predicted incidence in England and Wales 
for 2012 population 
8,990 43,628 38,026 36,087 6,088 
Percentage difference -6.9% -2.4% 4.2% -5.6% -2.2% 
Model predicted incidence in England and Wales 
for 2015 population 
9,458 45,047 39,968 38,137 6,315 
 
5.4 Estimating life expectancy and mortality with cancer 
For the economic model to represent the benefits of a stage shift the life expectancy for cancer 
patients by stage is required. The life expectancy of cancer patients was estimated by calculating 
their probability of death in each year since diagnosis, calculating the cumulative survival of patients 
(applying a half-cycle correction) and adding the average life years gained. To calculate a patient’s 
probability of death, two pieces of information were required in each year after a patient was 
diagnosed: 1) Cancer survival and 2) Other cause survival. All cause survival was calculated by 
multiplying the other cause survival with the fitted cancer survival models. 
1) Cancer survival 
A fractional survival model assumes that the population is split into two fractions: those who will die 
from their cancer (which we will refer to as terminal cancer patients) and those who will not (which 
we will refer to as non-terminal cancer patients). Fractional survival models were used to model 
stage specific cancer survival as this fits with the observation that some patients (particularly those 
diagnoses at an early stage) may have non-terminal cancer. The first model parameter is the 
proportion of patients with non-terminal cancer, which we will refer to as γ. For the proportion of 
patients with terminal cancer, (1- γ), an exponential model was fitted (as there were insufficient data 
points to allow statistical testing of other curve types) parameterised by λ, the constant risk of 
death. The formula for the survival model used is: 
  𝑆𝑆(𝑡𝑡) =γ+ [1 −γ] ∗ 𝑒𝑒𝑒𝑒𝑒𝑒(− λ ∗ t) 
Firstly we estimated the proportion of patients who have non-terminal cancer for each stage, γ. Long 
term survival information was not available by stage at diagnosis; therefore γ could not be obtained 
from observed data. An estimate for γ was calculated using long term all stage survival data which 
was available for up to 10 or 20 years.(52) The parameter γ was estimated as follows: if the most 
recent stage specific survival data was from year T, then for stage A γ =(T year stage A specific 
survival)*(10/20 year all stage survival/T year all stage survival). For example, for breast cancer stage 
1: γ = (5 year stage 1 survival)*(20 year all stage survival/5 year all stage survival) = 74.4%. The 
precise value for γ was then calibrated (using the Microsoft Excel® solver add-in) so that the 
predicted and observed mortality matched. When comparing predicted to observed mortality, the 
observed mortality was adjusted for the modelled incidence rates. All calibrations were conducted 
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for the year 2012 which had the most recent observed incidence data for England and Wales 
available.  
The calibration used the assumption that the ratio (long term survival: short term survival) was the 
same for all stages of cancer, but could vary between cancer types. Scenario analyses were 
undertaken to test the impact of this assumption. The rationale behind these analyses was the belief 
that patients with an earlier stage of cancer were more likely to have non-terminal cancer than 
patients with a later stage of cancer.  In the first scenario analysis, γ was increased by 10% for stage 
1 patients and decreased by 10% for stage 4 patients. In the second scenario analysis γ was: 
increased by 10% for stage 1 patients, increased by 5% for stage 2 patients, decreased by 5% for 
stage 3 patients and decreased by 10% for stage 4 patients. The relative survival of Stage 2 patients 
is generally lower than Stage 1 patients and the relative survival of Stage 3 patients generally higher 
than Stage 4 patients. Therefore it was expected that the impact on γ would be smaller in Stage 2 
and 3 patients than Stage 1 and 4 patients respectively. As can be seen in the formula below, by 
changing γ the constant risk of death changes as a different proportion of patients have a terminal 
cancer. 
For the fraction with terminal cancer, (1 -  γ), the formula for the constant risk of death, λ, for the 
exponential distribution is as follows: 
λ = �− 1
𝑇𝑇
� ∗ ln (𝑆𝑆(𝑇𝑇)−γ(1− γ) ), where T = time at which the last stage specific survival data is available.  
The fitted survival curve for breast cancer is shown in Figure 5.4. The modelled survival curves for 
the other cancer types are provided in the Appendix. A good fit was observed for all cancer types 
except bladder cancer. For bladder cancer modelled survival was better than observed survival but it 
is suspected that this is because survival may have improved between the date of the survival data 
(2006-2010) and the date of the mortality data. The method used ensures a perfect fit to the most 
recent mortality data (2012) for all cancer types.  
Figure 5.4: The fitted survival curve for breast cancer by stage at diagnosis 
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2) Other cause survival 
The probability that a patient would die from any cause other than their cancer was calculated by 
taking the office for national statistics (ONS) life tables and subtracting the average proportion of 
mortality associated with each cancer type from the ONS mortality statistics in 2011- 2013 (to match 
the all cause death data used) (68-70). The probability that a patient would die from any cause other 
than their cancer varies by age, so the life expectancy of cancer patients was calculated for patients 
with different ages at diagnosis.  
To obtain the mortality for each type of cancer, it was necessary to use the ICD-10 code associated 
with each cancer type: (Bladder C67, Breast C50, Colon C18, Rectal C19-C20& C21.8, Lung C34, and 
Ovarian C56-57). There were no separate ICD – 10 codes for small cell and non-small cell lung 
cancer. Therefore all lung cancer deaths were removed from the all cause death in the ONS life 
tables for both types of lung cancer. This approach of removing all lung cancer related deaths, was 
previously used in a cost-effectiveness study on the early detection of non-small cell lung cancer(71).  
  
5.4.1  Predictions of cancer life expectancy and mortality 
The incidence and survival models were used to estimate the life expectancy and number of deaths 
of patients with cancer by age and stage at diagnosis for each cancer type.  
From the survival data, life years gained were calculated assuming that the patients who died in any 
given year died at 6 months (half-cycle correction). The life years gained were summed across all 
years after the patient was diagnosed with cancer. An incidence weighted average over age was 
taken to calculate the life expectancy of patients with cancer by stage, see Tables 5.4a and 5.4b.   
Table 5.4a: Model-predicted life expectancy by cancer type (2015) 
Life expectancy (years) 
  Bladder Breast  Colorectal NSCLC SCLC Ovarian 
Stage 1/Duke's stage A 10.3 23.8 14.4 5.2 4.2 18.7 
Stage 2/Duke's stage B 7.0 19.2 12.8 4.1 4.2 9.5 
Stage 3/ Duke's stage C 6.3 12.3 9.6 2.5 2.9 4.8 
Stage 4/stage D 4.3 4.6 3.0 1.4 1.4 1.6 
Early stage 8.8 21.3 13.2 4.8 4.2 17.3 
Late stage 4.6 9.5 7.4 1.8 1.9 3.6 
Difference between early and late stage 4.2 11.9 5.8 3.0 2.3 13.7 
 NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer 
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Table 5.4b: Model-predicted life expectancy by cancer type (2015, discounted) 
Discounted life expectancy (years) 
  Bladder Breast  Colorectal NSCLC SCLC Ovarian 
Stage 1/Duke's stage A 7.8 14.2 10.0 4.1 3.3 12.3 
Stage 2/Duke's stage B 5.3 11.6 8.9 3.2 3.2 6.5 
Stage 3/ Duke's stage C 4.8 7.2 6.7 2.0 2.3 3.4 
Stage 4/stage D 3.2 2.1 2.0 1.0 1.2 1.4 
Early stage 6.6 12.9 9.2 3.8 3.3 11.4 
Late stage 3.5 5.3 5.1 1.5 1.5 2.7 
Difference between early and late stage 3.1 7.5 4.1 2.3 1.7 8.7 
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer 
  
Table 5.4c: Model-predicted life expectancy by cancer type: scenario analyses testing alternate 
modelling assumptions (2015) 
  Base 
Case 
Scenario 1: γ increased by 
10% for stage 1 patients and 
decreased by 10% for stage 4 
patients 
Scenario 2: γ +10% for stage 1 
patients, +5% for stage 2 patients, -
5% for stage 3 patients   and -10% for 
stage 4 patients 
Cancer 
type 
 Cancer 
Stage 
Undiscounted Life Expectancy (years) 
Bladder Early 8.8 9.0 9.1 
Late  4.6 4.3 4.3 
Difference 4.2 4.7 4.8 
Breast Early 21.4 21.4 21.5 
Late  9.4 9.4 9.2 
Difference 11.9 11.9 12.3 
Colorec
tal 
Early 13.2 13.2 13.6 
Late  7.4 7.4 7.2 
Difference 5.8 5.8 6.4 
NSCLC Early 4.8 5.0 5.0 
Late  1.8 1.7 1.7 
Difference 3.0 3.2 3.3 
SCLC Early 4.2 4.4 4.4 
Late  1.8 1.8 1.8 
Difference 2.3 2.5 2.6 
Ovarian Early 17.3 18.1 18.1 
Late  3.6 3.6 3.6 
Difference 13.7 14.5 14.5 
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; γ, proportion of patients who have 
non-terminal cancer for each stage   
 
The scenario analyses testing different survival modelling assumptions resulted in a slightly greater 
difference between life expectancy for early and late stage cancers than in the base case. The effect 
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of these scenarios on the cost-effectiveness of the generic cancer screening programme will be 
shown in the results. 
The number of deaths due to cancer was calculated as follows. The proportion of deaths attributable 
to other causes was calculated for each year after the patient was diagnosed with cancer. All deaths 
that were not attributable to other causes were attributable to cancer. The number of deaths is not 
calculated as simply the difference between the relative survival and cumulative other cause survival 
curves. Taking this approach would wrongly count most of those patients whose cause of death was 
due to cancer as having died from other causes. 
 
Table 5.4d: Model-predicted number of deaths attributable to each cancer type 
 Bladder Breast Colorectal Lung Ovarian 
Observed mortality in England 
and Wales in 2012 
4646 10311 14191 30257 3769 
Expected mortality (The 
observed mortality in England 
and Wales in 2012 adjusted for 
the modelled incidence rates) 
4324 10060 14786 30175 3686 
Model predictions of deaths in 
2015 
4548 10371 15536 32520 3824 
Source, Office for National Statistics (69) 
 
Table 5.4d shows that the model predicts a higher number of cancer deaths in 2015 than 2012. It is 
expected these differences are due to differences in population size and population age distributions 
(2012 (56.6 million) and 2015 (58.1 million)). The model predictions in the 2012 English and Welsh 
exactly match the expected mortality in 2012. 
5.5 Model structure 
As no data on the test characteristics of the generic cancer screen was available a simple approach 
to modelling was taken. It was assumed that the screening intervention would result in a proportion 
of individuals who presented with a late stage cancer (stage III or IV) at a given age being stage 
shifted to having an early stage cancer (stage I or II).  This approach only enabled the evaluation of 
impacts (costs and QALYs) for one screening round.  This approach was appropriate given data 
available however it was associated with the following limitations: 
• The model scope only includes five cancer types, rather than all cancer types 
• Any effects of overdiagnosis are excluded from the economic model  
• Any survival improvements within stages, due to an individual’s cancer been detected in the 
screening programme is not included 
• Precancerous conditions are excluded from the model 
• Multiple screening rounds cannot be included in the current model structure 
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• Scenarios around the use of the new screening programme as a replacement to rather than 
an addition to current screening programmes cannot be conducted 
• The individual’s disease history remains unknown.  Therefore the health benefits of repeat 
screening for individuals with an unclear result cannot be included in the model. 
• Much of the data for the generic cancer screening programme comes from the existing type 
specific screening programmes.   
Due to the limitations and exclusions discussed ICER values presented are not considered robust or 
reliable. However the analyses do identify key parameters which are likely to influential on the cost-
effectiveness of a new generic cancer screening programme 
5.6 Analyses undertaken 
The model was run for the population of England and Wales in 2015 undertaking one round of 
screening as an addition to the type specific screening programmes. The total costs associated with 
the screening programme were estimated including: cost of generic cancer screen; cost of follow-up; 
and cancer treatment costs. The totals QALYs gained were estimated which incorporated: QALY 
gains due to earlier diagnosis (as a result of better survival) and QALY decrements due to false 
positives. The following model outputs were produced: cancer deaths prevented, life years saved, 
QALY gain, change in cancer treatment costs, cost of screening and follow up, total costs and ICER.  
The first base case analysis was conducted where parameters mostly took average from the existing 
screening programmes (details in Table 5.6a).  A second base case analysis (base case 2) was 
conducted where parameters took favourable values from the existing screening programme data 
(details in Table 5.6a). The parameters used in all model runs are detailed in Table 5.6a. If there is no 
parameter value in the base case 2 column, then it took the same value in both base case 1 and base 
case 2.  In addition to the base case deterministic analysis several scenario analyses were run to 
explore the impact of key modelling assumptions. These analyses are detailed below.  
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Table 5.6a: The model parameters used in in the base cases and all scenario analyses  
Screening Parameters       
  
  
  Base case 
1 
Base 
case 2 
Scenario 
analysis 
values 
 Source 
Screening starting age 40  * 45, 50 ECDC opinion 
Screening finishing 
age 
75  * 70, 80 ECDC opinion 
Screening interval 4 years  * 1 year, 3 
years, 5 years, 
10 years 
ECDC opinion 
Uptake 55% 73.4% 45%, 73.4% NHS bowel screening programme, 
Other NHS screening programmes 
and ECDC opinion 
Positivity rate 2%  * 1%, 4% NHS bowel screening programme, 
exploratory value, Other NHS 
screening programmes 
False positive rate 1.6% 1.5% 1.5%, 1.8%, 
0% 
NHS breast cancer screening 
programme, exploratory value, NHS 
bowel screening programme. 
Unclear rate 9.7% * 5%, 20% NHS cervical screening programme 
& exploratory values 
Screening costs parameters and pathway assumptions 
Stage shift due to 
screening 
31% 56.9% 90% NHS Breast cancer screening 
programme, NHS bowel cancer 
screening programme, exploratory 
value 
Percentage of patients 
with unclear or false 
positive results who 
visit their GP 
40%  * 0%   
Cost of a GP 
appointment 
£37   Curtis et al.(11) 
Cost of invitations per 
invitee 
£2.09  * * Whyte et al.(10) 
Cost of taking the blood 
sample (including staff 
time) 
£6.17 £4.08 £9.33, £4.08 ECDC opinion & exploratory values 
Cost of the biomarkers £66 £10 £10, £49, 
£99 
ECDC opinion & the cost of 
individual biomarkers at a large 
district hospital 
Cost of follow up for 
false positive patients 
£3,124 £361 £361 The cost of the most expensive and 
the cheapest follow up pathway 
Cost of cancer nurse 
specialist support per 
positive patient 
£20  * £0 NHS breast cancer screening 
programme  
Health state utility values 
HRQoL for non-lung 0.697  * None  Ara and Brazier(61) 
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cancer patients  
HRQoL for non- 
metastatic NSCLC  
0.718 * *  
  
Sturza(62) 
  
 
HRQoL for metastatic 
NSCLC 
0.466 * * 
HRQoL for non-
metastatic SCLC  
0.496 * * 
HRQoL for metastatic 
SCLC 
0.244 * * 
HRQoL decrement due 
to false positives 
0  * -0.02, -0.04 Madan et al(20) 
Cancer treatment & diagnosis costs 
Stage 1 Bladder cancer £4,094 * (+25%, -25%) 
Assumed to be equal to colorectal 
cancer 
Stage 2 Bladder cancer £4,551 * (+25%, -25%) 
Stage 3 Bladder cancer £5,836 * (-25%, +25%) 
Stage 4 Bladder cancer £5,134 * (-25%, +25%) 
Stage 1 Breast cancer £24,974 * (+25%, -25%) 
Assumption, Ward et al.(24), 
Cameron et al. (23) 
Stage 2 Breast cancer £24,985 * (+25%, -25%) 
Stage 3 Breast cancer £13,001 * (-25%, +25%) 
Stage 4 Breast cancer £12,891 * (-25%, +25%) 
Stage 1 CRC £4,094 * (+25%, -25%) 
Incisive Health (16), Whyte et 
al.(36) 
Stage 2 CRC £4,551 * (+25%, -25%) 
Stage 3 CRC £5,836 * (-25%, +25%) 
Stage 4 CRC £5,134 * (-25%, +25%) 
Stage 1 NSCLC £9,456 * (+25%, -25%) 
Fleming et al.(28) 
Stage 2 NSCLC £16,972 * (+25%, -25%) 
Stage 3 NSCLC £21,009 * (-25%, +25%) 
Stage 4 NSCLC £13,078 * (-25%, +25%) 
Stage 1 SCLC £10,563 * (+25%, -25%) 
Incisive Health(16)   
Stage 2 SCLC £10,563 * (+25%, -25%) 
Stage 3 SCLC £6,513 * (-25%, +25%) 
Stage 4 SCLC £6,513 * (-25%, +25%) 
Stage 1 Ovarian cancer £6,832 * (+25%, -25%) 
Incisive Health (16) 
Stage 2 Ovarian cancer £18,840 * (+25%, -25%) 
Stage 3 Ovarian cancer £23,483 * (-25%, +25%) 
Stage 4 Ovarian cancer £15,081 * (-25%, +25%) 
Predicted life years gained (undiscounted) 
Stage 1 bladder cancer 10.3 * 10.8, 10.7 ONS(68-70;72), National 
Collaborating Centre for Cancer(31), 
calculation 
Stage 2 bladder cancer 7.0 * 7.0, 7.2 
Stage 3 bladder cancer 6.3 * 6.3, 6.1 
Stage 4 bladder cancer 4.3 * 3.9, 4.0 
Stage 1 breast cancer 23.8 * 23.8, 23.8 
ONS(68-70;72), Cancer Research 
UK, calculation 
Stage 2 breast cancer 19.2 * 19.2, 19.5 
Stage 3 breast cancer 12.3 * 12.3, 12.0 
Stage 4 breast cancer 4.6 * 4.5, 4.5 
Stage 1 CRC  14.4 * 14.9, 14.9 ONS (68-70;72), Maringe et al.(38), 
calculation Stage 2 CRC 12.8 * 12.8, 13.1 
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Stage 3 CRC 9.6 * 9.6, 9.3 
Stage 4 CRC 3.0 * 2.9, 2.9 
Stage 1 NSCLC 5.2 * 5.4, 5.4 
ONS (68-70;72), Walters et al.(55), 
calculation 
Stage 2 NSCLC 4.1 * 4.1, 4.2 
Stage 3 NSCLC 2.5 * 2.5, 2.4 
Stage 4 NSCLC 1.4 * 1.3, 1.3 
Stage 1 SCLC 4.2 * 4.5, 4.5 
ONS (68-70;72), Walters et al.(55), 
calculation 
Stage 2 SCLC 4.2 * 4.2, 4.3 
Stage 3 SCLC 2.9 * 2.9, 2.8 
Stage 4 SCLC 1.4 * 1.3, 1.3 
Stage 1 Ovarian cancer 18.7 * 19.6, 19.6 ONS (68-70;72), Cancer Research 
UK, calculation Stage 2 Ovarian cancer 9.5 * 9.5, 9.7 
Stage 3 Ovarian cancer 4.8 * 4.8, 4.7 
Stage 4 Ovarian cancer 1.6 * 1.6, 1.6 
*, Base case 2 uses the same parameter values as base case 1 for these parameters 
HRQoL, health related quality of life; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer 
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5.6.1 Scenario analysis: Impact of generic cancer screen on stage distribution 
As stated in Section 5.2, stage shift was defined in the model as the proportion of patients who 
would have been detected as a stage 3 or 4 cancer in the absence of screening but in the presence of 
screening were detected as having a stage 1 or 2 cancer. In the base case 1, the stage shift 
associated with breast screening was used (51). As data was also available on the stage shift 
associated with colorectal cancer screening  in the UK, this was used as a scenario analysis(49;50). As 
the new screening programme may have a different effectiveness than breast or bowel screening in 
the UK, a scenario analysis was conducted where the stage shift was assumed to be 90%.  
 
5.6.2 Scenario analysis: Modelling life expectancy gains associated with stage shift 
Predicted life expectancy gains are dependent on the stage distribution of long term survivors. Two 
different scenarios were considered and full details are in Section 5.4. In summary, the proportion of 
long term survivors with stage 1 cancer will increase by 10% from the base case and the proportion 
of long term survivors with stage 4 cancer will decrease by 10% from the base case in the scenario 1. 
In scenario 2, the proportion of long term survivors with stage 1 and 4 cancer will be the same as the 
scenario 1 and the proportion of long term survivors with stage 2 cancer will increase by 5% from 
the base case and the proportion of long term survivors with stage 3 cancer will decrease by 5% 
from the base case  
 
5.6.3 Scenario analysis: Screening costs 
Three components of the cost of the screening programme were varied in the scenario analyses: the 
cost of the biomarkers used in the generic cancer screening test, the cost of conducting the generic 
cancer screening test and the cost of follow up for people with a positive screening test result.  
Cost of biomarkers 
As stated in Section 4.3, it was assumed that the cost of a single biomarker was £33 and the number 
of biomarkers in the generic cancer screening programme would be between 1.5 and 3 biomarkers 
per test. In base case 1, it was assumed that the average cost of the biomarkers was £66 (on average 
2 biomarkers per test). Scenario analyses were conducted in which the cost of biomarkers in the 
generic cancer screening programme were assumed to be £99 and £49 (on average 3 and 1.5 
biomarkers per test respectively). Currently the cancer biomarkers reported in Section 4.3 are not 
used in the UK for a cancer screening programme. Therefore, there is the potential for economies of 
scale if these biomarkers were to be used in a cancer screening programme. With this in mind a 
further scenario analysis was conducted where the cost of the biomarkers used in the generic cancer 
screening programme was assumed to be £10. 
Cost of delivering generic cancer screening test 
The impact of lowering the cost of the generic cancer screening programme on the ICER was 
assessed. One way in which this may be possible would be to deliver the generic cancer screening as 
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part of the NHS health checks. In base case 1 the cost of taking the blood sample for the generic 
cancer screening programme includes: delivering the sample to laboratory, consumables which will 
be used when the sample is taken, additional staff time and the cost of vials, needles and labels for 
the blood sample. In the scenario analyses, only the cost of staff time and the cost of vials, needles 
and labels for the blood sample will be included in the cost of taking the blood sample. The cost of 
conducting the generic cancer screening test is £27 per attendee in base case 1, and this will be 
changed to £4 and £9 per attendee in the scenario analyses.  
Cost of screening follow up 
The cost of follow up given to a patient with a false positive result was varied from £3,124 in the 
base case 1 (the most expensive diagnostic pathway) to £361 (the least expensive diagnostic 
pathway) in the scenario analyses.  
A scenario analysis was also conducted where the cost of the biomarkers, the cost of delivering the 
generic cancer screening programme and the cost of follow up for people with false positive 
screening results were set to their minimum values (£10, £4 and £361 respectively). 
Scenario analyses excluding the cost of additional cancer nurse specialists to support people through 
the diagnosis pathways, and excluding the cost of self-referrals of false positive results to GPs were 
also undertaken. 
 
5.6.4 Scenario analysis: HRQoL decrement for false positives 
As stated in Section 5.5, scenario analyses were conducted on the QALY decrement due to a person 
receiving a false positive result.  In base case 1 a QALY decrement of -0.02 per false positive was 
applied; this was varied to 0 and -0.04 in the scenario analyses.   
 
5.6.5 Scenario analysis: Screening age ranges and interval 
As the generic cancer screening test is yet to be developed, the ages at which people will be 
screened and the screening interval are highly uncertain. The age at which the screening programme 
starts was varied from 40 in base case 1 to 45 and 50 in the scenario analyses. Further scenario 
analyses were conducted on the age at which screening was stopped was varied from 75 in base 
case 1 to 70 in the scenario analyses. Finally the interval between screening rounds was varied from 
every 4 years in base case 1 to every year, every 3 years, every 5 years and every 10 years in the 
scenario analyses.  
 
5.6.6 Scenario analysis: Unclear results, positivity rate, false positivity rate and uptake  
As the generic cancer screening test is yet to be developed, the uptake, unclear, and positivity rates 
of the programme are uncertain. The unclear results rate was varied from 9.7% in base case 1 to 5% 
and 20% in the scenario analyses. The positivity rate was varied in a separate analysis from 2% in 
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base case 1 to 1% and 4% in the scenario analyses. The false positivity will adjust to be just over 80% 
of the positivity rate based on the NHS breast screening programme (39) Given the positivity rate of 
2% in base case 1, the false positive rate was varied from 1.6% in the base case to 0.8% and 1.8% in 
the scenario analyses. This analysis was conducted by varying the proportion of patients with 
positive results who were assumed to be truly false positives. The uptake of the generic cancer 
screening programme was varied from 55% in base case 1 to 45% and 74% in the scenario analyses.  
 
5.6.7 Scenario analysis: The cost of cancer treatment 
The cost of treating each cancer stage is highly uncertain. In the future, treating each cancer stage 
may become more expensive as new cancer drugs become available. However, treating each cancer 
stage may become cheaper as existing drugs come off patent. The important consideration for cost-
effectiveness will be how the cost of treating early stage and late stage cancer changes over time. 
Therefore two scenario analyses were conducted. In the first scenario analysis, the cost of treating 
early stage cancer was increased by 25% whilst the cost of treating late stage cancer was reduced by 
25%. In the second scenario analysis, early stage cancer been 25% cheaper to treat and late stage 
cancer been 25% more expensive to treat.  
 
5.6.8 Two-way sensitivity analyses 
To understand how the ICER may change when the cost of the biomarkers and the effectiveness of 
screening were varied, a two way sensitivity analysis was conducted were both of these parameters 
were varied at the same time.  
 
5.6.9 Validation exercise 
Comparison of QALY gains 
As a way of validating the model predictions of QALY gains, the ECDC economic model was 
compared to the ScHARR Bowel cancer screening model (BCSP model). The BCSP model represents 
up to 8 screening rounds (biennial from 60-74) so it was run for a single screening round (single 
screen at age 64 for a cohort of size 100,000) to allow comparison with base case 2 from the ECDC 
economic model. In both models discounting was applied from age 65 at 3.5%.  
 
The BSCP model includes QALY gains as a result of 1) earlier diagnosis of cancer (leading to better 
survival) and 2) reduced cancer incidence (due to removal of precancerous conditions). The ECDC 
economic model does not include the impacts on cancer incidence of treatment of precancerous 
conditions because 1) the generics screening test is not designed to detect pre-cancerous conditions 
and 2) the simple model structure used does not include a natural history component to allow such 
impacts to be modelled. 
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6 Draft economic model: Results 
6.1 Model Results (base-case) 
The model outputs were intended to be used to inform the development of the generic cancer 
screening test. Several outcomes are presented which include: cancer deaths prevented, life years 
saved, QALY gain, change in cancer treatment costs, cost of screening and follow up, total costs and 
ICER. Model predictions were generated relating to one year of screening although the lifetime 
benefits associated with earlier stage of diagnosis are included. 
Table 6.1a shows that in base case 1; 24.5 million people were predicted to be eligible for screening 
in 2015. The model predicts that 3.5 million people attend the screening programme resulting in 
1,341 cancers being detected at an earlier stage and the prevention of 403 cancer deaths. The model 
also predicts that 337,490 people required repeat tests due to an unclear test result. The results 
show that screening leads to more life years accrued by people and the number of cancer cases 
diagnosed in an early stage increases.  
The cost of the screening programme includes the cost of inviting people to be screened and the 
cost of conducting the screening test. This cost is more than double the follow up costs for those 
patients who have been screened. The follow up costs include all diagnosis costs, cost of GP 
appointments for some patients who received a false positive screening test result, the cost of 
cancer nurse specialists, the cost of unnecessarily treating people with false positive screening test 
results and the cost of re-inviting and re-screening people with unclear test results. The cost savings 
from treating cancer patients earlier are much smaller than the cost increases associated with the 
screening programme. The model predicts a cost saving from earlier treatment of £0.5 million and a 
cost increase from introducing screening of £447.5 million in 2012/13 prices. The incremental cost-
effectiveness ratio (ICER) of this screening programme is around £98,000 per QALY gained. 
Table 6.1b shows that in base case 2, 24.5 million people were predicted to be eligible for screening 
in 2015 and 3.5 million people attended the screening programme. 10,447 cancers were detected by 
the screening programme with 3,294 of these cancers been detected at an earlier stage preventing 
991 cancer deaths. The model predicts that the same number of people require repeat tests in both 
base case 2 and base case 1. This is as; both base cases use the same parameter value for the 
unclear rate which determines the number of people who were invited for a repeat screening test.  
The cost of conducting screening in base case 2 is approximately double the cost of follow up. 
However both the cost of conducting screening in base case 2 is less than 1/3 of the cost of 
conducting screening in base case 1. A similar reduction in the cost of follow up was observed 
between base case 1 and 2. The cost savings associated with earlier diagnosis are higher than in base 
case 1, but are still much smaller than the cost increases caused by introducing the generic cancer 
screening programme. The model predicts a cost saving from earlier treatment of £1.3 million and a 
cost from introducing screening of £138.5m in 2012/13 prices. The ICER of this screening programme 
is around £12,000 per QALY gained.  
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Table 6.1a: The descriptive statistics and cost-effectiveness results for the generic cancer screening 
programme in base case 1 (Population: England and Wales 2015) 
   
 
 
  
Population in screening age range                                -   24,455,078
Persons invited to attend screening                                -   6,325,952
Persons completing screening                                -   3,479,274
Unclear results                                -   337,490
Positive results                                -   69,585
False positive results                                -   55,933
True positive results (screen detected cancer cases)                                -   13,653
True positive results (screen detected cancer cases) of 5 included 
cancer types
                               -   6,144
Cancer cases presenting symptomatically of the 5 included cancer 
types (in screening years)
21,875 15,731 -6,144
Cost of conducting screening
The cost of inviting people to screening £0.0m £13.9m
The cost of conducting the screening test (excluding biomarker 
costs) £0.0m £23.7m
The cost of the biomarkers in the screening test £0.0m £240.7m
Cost of screening follow up
Cost of follow up for true positives included in diagnositc costs below
Cost of diagnositic follow up for false postives £0.0m £145.0m
Cost of unnescessary treatment (false positives) £0.0m £21.8m
GP self referals £0.0m £0.8m
Cost of cancer nurse specalist support to the screening programme
£0.0m £1.4m
Cancer diagnosis and treatment costs
Cost of diagnosing cancer (in screening years) £30.1m £30.1m £0.0m
Cancer treatment costs (in screening years) £296.5m £295.9m -£0.5m
Clinical benefits
Cancer deaths (in screening years) 10,493 10,090 -403
Cancer cases diagnosed in an early stage (in screening years) 74,552 75,893 1,341
Life years gained (in screening years) 303,371 312,804 9,433
Quality adjusted life years (QALYs)
QALY decrement due to false positives 0 0 0
QALYs accured by persons diagnosed with one of the 5 included 
cancer types (in screening years)
132,894 137,444 4,550
Summary
Total cost of conducting screening £0.0m £278.4m £278.4m
Total cost of follow up £0.0m £169.1m £169.1m
Cancer diagnosis and treatment costs £326.6m £326.0m -£0.5m
TOTAL COST £326.6m £773.5m £447.0m
TOTAL QALYs 132,894 137,444 4,550
Incremental cost-effectiveness ratio (ICER) (£/QALY) £98,246
Population
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Table 6.1b: The descriptive statistics and cost-effectiveness results for the generic cancer screening 
programme in base case 2 (Population: England and Wales 2015) 
 
  
No Screening Screening Incremental
Population in screening age range                                -   24,455,078
Persons invited to attend screening                                -   6,325,952
Persons completing screening                                -   4,643,249
Unclear results                                -   450,395
Positive results                                -   92,865
False positive results                                -   69,649
True positive results (screen detected cancer cases)                                -   23,216
True positive results (screen detected cancer cases) of 5 included 
cancer types
                               -   10,447
Cancer cases presenting symptomatically of the 5 included cancer 
types (in screening years)
21,875 11,428 -10,447
Cost of conducting screening
The cost of inviting people to screening £0.0m £14.2m
The cost of conducting the screening test (excluding biomarker 
costs) £0.0m £21.7m
The cost of the biomarkers in the screening test £0.0m £49.7m
Cost of screening follow up
Cost of follow up for true positives included in diagnositc costs below
Cost of diagnositic follow up for false postives £0.0m £20.9m
Cost of unnescessary treatment (false positives) £0.0m £29.1m
GP self referals £0.0m £1.0m
Cost of cancer nurse specalist support to the screening programme
£0.0m £1.9m
Cancer diagnosis and treatment costs
Cost of diagnosing cancer (in screening years) £30.1m £30.2m £0.1m
Cancer treatment costs (in screening years) £296.5m £295.1m -£1.3m
Clinical benefits
Cancer deaths (in screening years) 10,493 9,502 -991
Cancer cases diagnosed in an early stage (in screening years) 74,552 77,846 3,294
Life years gained (in screening years) 303,371 326,551 23,181
Quality adjusted life years (QALYs)
QALY decrement due to false positives 0 0 0
QALYs accured by persons diagnosed with one of the 5 included 
cancer types (in screening years)
132,894 144,074 11,180
Summary
Total cost of conducting screening £0.0m £85.6m £85.6m
Total cost of follow up £0.0m £52.9m £52.9m
Cancer diagnosis and treatment costs £326.6m £325.3m -£1.3m
TOTAL COST £326.6m £463.8m £137.3m
TOTAL QALYs 132,894 144,074 11,180
Incremental cost-effectiveness ratio (ICER) (£/QALY) £12,277
Population
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6.2 Scenario analyses 
A series of scenario analyses are presented to demonstrate the impact of model parameters on the 
cost-effectiveness of the screening programme, see Tables 6.2a and 6.2b. Several outcomes are 
presented which include: cancer deaths prevented, life years saved, QALY gain, change in cancer 
treatment costs, cost of screening and follow up, total costs and ICER.  
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Table 6.2a: Scenario analysis results 
  
Cost of 
screening 
and follow 
up
Cancer 
treatment 
costs
Total 
costs
Total 
QALYs 
gained
ICER 
(£/QALY)
Scenario analyses
Base Case 1 £447.5m -£0.5m £447.0m 4,550     £98,246
Scenario analyses: The stage shift associated with screening
Base case 1: the stage shift associated with screening = 31% £447.5m -£0.5m £447.0m 4,550     £98,246
The stage shift associated with screening = 57% £447.5m -£0.9m £446.6m 8,377     £53,304
The stage shift associated with screening = 90% £447.5m -£1.5m £446.0m 13,259  £33,638
Scenario analyses: Survival modelling 
Base case 1: The base case survival models are used £447.5m -£0.5m £447.0m 4,550     £98,246
Survival model scenario 1 £447.5m -£0.5m £447.0m 4,716     £94,782
Survival model scenario 2 £447.5m -£0.5m £447.0m 4,864     £91,888
Scenario analyses: The cost of generic cancer screening test
Base case 1: cost = £66 £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of the biomarkers in the generic cancer screening test = £10 £243.4m -£0.5m £242.9m 4,550     £53,394
The cost of the biomarkers in the generic cancer screening test = £49 £387.3m -£0.5m £386.8m 4,550     £85,019
The cost of the biomarkers in the generic cancer screening test = £99 £567.8m -£0.5m £567.3m 4,550     £124,699
Scenario analyses: The cost of delivering the generic cancer screening 
Base case 1: cost = £6 £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of delivering the generic cancer screening programme = £4 £439.5m -£0.5m £439.0m 4,550     £96,482
The cost of delivering the generic cancer screening programme = £9 £459.7m -£0.5m £459.2m 4,550     £100,926
Scenario analyses: The cost of following up false positives
Base case 1: cost = £3,124 £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of follow up for false positives is £361 £319.2m -£0.5m £318.7m 4,550     £70,056
Base case 1: cost of support = £1.4m £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of cancer nurse specalists and GPs are £0 £445.2m -£0.5m £444.7m 4,550     £97,751
Base case 1 £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of follow up for patients with false positive test results = 
£361, the cost of delivering the generic cancer screening programme = 
£4 the cost of the biomarkers = £10 no cancer nurse specalist support or 
GP self-referals
£104.9m -£0.5m £104.4m 4,550     £22,946
Base case 1: HRQoL decrement = 0 £447.5m -£0.5m £447.0m 4,550     £98,246
HRQoL decrement due to false positive results is -0.02 £447.5m -£0.5m £447.0m 3,431     £130,278
The HRQoL decrement due to patients receiving false positive results = 
-0.04
£447.5m -£0.5m £447.0m 2,404     £185,911
Scenario analyses: Screening age range and interval
Base case 1: age 40-75, interval = 4 years £447.5m -£0.5m £447.0m 4,550     £98,246
Age range is 45-75 and interval = 4years £378.8m -£0.6m £378.3m 4,376     £86,433
Age range is 50-75 and interval = 4 years £315.2m -£0.9m £314.3m 4,254     £73,891
Age range is 40-70 and interval = 4 years £412.2m -£0.1m £412.1m 3,823     £107,810
Age range is 40 - 75 and interval =  1 year £1,730.1m -£2.7m £1,727.4m 18,678  £92,487
Age range is 40 - 75 and interval = 3 years £582.7m -£0.8m £581.9m 6,019     £96,681
Age range is 40 - 75 and  interval = 5 years £372.4m -£0.9m £371.5m 4,523     £82,138
Age range is 40 - 75 and  interval = 10 years £191.6m -£0.4m £191.3m 2,163     £88,443
Age range is 50 - 70 and  interval = 4 years £287.0m -£0.6m £286.5m 3,715     £77,114
Age range is 50-75 and  interval = 1 year £1,173.0m -£3.6m £1,169.4m 16,425  £71,193
Base case 1:  unclear rate 9.7%, positivity rate 2% £447.5m -£0.5m £447.0m 4,550     £98,246
 unclear rate 5% £440.1m -£0.5m £439.6m 4,550     £96,628
 unclear rate  20% £463.6m -£0.5m £463.1m 4,550     £101,790
The positivity rate = 1%, false positivity rate = 0.8% £369.0m -£0.5m £368.5m 4,550     £80,989
The positivity rate = 4%, false positivity rate  = 3.2% £608.9m -£0.5m £608.4m 4,550     £133,726
Scenario analyses: The uptake  of the generic cancer screening 
Base case 1: uptake rate 55% £447.5m -£0.5m £447.0m 4,550     £98,246
Uptake rate = 45% £366.4m -£0.4m £366.0m 3,722     £98,313
Uptake rate = 73% £599.2m -£0.7m £598.6m 6,072     £98,581
Base case 1: false positive rate = 1.6% £447.5m -£0.5m £447.0m 4,550     £98,246
The false positive rate = 1.5%, positivity rate = 2% £437.7m -£0.5m £437.2m 4,550     £96,100
The false positive rate = 1.8%, positivity rate = 2% £465.0m -£0.5m £464.4m 4,550     £102,082
Scenario analyses: The cost of cancer treatment
Base case 1 £447.5m -£0.5m £447.0m 4,550     £98,246
The cost of treating early stage cancer is 25% higher and the cost of 
treating late stage cancer is 25% lower than the base case
£447.5m £6.2m £453.7m 4,550     £99,722
The cost of treating early stage cancer is 25% lower and the cost of 
treating late stage cancer is 25% higher than the base case £447.5m -£7.2m £440.3m 4,550     £96,770
Scenario analysis: Multiple costs are changed 
Scenario analysis: No cancer nurse specalist support
Scenario analyses: HRQoL decrement due to false positive screening results
Scenario analyses: The false positive rate of the generic cancer screening programme
Scenario analyses: The unclear and positivity rates associated with screening
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 6.2.1 Scenario analysis: Impact of generic cancer screen on stage distribution 
The scenario analysis results demonstrate that when the stage shift associated with screening is 
increased, the screening programme is more effective thus the ICER is lower. In base case 1, the 
stage shift is 31% and the ICER is £98,000per QALY gained. When the stage shift is 90%, the ICER falls 
to £37,000per QALY gained.  
 
6.2.2 Scenario analysis: Modelling life expectancy gains associated with stage shift 
The scenario analyses testing different survival modelling assumptions resulted in a slightly greater 
difference between life expectancy for early and late stage cancers than in base case 1. It is expected 
that when the survival models used in Scenario 1 and Scenario 2 are used, that the QALYs associated 
with early detection will increase. This is as those patients who are detected with an early stage 
cancer are expected to live longer than in base case 1. Conversely, those patients who are detected 
with a late stage cancer are expected to have a shorter life expectancy than in base case 1. 
Therefore, it is expected that the incremental gains in life expectancy due to the introduction of a 
new screening programme will be greater in these scenarios. This expectation was matched by an 
increase in the total QALYs and a fall in the ICER, as costs remained constant. The overall impact on 
the ICER is smaller than some of the other scenarios, in scenario 1 the ICER is £94,000per QALY 
gained and in scenario 2 the ICER is £91,000 per QALY gained. The ICER has fallen by £4,000per QALY 
gained from base case 1 in scenario 1 and £7,000per QALY gained from base case 1 in scenario 2.  
 
6.2.3 Scenario analysis: Screening costs 
The scenario analyses on the costs of screening demonstrate that as the costs increase, the total cost 
of the generic cancer screening programme also increases but the effectiveness is constant which 
results in a significant increase in ICER values. The ICER varies from £53, 000per QALY gained when 
the cost of the biomarkers are £10 to £125,000 per QALY gained when the cost of the biomarkers 
are £99. This suggests that the cost of the biomarkers will have a substantial impact upon the ICER. 
The ICER varies from £96,000per QALY gained when the cost of conducting the screening test is £4 
to £101,000per QALY gained when the cost of conducting the screening test is £9. This suggests that 
controlling the cost of conducting the test is important in controlling the cost of a new screening 
programme when the cost of following up of false positives falls from £3,124 to £361 the ICER falls 
to £70,000per QALY gained. Finally, when the cost of cancer nurse specialists and GPs are removed 
from the costs of screening the ICER falls by around £500 per QALY gained compared to base case 1. 
This is as the overall cost of the providing these services is £2.2m and this is very small compared to 
the overall screening costs of £447.0m This would suggest that thought needs to be given as to how 
people with positive results will be followed up in a generic cancer screening programme, as the 
overall cost of follow up will have a significant impact on the cost-effectiveness of the new screening 
programme.  
54 
 
When the cost of follow up for false positives, the cost of delivering the screening programme and 
the cost of the biomarkers are set to their lowest parameter values and the cancer nurse specialists 
and GPs are removed from the screening programme costs, the total cost of the screening 
programme is £350m lower than base case 1. Again there is no change in the effectiveness of the 
screening programme. The ICER in this scenario is £23,000per QALY gained, which is lower than 
when only one aspect of the screening programme costs is varied. This demonstrates that the cost of 
all aspects of the screening, not just the cost of the biomarkers in the generic cancer test, need to be 
minimised to increase the chance that the programme will be considered cost-effective.  
 
6.2.4 Scenario analysis: HRQoL decrement for false positives 
These scenario analyses show that for higher HRQoL decrements for false positives the QALY gain 
associated with screening is lower and hence the ICER increases. The ICER ranges from £186,000per 
QALY gained when the HRQoL decrement for false positives is -0.04 to £98,000 per QALY gained 
when there is no HRQoL decrement for false positives (base case 1). 
 
6.2.5 Scenario analysis: Screening age ranges and screening interval 
In this analysis the age ranges in which people are eligible for screening and the screening intervals 
have been varied. As the model used here does not represent the natural history of cancer disease 
the cumulative effect of several screening rounds cannot be estimated. Hence the optimal screening 
age range and interval cannot be established.  
However, these analyses provide useful information on the first year costs associated with running a 
screening programme in different age ranges and screening intervals. It can be seen that as the 
interval is decreased and as the age range of people who are screened is widened, the cost of 
running the screening programme increases. This expected as increasing the screening interval and 
widening the age range of the population been screened increases the number of people been 
screened every year. In these analyses the cost of the generic cancer screening programme ranges 
from £191.3m to £1,727.4m. 
 
6.2.6 Scenario analysis: Unclear rate, positivity rate and uptake 
For higher unclear rates, the cost of screening is higher but there is no effect on QALYs gained hence 
the screening programme is less cost-effective.  This is likely due to the limitations with the model 
structure, as without a more complicated model it is unknown how many individuals with an unclear 
result will have a cancer one year later.  As the positivity rate is increased, the costs of screening 
increase and the QALYs gained decrease. It is expected that the total QALYs will decrease as the false 
positivity rate in the model is increases with the positivity rate. Therefore, when the number of 
people who receive positive results increase, the number of people who receive false positives also 
increases. This increase in people who receive false positives drives the fall in QALYs due to the QALY 
decrement experienced by people who receive false positive results. Overall, as the positivity of the 
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screening programme increases, the programme is less likely to be cost-effective. When the 
positivity of the generic cancer screening programme is 1%, the ICER is £80,000per QALY gained and 
when the positivity of the generic cancer screening programme is 4%, the ICER is £133,000 per QALY 
gained. 
The false positive rate was also changed independently from the positivity rate. When the positivity 
was 2% and the false positive rate was 0.8%, the ICER was £96,000 per QALY gained. When the 
positivity was 2% and the false positive rate was 1.8%, the ICER was £102,000 per QALY gained. This 
would indicate that controlling the number of people who receive false positive screening test 
results will be an important determinant of the cost-effectiveness of the generic cancer screening 
programme.  
6.2.7  Scenario analysis: The cost of cancer treatment 
Changing the cost of cancer treatment overall had very little impact on the ICER. In the first scenario 
the cost of treating early stage cancer was 25% higher and the cost of treating late stage cancer was 
25% lower than base case 1. In the first scenario lead the total costs were £453.7m and the ICER was 
£100,000per QALY gained. In the second scenario the cost of treating early stage cancer was 25% 
lower and the cost of treating late stage cancer was 25% higher than base case 1. In this scenario, 
the total costs were £440.3m and the ICER was £97,000per QALY gained. The reason for the 
relatively small changes in the ICER is due to the relatively small changes in total cost. The total cost 
changed from base case 1 by +£6.7m in the first scenario and -£6.7m in the second scenario. These 
changes in total cost are just over 1% of base case 1 total cost, hence the relatively small differences 
in the ICERs.  
 
6.2.8 Scenario analysis: Summary of the one way scenario analyses 
In conclusion, the one way scenario analyses which reflect the costs of the screening programme 
(cost of the test, cost of conducting the test and the cost of follow up) and the clinical characteristics 
of the test (stage shift associated with screening, positivity and false positivity) have the largest 
impact on the ICER. Therefore the cost of the generic cancer screening programme should be 
considered whilst the generic cancer screening test is being developed as well as the clinical 
effectiveness of the test. Another parameter which has relatively large impacts on the ICER is the 
HRQoL decrement due to false positives. 
 
6.2.9 Two-way sensitivity analyses 
The two way sensitivity analyses show that when the impact of generic cancer screen on stage 
distribution is 90% and the cost of the biomarkers is £10, then the ICER is £18,248. Two other ICERs 
in the Two way sensitivity analyses are within the £20,000 to £30,000 per QALY gained threshold 
used by NICE when considering whether a technology is a cost-effective use of NHS resources(9). 
This confirms that the combined cost and effectiveness of the generic cancer screening test will be 
one of the key drivers of the cost-effectiveness of any generic cancer screening programme. 
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Therefore both of these factors should be considered when the generic cancer screening test is 
being developed. 
Table 6.2b: Two way scenario analysis on cost of screening test and impact of screening test of stage 
distribution 
 
6.2.10 Validation exercise 
The results of the validation exercise illustrate that the total QALYs associated with the ECDC are less 
than with the BCSP model because the treatment of precancerous conditions does not occur with 
the generic cancer screen. In the BCSP model 66% of QALYs gained are predicted to be associated 
with the treatment of precancerous conditions rather than earlier diagnosis. Hence the diagnosis of 
precancerous conditions is important for colorectal cancer. However, the same may not be the case 
for other cancer types and each cancer type will need to be considered individually.  The results of 
the validation exercise are in Table 6.2c.  
 
Table 6.2c: Comparison of ECDC economic model and ScHARR Bowel cancer screening model 
predictions for a cohort of 100,000 64 year old being offered one screen 
 ECDC 
economic 
model (five 
modelled 
cancers) 
ECDC economic 
model 
(restricted to 
colorectal 
cancer) 
ScHARR 
Bowel cancer 
screening 
model 
ScHARR Bowel cancer 
screening model 
(excluding detection of 
precancerous 
conditions) 
Reduction in 
symptomatically 
presenting cancers 
165 45 191 191 
Persons with a 
screen detected 
cancer  
165 45 67 67 
Persons with 
precancerous 
conditions detected 
0 0 356 0 
Total QALYs gained 974 95 511 176 
 
Incr. Costs= £243.0m Incr. Costs= £242.9m Incr. Costs= £242.5m Incr. Costs= £241.9m
Inc. QALYs= 3,683     Inc. QALYs= 4,550     Inc. QALYs= 8,377    Inc. QALYs= 13,259    
ICER= £65,984 ICER= £53,394 ICER= £28,946 ICER= £18,248
Incr. Costs= £386.9m Incr. Costs= £386.8m Incr. Costs= £386.4m Incr. Costs= £385.8m
Inc. QALYs= 3,683     Inc. QALYs= 4,550     Inc. QALYs= 8,377    Inc. QALYs= 13,259    
ICER= £105,050 ICER= £85,019 ICER= £46,121 ICER= £29,099
Incr. Costs= £446.0m Incr. Costs= £447.0m Incr. Costs= £446.6m Incr. Costs= £446.0m
Inc. QALYs= 13,259  Inc. QALYs= 4,550     Inc. QALYs= 8,377    Inc. QALYs= 13,259    
ICER= £33,638 ICER= £98,246 ICER= £53,304 ICER= £33,638
Incr. Costs= £567.4m Incr. Costs= £567.3m Incr. Costs= £566.9m Incr. Costs= £566.4m
Inc. QALYs= 3,683     Inc. QALYs= 4,550     Inc. QALYs= 8,377    Inc. QALYs= 13,259    
ICER= £154,066 ICER= £124,699 ICER= £67,671 ICER= £42,715
Cost of the 
biomarkers 
in the 
generic 
cancer 
screening 
test
£10
£49
£66
£99
25%
Impact of generic cancer screen on stage distribution: reduction in late stage incidence 
for those complying with screening
31% 57% 90%
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Therefore there are three reasons why the QALYs gained due to the earlier detection of colorectal 
cancer are lower in the ECDC economic model and BCSP model: 1) differences in the survival models, 
2) differences in the stage distribution of colorectal cancer incidence in the UK before and after the 
NHS bowel cancer screening programme and 3) differences in the model structures. 
 
The survival models used in the ECDC and BCSP models to predict the life expectancy of colorectal 
cancer patients used the same technique. The models use the same data source, however in the 
ECDC economic model bowel and colon cancers are treated separately as the combined information 
is not in the public domain. Any difference between expected colorectal cancer survival used in the 
two models is likely to be small.   
 
Table 6.2c shows the difference in stage distribution in the absence of the bowel cancer screening 
programme and in 2012 when the bowel cancer programme was running (but not fully rolled out up 
to age 74).  This has important implications when modelling the ECDC proposed screening 
programme. The potential for shifting diagnoses to earlier stages is obviously greater in the absence 
of the Bowel cancer screening programme. This partly explains why a smaller QALY gain is seen for 
the ECDC compared with the BCSP. 
 
Table 3: The Stage distribution of colorectal cancer before and after the introduction of the NHS 
bowel cancer screening programme. 
 
 
It should be noted that these results also support the hypothesis that a simple model structure is not 
accurately capturing the full benefits of a new screening programme, as a simple cannot include any 
benefits due to the early treatment of precancerous conditions.  
 
6.2.11 Extrapolation of the model results to all cancer types 
The base cases and scenario analyses undertaken just incorporate QALY gains and treatment cost 
differences due to earlier diagnosis of the five included cancer types. The five included cancer types 
account for 45.1% of the incidence of all cancer types in the UK in 2011.  Intuitively, it would be 
expected that if all cancer types could be detected by this test then the QALY gains by cancer type 
would increase.   The cost of treating early stage cancer was lower than treating late stage cancer for 
most, but not all of the cancers included in the model.  The direction of effect due to including more 
cancer types in the model is unknown, as the treatment cost differences between late and early 
stage cancer may not be similar to the cancers currently included in the model. 
As life expectancy gain due to earlier diagnosis varies significantly by cancer type (ranging from 1.7 
years for non-small cell lung cancer and 8.7 years for ovarian cancer) the average QALY gain for the 
five modelled cancer types may differ significantly from the average QALY gain for all cancer types. 
Therefore the same fall in the ICER may not be achieved when all cancer types are accurately 
included in the economic model. Although this analysis is merely exploratory it does indicate that 
Dukes A Dukes B Dukes C Dukes D Dukes A and B Dukes C and  D
Stage distribution of bowel cancer based on 2004-6 
incidence rates (pre NHS bowel screening) 11% 25% 35% 29% 36% 64%
Stage distribution of bowel cancer based on 2012 
incidence rates (post NHS bowel screening) 13% 35% 35% 17% 48% 52%
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the potential for the generic cancer screening programme ICER to be significantly lower if the 
benefits of early diagnosis of all cancer types are included. 
7 Conclusions 
7.1 Key considerations for the cost-effectiveness of screening programme 
An economic model was developed to assess the economic headroom of introducing a new generic 
cancer screening programme which would detect multiple cancer types. The scope of the economic 
model was restricted to include five cancer types (bladder, breast, colorectal, lung and ovarian) for 
feasibility reasons. The effect of a stage shift due to a single round of generic cancer screening on 
the stage distribution of cancer incidence for the English and Welsh population in 2015 is modelled. 
The lifetime effect of earlier cancer detection on the stage distribution, life expectancy of cancer 
patients, total QALYs gained, cost of conducting the generic cancer screening programme, cost of 
diagnosing each cancer type and the cost of treating each cancer were calculated. All analyses took 
an NHS and personal social services perspective.  
In the base case analysis: one screening round was modelled, the screening effectiveness data was 
based on the stage shift from the breast cancer screening programme, and people aged 40 to 72 
were invited to be screened at four yearly intervals. Full details on all the parameters and 
assumptions used in the base case are given in Section 4. In base case 1, the ICER of a new generic 
cancer screening programme in addition to the existing UK type specific screening programmes 
compared to no generic cancer screening programme was around £96,770 per QALY gained. In base 
case 2, the ICER of a new generic cancer screening programme in addition to the existing UK type 
specific screening programmes compared to no generic cancer screening programme was around 
£12,000 per QALY gained. In base case 1, the model parameters were the average values in a range 
and in base case 2 the model parameters were generally the most favourable values from the 
parameter range. Several scenario analyses were undertaken on base case 1 which resulted in ICERs 
ranging from £18,248 per QALY gained to £185,911 per QALY gained. The parameters with the 
biggest impact on the ICER are total cost of screening (includes: biomarker costs, the costs of 
delivering screening and the cost of following up false positives), the stage shift associated with 
screening, the positivity and false positivity of the screening programme and the HRQoL decrement 
due to false positive results. All of these factors should be considered when designing screening 
programme. The ICER values estimated here only incorporate the benefits of earlier diagnosis for 5 
cancer types (45.1% of incidence) and an exploratory analysis indicates that the ICER could be 
significantly lower if the impact on all cancer types is included. 
Considering the normal NICE cost-effectiveness threshold (£20,000 to £30,000 per QALY gained) the 
screening programme may be cost-effective (9). As the generic cancer screening programme is 
predicted to result in a QALY gain, controlling the cost of all aspects of the screening programme, 
not just the cost of the generic cancer screening test, will be a key determinant of the cost-
effectiveness of the screening programme. 
It is intended that the generic cancer screening programme will detect most cancer types, however 
not all cancer types are included in the economic model. Hence the results presented here provide a 
lower bound for the likely QALY gain. Whether the estimates of total costs are an upper or lower 
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bound will depend on whether the cost of diagnosing and treating the other cancer types is cheaper 
in the earlier or later stages of the disease. If the cost of diagnosing and treating other cancer types 
is cheaper in the earlier stage of the disease, then total costs will be upper bounds. Conversely if the 
cost of diagnosing and treating other cancer types is more expensive in the earlier stages of the 
disease, then total costs will be lower bounds. 
7.2 Cost of cancer screening programmes 
The estimated annual cost of the generic cancer screening programme ranges between £104.4m and 
£1,727.4m. This is associated with considerable uncertainty as the cost of the biomarkers, the cost of 
follow up and the screening intervals have not yet been established. 
For comparative purposes the annual cost of the current NHS screening programmes is given in 
Table 7.2. The estimated annual cost of the type specific screening programmes in England is £348.3 
m. In the long term the need for the cervical cancer screening programme will decrease as younger 
cohorts receive vaccination. If a successful generic cancer screening programme can be developed 
then disinvestment in type specific cancer screening programmes may be considered. 
The cost of the current NHS screening programmes is given in Table 7.2 and they vary from £77.3m 
to £175m per year. The cost of the generic cancer screening programme varies from £104.4m to 
£1,727.4m. Whilst the range of costs for the generic cancer screening programme are higher than 
the cost of the current cancer type specific screening programmes, it should be kept in mind that the 
generic cancer screening programme is intended to be able to detect multiple cancer types. If the 
existing type specific programmes were to be replaced with the generic cancer screening 
programme, this would result in substantially lower incremental total costs than are presented in 
this report as £348.3 million could be saved. The current model cannot assess the health 
consequences of removing the existing screening programme, as it does not contain the prevalence 
of a symptomatic cancer (in the absence of all screening) therefore the impact on the ICER cannot be 
quantified. 
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Table 7.2: Comparison of costs from the generic cancer screen, type specific cancer screening programmes and the NHS health check 
 
Programme
Total cost of 
programme Source
Annual number of 
people invited Source
Annual number of 
people screened Source
Cost per 
invitee
Cost per 
person 
screened Cost per test Cost of followup
NHS breast cancer screening £96.0m
NHS breast cancer 
screening programme 
website* 
2,862,370
NHS breast cancer 
screening 
programme annual 
review 2012
2,100,799
NHS breast cancer 
screening programme 
annual review 2012
£33.54 £45.70
Mammography: £47.92  (NHS 
reference costs 2005/6 inflated 
to 2012/13 prices)
Biopsy : £304 NHS reference 
costs 2005/6 inflated to 
2012/13 prices
NHS bowel cancer screening £77.3m
NHS bowel cancer 
screening programme 
website* 
4,641,593
Calculated from 
the ECDC economic 
model
2,552,876
Calculated from the 
ECDC economic model
£16.65 £30.28
gFOBT test: £2.13  Whyte et al 
2011 inflated to 2012/13 prices
Colonoscopy: £222 to £596 
Whyte et al. 2011 inflated to 
2012/13 prices
NHS cervical cancer screening £175.0m
NHS cervical cancer 
screening programme 
website*
4,240,000
Health & Social 
Care Information 
Centre 2013
3,320,000
NHS cervical cancer 
screening programme 
annual review 2012
£41.27 £52.71
LBC: £29.32 Karnon et al 2004 
inflated to 2012/13 prices
Coloposcopy and conisation: 
£238 (range £174 to £302) 
Karnon et al 2004 inflated to 
2012/13 prices
Total cost of 3 cancer 
screening programmes
£348.3m total of above
NHS Health checks £373.5m
Department of Health 
2008
3,045,628
Department of 
Health,NHS health 
check - data for 
England from July 
2015
1,352,020
Department of 
Health,NHS health 
check - data for 
England from July 2015
£123 £276
Test costs range from £0.79 to 
£13.84 per test used. 
Department of Health 2008 
inflated to 2012/13 prices
Unclear
Generic cancer screening 
programme- base case 1
£447.0m ECDC economic model 6,325,952 3,479,274 £70.66 £128 £73.94 £3,124
Generic cancer screening 
programme- base case 2
£137.3m ECDC economic model 6,325,952 4,643,249 £21.70 £29.56 £16.18 £361
* date not provided and it is unclear if the costs include follow up costs
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7.3 The cost-effectiveness of other cancer screening programmes 
Incremental cost-effectiveness ratios (ICERs) are used by NICE to determine whether new 
technologies should be funded on the NHS. Generally technologies are considered if the ICER is less 
than £20,000-£30,000 per QALY gained (9). A recent study suggests that the threshold should in fact 
be £13,000 per QALY gained.(73). The ICERs associated with screening programmes are often 
considerably below this threshold, see Table 7.3. 
Table 7.3: A summary of estimated cost-effectiveness of screening programmes 
Screening 
Programme 
Setting Year Methods Results Source 
Breast screening 
programme 
UK NHS 1986 Cost-
effectiveness 
analysis 
£3,309 per 
QALY gained 
Forrest 
report (74) 
Breast Screening 
programme 
UK NHS 1993 Cost-
effectiveness 
analysis  
£1,800 per life 
year gained 
Van Ineveld 
et al. (75) 
Breast screening 
programme 
UK NHS 2013 Cost-
effectiveness 
analysis 
£20,800 per 
QALY gained 
Pharoah et 
al. (76) 
Bowel screening 
programme 
UK NHS 2012 Cost-
effectiveness 
analysis 
Screening 
dominates no 
screening 
Whyte et 
al.(10) 
Bowel screening 
programme 
US third party 
payer 
2002 Systematic 
review of cost-
effectiveness 
analyses 
$10,000 to 
$25,000 per 
life year 
gained 
Pignone et 
al. (77) 
Cervical 
screening 
programme 
UK NHS 2004 Cost-
effectiveness 
analysis 
New method 
dominated the 
old  method 
Karnon et al. 
(78) 
Cervical 
screening 
programme 
UK NHS 2004 Cost-
effectiveness 
analysis 
£4588 per life 
year gained 
Sherlaw-
Johnson et 
al. (79) 
 
The highest ICER associated with an existing screening programme is £20,800 per QALY gained, see 
Table 7.3. The lowest ICER of the generic cancer screening programme is about £12,000per QALY 
gained. This would suggest that it is plausible that the generic cancer screening programme may be 
considered cost-effective by UK decision makers. Whether or not the generic cancer screening test is 
considered to be cost-effective will depend on many variables which are outlined in Section 6.2. 
7.4 The criteria for the implementation of a new screening programme 
The National Screening Committee has a list of criteria which must be satisfied by a potential new 
screening programme. The full list of criteria is included in the Appendix. (80)  One of the criteria is 
the opportunity cost of a new screening programme, which can be assessed using a cost-
effectiveness analysis.  However,   the natural history of the disease must be adequately understood 
for a new screening programme to be approved. At this stage, it is unclear whether or not all 
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included cancers would meet these criteria. It is also worth noting that evidence from a high quality 
randomised controlled trial on the impact of the new screening programme mortality or morbidity 
must also be available. Therefore a full randomised controlled trial would be necessary after work 
package three if a generic cancer screening test is to be implemented as part of a screening 
programme in the UK. 
7.5 Limitations: Areas where further data is required 
This study has identified several areas where additional data is required for the economic model. 
These areas are the cost of diagnosing, treating and following up cancer; the clinical characteristics 
of the generic cancer screening test; and the screening pathways. As was discussed in detail in 
Section4, these parameters were a significant limitation for the economic modelling.  It was not 
feasible to develop a natural history model for each included cancer type in the economic modelling 
in the time frames of this project.  However the data discovered in this project suggests that 
developing these models also be subject to data limitations. It is expected that more information on 
the clinical characteristics of the generic cancer screening test and the screening pathways will be 
generated by future ECDC work packages. It should also be noted that more recent cancer incidence 
and survival data may be available at a later date, where available this data will be included in the 
economic model. This research has highlighted both the areas where data is most sparse/uncertain 
and the model parameters which are most important in reducing uncertainty in cost-effectiveness 
estimates. 
7.6 Limitations: modelling approach 
7.6.1 The model scope 
The economic modelling is restricted to five cancer types however it is the intention that the generic 
cancer screening test will cover numerous cancer types. Therefore the benefits (QALY gains) of 
detecting other cancer types (outside the five modelled) are not accounted for. Similarly the cost 
differences associated with diagnosing other cancer types are not included. 
If the missing cancers were to be included it would be expected that the screening programme 
would yield more benefits, as more cases of cancer would be detected in an earlier stage. This would 
result in patients with cancer living longer, increasing the QALY gains from introducing the generic 
cancer screening programme. 
The net effect of the inclusion of other cancer types is likely to be a decrease in total costs, as this is 
observed on average for the five currently included cancer types. However for breast and small cell 
lung cancer the cost of diagnosing and treating patients in a later stage is less than the cost of 
treating and diagnosing patients in an earlier stage. If the cost of diagnosis and treatment for the 
other cancer types are similar to breast and small cell lung cancer (i.e. more expensive in earlier 
stages) then the total costs may increase. This would lead to the current estimates of ICER being a 
lower bound. Conversely, if the cost of diagnosis and treatment is lower in earlier stages than the 
later stages for other cancer types then the incremental total costs will decrease. This will lead to the 
ICER’s presented in the results being upper bounds. On average for the five included cancer types, 
the costs are lower in the earlier disease stages than the later disease stages. This would indicate 
that this is likely to be the case for other cancer types, hence the ICERs are likely to be upper bounds.  
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Inclusion of other cancer types in the model could also result in higher costs of follow up for false 
positives (due to potentially more complicated follow up pathways) than have been included in this 
model so this should also be considered. 
Future research will expand this analysis to include more cancer types to obtain a more accurate 
estimate of the ICER. The five cancers included in this analysis comprise 45.1% of all cancer 
incidence. Expanding the analysis to the 11 most common cancers could cover 75% of cancer 
incidence. 
7.6.2 Overdiagnosis 
The economic model does not include overdiagnosis. Therefore the estimates of total cost were 
lower bounds, as the cost of treating overdiagnosed cases has not been included. The QALYs are 
upper bounds, as any HRQoL decrements for someone getting cancer who would not have 
presented symptomatically within their remaining lifetime is also not included. As total costs are 
likely to be higher when overdiagnosis is included and the total QALYs are likely to be lower, the 
ICERs are likely to be higher than those found here when overdiagnosis is included. 
 
7.6.3 Survival improvements due to screening 
Basing the improvements in survival between the screening and non-screening model arms on shifts 
in the stage distribution will not include any survival differences that may occur between screen 
detected cancers and a non-screen detected cancers with the same stage at diagnosis. Evidence for 
this effect exists in one trial of ovarian cancer screening in which there were statistically significant 
survival differences in the trial arms, but there was no statistically significant difference in the stage 
distributions.(81) 
 
7.6.4 Model structure 
Due to an absence of data on the test characteristics of the generic cancer screen a simple approach 
to modelling was taken here (without cancer natural history models). This approach was appropriate 
given the level of data available however it is associated with limitations which we describe here: 
Pre-cancerous conditions 
It is unknown if the generic cancer screen will result in the detection of a significant number of 
precancerous conditions. Treatment of precancerous conditions can prevent cases of cancer and 
thus result in QALY gains. Without a natural history model it is not possible to estimate the number 
of pre-cancerous conditions in a population or the number detected by a screening test. If detected, 
pre-cancerous conditions can be treated, although the benefits/disbenefits associated with treating 
some precancerous conditions (e.g. ductal carcinoma in situ for breast cancer) are unclear. Hence 
the possible benefits/disbenefits associated with treating precancerous conditions are not included 
within the economic model results. 
Screen detection of undiagnosed (primarily asymptomatic) cancers 
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The economic model is restricted to five cancer types (for reasons of feasibility) which account for 
45% of cancer incidence. Hence the model predictions do not describe the likely cost-effectiveness in 
relation to all cancer types. In addition the model is assumed to result in a stage shift in current 
cancer incidence but may also result in the diagnosis of cases of cancer which would not present 
symptomatically (likely asymptomatic cancer cases). This would only be possible for cases of cancer 
which remain undiagnosed for over 1 year hence this limitation is not expected to have a significant 
impact on model results. 
7.6.5 Stage shift  
The stage shift was calculated using a definition of Stage I and II cancers as early stage cancers and 
Stage III and IV cancers as late stage cancers for all included cancer types.  However, after a new 
generic cancer screening test could stage shift all individuals to Stage I from Stages II to IV.  The exact 
mechanism of a stage shift due to a new test would have to be determined based upon the clinical 
evidence developed during the creation of such a test.  However, the net effect of using this 
definition of the stage shift distribution remains unknown.  This is because, more QALYs would be 
achieved by detecting people at Stage I rather than Stage II.  However the number of people who 
would experience a Stage shift remains unknown.  If sufficiently less people are detected at an early 
stage using this definition, then the overall QALY gains could be smaller than a test that shifts people 
with Stage III or IV cancer to Stage I or II.  
7.6.6 Reassurance from a negative generic cancer screening test result 
It was believed by some members of the ECDC that it was possible that a screening programme 
would reassure people that they did not have cancer leading to 1) fewer people without cancer 
seeking symptomatic diagnosis and 2) people with false positive results potentially been diagnosed 
at a later stage than in the absence of screening.  These effects were not included in the model as: 1) 
there was limited evidence for these effects in the existing type specific programmes and 2) these 
effects had not been considered in cost-effectiveness model to reappraise the NHS bowel screening 
programme for the national screening committee.(10)  
Figure 7.6a: Cancer types and incidence included within the economic modelling  
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Reduced cancer prevalence at subsequent screening rounds 
Screening may result in the detection of cancers that would have presented symptomatically in 
years after the screening round has taken place i.e. a screening round will impact on the future 
incidence and prevalence of cancer. Without a natural history model this future change in cancer 
incidence/prevalence cannot be predicted hence the economic model cannot predict the cost-
effectiveness of more than one screening round. Hence the optimal screening interval and age 
ranges cannot be determined by the model developed here. 
7.7 Recommendations for future research 
The study has highlighted that further research is required to generate data to enable a robust 
economic analysis of a generic cancer screening programme. The three key areas for further 
research are: the lifetime cost of treating cancer by stage at diagnosis, the natural history of each 
cancer type and the QALY gains associated with earlier cancer detection.  These research areas 
should be prioritised, as this information is necessary for a robust economic assessment of any early 
cancer detection strategy, not just the ECDC workpackages.  
The lifetime cancer treatment costs were found to be poorly understood.  A recent research study 
attempted to address this gap.(16) The study is useful, however it had some limitations 1) costing 
was restricted to four cancer types, 2) the pathways were based on national guidelines and expert 
opinion so may not reflect actual use and 3) some parts of the pathway were implausible to ECDC 
experts.  Research should be conducted to establish the lifetime treatment costs by stage at 
diagnosis and cancer type.  Two study designs are possible to calculate the lifetime cost: 1) using 
observational data on the actual pathways which patients follow or 2) using recommended 
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pathways from NICE guidelines and expert opinion.  There may be value in comparing costing 
obtained using both methods. As treatment pathways for cancer will continue to change, a research 
programme involving regular updating of the costs (e.g. every five years) is suggested 
The natural history of each cancer type detected by a generic screening programme needs to be 
understood in order to adequately represent the benefits of screening within a model.  Natural 
history parameters include: the rate at which precancerous conditions develop; the rate of 
progression between the different precancerous and cancerous stages of the disease, and an 
understanding of symptomatic presentation rates.  An understanding of the natural history of the 
disease is also one of the criteria that the National Screening Committee uses to approve or reject 
new screening programmes.  Further research by experts in the field of cancer into the natural 
history of cancer types which would not have previously been considered for detection in a cancer 
screening programme is recommended.  
QALY gains associated with earlier detection were calculated in this study using published incidence 
and survival data.  The available data was adequate however; it is essential that up to date incidence 
and survival data for all cancer types is regularly published.  This will enable accurate estimation of 
QALY gains in health economic modelling which incorporate improvements in survival over time due 
to the introduction of new treatments and technologies. 
7.8 The ECDC planned research programme  
The report details a draft economic model which was constructed as part of the ECDC WP2. A case 
control study which will result in a combination of biomarkers being identified for the screening test 
(WP3) and a screening trial (WP4) are planned. 
 
WP3 
The existing draft model will be refined further.  The economic modelling will inform decisions 
regarding the screening programme to be trialled in WP4. This will include: The screening age range 
and interval; the range of acceptable costs for the screening test; the importance of parameters such 
as false positive rate, the unclear rate, the cost of following up false positives etc. on the cost-
effectiveness of the programme. 
 
Alongside case control study: 
• Seek more robust data on treatment costs by stage: Data obtained in WP2 however data 
quality is poor. In WP3 we will look into obtaining better data e.g. from NHS Leeds (Michael 
Messenger). 
• the follow up pathways costings will be finalised 
• Cancer incidence and survival data used in the model will be updated with newer data when 
available. 
 
Following results of case control study: 
• The biomarkers to be included will be identified and the cost estimates can be refined 
further. 
• Estimates of test characteristics from the case control study will be incorporated into the 
economic model.  
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• Detection of pre-cancerous conditions. WP2 assumed that the test would be designed so 
that pre-cancerous conditions are not detected. If the test developed in the case control 
study identifies pre-cancerous conditions then their prevalence and cost and benefits of 
treating them will be incorporated into the modelling. 
• Mode of delivering test will be finalised: 1) sample taken by nurse or phlebotomist and 2) 
within or outside health checks. 
 
 
WP4 
The results of the trial can be used to update the economic model. In particular the trial will provide 
data on the following: 
• Screening uptake 
• Stage shift due to screening 
• Positivity rate in the general population 
• Cost of running the screening programme 
• Will capture any false reassurance effects (later diagnosis) in the results 
The following data could be collected in WP4 and would inform the health economics: 
• HRQoL decrement associated with false positive result 
• HRQoL of patients with different cancers by stage at diagnosis 
• Data on the treatment of false positives  
• The treatment costs of cancer types by stage at diagnosis in the last screening round 
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 1 Appendix: Expert Input  
This appendix addresses the expert input into the economic model.  
1.1 Expert input received from members of the Early Cancer Detection Consortium 
Robert Dann (Strategic Marketing Leader, GE Healthcare) suggested that instead of having a CT scan, 
people with a positive generic cancer screening test would be referred to the suspected cancer site. 
This approach was adopted in the model. Robert Dann also suggested that people with multiple 
suspected cancer sites would be treated as having an unclear test result. As the model did not have a 
complex natural history component, this advice was not incorporated into the analyses but will be 
considered in future work.  
Professor Frank Sullivan (Professor, Department of Family & Community Medicine, University of 
Toronto; Honorary Professor, Population health sciences, University of Dundee and academic 
general practioner) advised that patients in a new screening programme would consult with their 
GP. As such, additional training should be provided to GPs.  
Sian Taylor Phillips (NIHR postdoctoral Research Fellow, University of Warwick) advised that:  
• using the NHS health checks as the basis of a new cancer screening programme could be 
problematic. 
•  screening older people could increase the harms from over treatment  
• All results which we don’t know are clinically meaningful (unclears) should be suppressed as 
far as possible 
• The new test may detect pre-cancerous conditions which we don’t know exist yet.  
• GPs should be avoided in the screening pathways as far as possible, as this may lead to 
increases in off-protocol referrals and they are relatively expensive. 
• Counselling on negative results would be provided by a cancer care nurse. This care should 
be modelled on data from the NHS breast cancer screening programme.  
This advice informed the age ranges for the new screening programme, the screening interval, the 
method of test delivery and how unclear results were treated in the screening pathways 
Professor Ian Cree (Yvonne Carter Professor of Pathology, Warwick Medical School. Hon. Consultant 
Pathologist, University Hospitals Coventry and Warwickshire NHS Trust. Senior Clinical Advisor, NIHR 
Evaluation Trials and Studies Coordinating Centre, EME programme) advised that: 
• That the screening interval of the new screening programme would be somewhere between 
1 and 5 years 
• That unclear test results would be followed up with a further blood test within a year.  
• Screening test cost may be £10 per case. 
• The cost of several tumour markers 
• The NHS health checks will likely take a large enough blood sample to be used in the generic 
cancer screening programme 
• Screening would not be delivered by GPs. Screening would be delivered by nurses or 
phlebotomists 
• Screening would take no more than five minutes 
• Cost of taking the blood sample would be £25 outside of the NHS health checks and £2 
inside the NHS health checks. This advice was based upon the SPUTNIK trial.  
• The lifetime cost of late stage breast cancer should be in the region of £23,500.  
Ian Cree also provided the current cost of several known biomarkers.  
James Covington provided information on the cost of testing volatile organic compounds.  
1.2 Lung cancer expert advice 
Lesley Bishop (Consultant Respiratory Physician, Portsmouth NHS) and Emma Helm (Consultant 
radiologist, University Hospitals Coventry and Warwickshire) provided clinical input to the cost, 
health related quality of life, incidence and survival of lung cancer patients.  There were clinical 
concerns about the appropriateness of the operations used in the Incisive Health report (1). The 
clinical belief was that more patients would receive CT scans, spirometry and chemotherapy than 
was the case in the Incisive Health report. Another concern with the Incisive Health report was that 
the surgery figures for people with stage 3 lung cancer were too low.  
There were concerns that the one year net survival statistics were too low, another source on the 
survival of lung cancer patients was found (2). This source presented the survival of patients in 20 
countries. It was not clear if the UK was included in this data set. As such, these survival statistics 
were not used in the model 
It was also established that there was not a 100% specific test for the diagnosis of lung cancer. 
However, a CT scan would be close to achieving 100% specificity.  
Judith Drought (University Hospitals of Coventry and Warwickshire), Jo Hamiliton (University 
Hospitals of Coventry and Warwickshire), Anoop Chauhan (Portsmouth Hospitals Trust) and Mya Gui 
(Portsmouth Hospitals Trust) were approached but did not respond.  
1.3 Colorectal cancer expert advice 
Ramesh P Arasaradnam (Honorary Associate Professor of Medicine and Consultant 
Gastroenterologist, University of Warwick and University Hospitals Coventry and Warwickshire) and 
Steve Smith (Director Midlands & NW bowel cancer screening hub) provided clinical input to the 
cost, health related quality of life, incidence and survival of colorectal cancer patients.  No issues 
were raised with the data obtained.  
Peter Correa (University Hospitals of Coventry and Warwickshire), Chris Harmston (University 
Hospitals of Coventry and Warwickshire),were also approached but did not respond.  
1.4 Breast cancer expert advice 
Dr Tim Gulliford (Consultant, Oncologist, Spire Portsmouth Hospital) responded, but did not feel 
qualified to answer the questions.  
Constantinos Yiangou (Portsmouth Hospitals Trust), Martin Wise (Portsmouth Hospitals Trust), 
Ramsey Cutress (Associate professor in Breast Surgery, University of Southampton) were also 
approached.  
1.5 Ovarian cancer expert advice 
Francis Gardener (Portsmouth Hospitals Trust), Christopher Poole (Professor of Oncology, Warwick 
University), Dirk Brinkman (Portsmouth Hospitals Trust), Alison Franks (University Hospitals of 
Coventry and Warwickshire) were approached for clinical input on ovarian cancer, but did not 
respond.  
1.6  Bladder Cancer expert advice 
Dr Siriram Rajapolan (University Hospitals of Coventry and Warwickshire), Mr Donald Macdonald 
(University Hospitals of Coventry and Warwickshire) and Mr Kieran Jefferson (University Hospitals of 
Coventry and Warwickshire) provided input into the costs of treating people with bladder cancer.  
However, even with their substantial input it was not possible to develop a robust model to estimate 
the cost of treating bladder cancer by stage at diagnosis.  
  
2 Appendix: HRQoL literature searches and results 
All searches were conducted using the ScHARR health utilities database. This database is an online 
resource that contains bibliographic details on studies reporting health state utility values.(3) The 
search terms used only included the name of the cancer. For example the search for bladder cancer 
used the search terms bladder and cancer.  No restrictions were placed on the instrument used to 
obtain the HSUV, the country of origin or the treatments used.  
Studies were deemed to be potentially relevant if they included UK patients, had an appropriate 
number of patients to draw inferences and if they considered all patients with a stage of disease 
(e.g. metastatic cancer). The searches were conducted in November 2014.    28 studies were found 
(this figure includes duplicates in the searches conducted for the different cancer types. One study 
was included after the exclusion criteria were applied.  The results of the searches and the reason 
why the studies were or were not included are given in Tables 2.1 – 2.4 below. The results for 
bladder cancer are not presented, as these searches returned no results. 
Table 2.1:  The results of the health state utility value search for breast cancer 
Author Title Journal Year Accept
/ 
reject 
Why? 
Bastani,P.,  
Kiadaliri,A.A. 
Cost-utility analysis of 
adjuvant therapies for 
breast cancer in Iran 
International 
Journal of 
Technology 
Assessment In 
Health Care 
2012 Reject  No British 
patients  
Lee,C.F.,  Ng,R.,  
Luo,N.,  Wong,N.S.,  
Yap,Y.S.,  Lo,S.K.,  
Chia,W.K.,  Yee,A.,  
Krishna,L.,  
Wong,C.,  Goh,C.,  
Cheung,Y.B. 
The English and Chinese 
versions of the five-level 
EuroQoL Group's five-
dimension questionnaire 
(EQ-5D) were valid and 
reliable and provided 
comparable scores in Asian 
breast cancer patients 
Supportive Care In 
Cancer 
2013 Reject  No British 
patients 
Moro-
Valdezate,D.,  
Peiro,S.,  Buch-
Villa,E.,  Caballero-
Garate,A.,  
Morales-
Monsalve,M.D.,  
Martinez-Agullo,A.,  
Checa-Ayet,F.,  
Ortega-Serrano,J. 
Evolution of Health-Related 
Quality of Life in Breast 
Cancer Patients during the 
First Year of Follow-Up 
Journal of Breast 
Cancer 
2013 Reject  No British 
patients 
Moro-
Valdezate,D.,  
Factors associated with 
health-related quality of 
Breast Cancer 2012 Reject  No British 
patients 
Buch-Villa,E.,  
Peiro,S.,  Morales-
Monsalve,M.D.,  
Caballero-
Garate,A.,  
Martinez-Agullo,A.,  
Checa-Ayet,F.,  
Ortega-Serrano,J. 
life in a cohort of Spanish 
breast cancer patients 
Postma,E.L.,  
Koffijberg,H.,  
Verkooijen,H.M.,  
Witkamp,A.J.,  van 
den Bosch,M.A.,  
van,Hillegersberg 
R. 
Cost-Effectiveness of 
Radioguided Occult Lesion 
Localization (ROLL) Versus 
Wire-Guided Localization 
(WGL) in Breast Conserving 
Surgery for Nonpalpable 
Breast Cancer: Results 
from a Randomized 
Controlled Multicenter 
Trial 
Annals of Surgical 
Oncology 
2013 Reject  No British 
patients 
Teckle,P.,  
Peacock,S.,  
McTaggart-
Cowan,H.,  van der 
Hoek,K.,  Chia,S.,  
Melosky,B.,  
Gelmon,K. 
The ability of cancer-
specific and generic 
preference-based 
instruments to 
discriminate across clinical 
and self-reported 
measures of cancer 
severities 
Health and Quality 
of Life Outcomes 
2011 Reject  No British 
patients 
 
  
 Table 2.2: The results of the health state utility value search for colorectal cancer 
Author Title Journal Year Accept
/ 
reject 
Why? 
Farkkila,N.,  Sintonen,H.,  
Saarto,T.,  Jarvinen,H.,  
Hanninen,J.,  Taari,K.,  
Roine,R.P. 
Health-related quality 
of life in colorectal 
cancer 
Colorectal 
Disease 
2013 No No British 
patients. 
Kim,S.H.,  Hwang,J.S.,  
Kim,T.W.,  Hong,Y.S.,  
Jo,M.W. 
Validity and reliability 
of the EQ-5D for cancer 
patients in Korea 
Supportive 
Care In 
Cancer 
2012 No No British 
patients 
Schwandner,O. Sacral neuromodulation 
for fecal incontinence 
and "low anterior 
resection syndrome" 
following neoadjuvant 
therapy for rectal 
cancer 
Internationa
l Journal of 
Colorectal 
Disease 
2013 No Only offered 
to a small 
subgroup of 
UK patients 
Teckle,P.,  Peacock,S.,  
McTaggart-Cowan,H.,  
van der Hoek,K.,  Chia,S.,  
Melosky,B.,  Gelmon,K. 
The ability of cancer-
specific and generic 
preference-based 
instruments to 
discriminate across 
clinical and self-
reported measures of 
cancer severities 
Health and 
Quality of 
Life 
Outcomes 
2011 No  No British 
patients 
Bennett,L.,  Zhao,Z.,  
Barber,B.,  Zhou,X.,  
Peeters,M.,  Zhang,J.,  
Xu,F.,  Wiezorek,J.,  
Douillard,J.Y. 
Health-related quality 
of life in patients with 
metastatic colorectal 
cancer treated with 
panitumumab in first- 
or second-line 
treatment 
British 
Journal of 
Cancer 
2011 No  Treatment is 
not 
recommende
d in the UK 
 
  
Table 2.3: The results of the health state utility value search for lung cancer 
Author Title Source Year Reject/ 
Accept 
Reason 
Chouaid,C.,  Agulnik,J.,  
Goker,E.,  Herder,G.J.,  
Lester,J.F.,  Vansteenkiste,J.,  
Finnern,H.W.,  
Lungershausen,J.,  
Eriksson,J.,  Kim,K.,  
Mitchell,P.L. 
Health-Related Quality of 
Life and Utility in Patients 
with Advanced Non-
Small-Cell Lung Cancer: A 
Prospective Cross-
Sectional Patient Survey 
in a Real-World Setting 
Journal of 
Thoracic oncology 
2013 Accept  
Iyer,S.,  Taylor-Stokes,G.,  
Roughley,A. 
Symptom burden and 
quality of life in advanced 
non-small cell lung cancer 
patients in France and 
Germany 
Lung Cancer 2013 Reject No British 
patients 
Pickard,A.S.,  Ray,S.,  
Ganguli,A.,  Cella,D. 
Comparison of FACT- and 
EQ-5D-based utility 
scores in cancer 
Value in Health 2012 Reject No British 
patients 
Roulston,A.,  Bickerstaff,D.,  
Haynes,T.,  Rutherford,L.,  
Jones,L. 
A pilot study to evaluate 
an outpatient service for 
people with advanced 
lung cancer 
International 
Journal of 
Palliative Nursing 
2012 Reject Based on six 
patients 
Schuette,W.,  Tesch,H.,  
Buttner,H.,  Krause,T.,  
Soldatenkova,V.,  
Stoffregen,C. 
Second-line treatment of 
stage III/IV non-small-cell 
lung cancer (NSCLC) with 
pemetrexed in routine 
clinical practice: 
evaluation of 
performance status and 
health-related quality of 
life 
BMC Cancer 2012 Reject Not 
recommended 
for these 
patients in the 
UK 
Sharples,L.D.,  Jackson,C.,  
Wheaton,E.,  Griffith,G.,  
Annema,J.T.,  Dooms,C.,  
Tournoy,K.G.,  
Deschepper,E.,  Hughes,V.,  
Magee,L.,  Buxton,M.,  
Rintoul,R.C. 
Clinical effectiveness and 
cost-effectiveness of 
endobronchial and 
endoscopic ultrasound 
relative to surgical staging 
in potentially resectable 
lung cancer: results from 
the ASTER randomised 
Health 
Technology 
Assessment 
2012 Reject HSUV are 
higher than 
the HSUV 
used for 
patient’s 
without 
cancer 
controlled trial 
Teckle,P.,  Peacock,S.,  
McTaggart-Cowan,H.,  van 
der Hoek,K.,  Chia,S.,  
Melosky,B.,  Gelmon,K. 
The ability of cancer-
specific and generic 
preference-based 
instruments to 
discriminate across 
clinical and self-reported 
measures of cancer 
severities 
Health and 
Quality of Life 
Outcomes 
2011 Reject No British 
patients 
Vogl,M.,  Wenig,C.M.,  
Leidl,R.,  Pokhrel,S. 
Smoking and health-
related quality of life in 
English general 
population: implications 
for economic evaluations 
BMC Public 
Health 
2012 Reject HSUVs for 
smokers not 
lung cancer 
patients 
Barton,R.,  English,A.,  
Nabb,S.,  Rigby,A.S.,  
Johnson,M.J. 
A randomised trial of high 
vs low intensity training 
in breathing techniques 
for breathless patients 
with malignant lung 
disease: a feasibility study 
Lung Cancer 2010 Reject Based on 
eleven 
patients in 
each arm 
Basch,E.,  Jia,X.,  Heller,G.,  
Barz,A.,  Sit,L.,  Fruscione,M.,  
Appawu,M.,  Iasonos,A.,  
Atkinson,T.,  Goldfarb,S.,  
Culkin,A.,  Kris,M.G.,  
Schrag,D. 
Adverse symptom event 
reporting by patients vs 
clinicians: relationships 
with clinical outcomes 
Journal of the 
National Cancer 
Institute 
2009 Reject No British 
patients 
Grutters,J.P.,  Joore,M.A.,  
Wiegman,E.M.,  
Langendijk,J.A.,  
de,Ruysscher D.,  
Hochstenbag,M.,  
Botterweck,A.,  Lambin,P.,  
Pijls-Johannesma,M. 
Health-related quality of 
life in patients surviving 
non-small cell lung cancer 
Thorax 2010 Reject No UK 
patients 
 
  
Table 2.4: The results of the health state utility value search for ovarian cancer 
Author Title Journal Year Accept/ 
reject 
Why? 
Fisher, M., Gore,M. Cost-effectiveness of 
trabectedin plus pegylated 
liposomal doxorubicin for the 
treatment of women with 
relapsed platinum-sensitive 
ovarian cancer in the UK: 
analysis based on the final 
survival data of the OVA-301 
trial 
Value in health 2013 Reject Only 
considered 
patients with 
relapsed 
platinum 
sensitive 
ovarian cancer 
Duffy, S.W., Mackay, J., 
Thomas, S., Anderson, E., 
Chen, T.H., Ellis, I., Evans, G., 
Fielder, H., Fox, R., Gui, G., 
Macmillan, D., Moss, S., 
Rogers, C., Sibbering, M., 
Wallis, M., Warren, R., 
Watson, E., Whynes, D., 
Allgood, P., Caunt, J. 
Evaluation of 
mammographic surveillance 
services in women aged 40-
49 years with a moderate 
family history of breast 
cancer: a single-arm cohort 
study 
Health 
Technology 
Assessment 
2013 Reject  Considers the 
screening of 
breast cancer. 
Harding, V., Fenu, E., Medani, 
H ., Shaboodien, R., Ngan, S., 
Li, H.K., Burt, R., Diamantis, 
N.,  Tuthill,M., Blagden,S.,  
Gabra,H., Urch,C.E.,  
Moser,S.,  Agarwal,R. 
Safety, cost-effectiveness 
and feasibility of daycase 
paracentesis in the 
management of malignant 
ascites with a focus on 
ovarian cancer 
British 
Journal of 
Cancer 
2012 Reject Does not 
report HSUV 
or QALY values 
Haldar, K., Giaougiannis,P., 
Wilson,C., Crawford,R. 
Laparoscopic salpingo-
oophorectomy for ovarian 
ablation in women with 
hormone-sensitive breast 
cancer 
International 
Journal of 
Gynaecology & 
Obstetrics 
2011 Reject  Considers 
breast cancer 
patients 
Guest, J.F., Ruiz,F.J., Greener, 
M.J., Trotman,I.F. 
Palliative care treatment 
patterns and associated 
costs of healthcare resource 
use for specific advanced 
cancer patients in the UK 
European 
Journal of 
Cancer Care 
 
2006 Reject Costing study 
Snowsill, T., Huxley, N., 
Hoyle, M., Jones-Hughes, T., 
Coelho, H., Cooper, C., 
Frayling, I., Hyde, C. 
A systematic review and 
economic evaluation of 
diagnostic strategies for 
Lynch syndrome 
Health 
Technology 
Assessment 
2014 Reject Does not 
consider 
ovarian cancer  
  
3 Appendix: Cost data literature searches 
A search was conducted to obtain cost-effectiveness and costing studies which reported the cost of 
treating the different cancer types. The searches were conducted in MEDLINE and MEDLINE in 
PROCESS in October 2014. The National Institute for Health Research (NIHR) Health Technology 
Assessment (HTA) journal was searched for publications on the treatment of all five cancer 
typescancer. The search terms relating to each disease were obtained and adpated were necessary 
from single technology appriasla submissions to the National Institute for Health and Care 
Excellence. The SIGN economic filters (4) were used and search terms were added to remove any 
potentially irrelevant materials from the searches. Additional terms were added to limit the search 
to UK studies, studies in English and studies published in 2006 or later.  The search strategies are 
presented in Tables 3.1 – 3.6.  
Articles were considered to be potentially relevant if they were published after December 2005. Cost 
data prior to this date was not included in the search, as it was deemed that data prior to this date 
may not reflect current practice in the UK for the treatment of breast cancer. Studies were limited to 
UK studies as the cost of treating cancer in other countries was deemed to be irrelevant.  
Table 3.1: The adapted SIGN filter for economic studies  
1 Economics/ 
2 "costs and cost analysis"/ 
3 Cost-benefit analysis/ 
4 Cost control/ 
5 Cost savings/ 
6 Cost of illness/ 
7 Cost sharing/ 
8 "deductibles and coinsurance"/ 
9 Medical savings accounts/ 
10 Health care costs/ 
11 Direct service costs/ 
12 Drug costs/ 
13 Employer health costs/ 
14 Hospital costs/ 
15 Health expenditures/ 
16 Capital expenditures/ 
17 Value of life/ 
18 exp economics, hospital/ 
19 exp economics, medical/ 
20 Economics, nursing/ 
21 Economics, pharmaceutical/ 
22 exp "fees and charges"/ 
23 exp budgets/ 
24 (low adj cost).mp. 
25 (high adj cost).mp. 
26 (health?care adj cost$).mp. 
27 (fiscal or funding or financial or finance).tw. 
28 (cost adj estimate$).mp. 
29 (cost adj variable).mp. 
30 (unit adj cost$).mp. 
31 (economic$ or pharmacoeconomic$ or price$ or pricing).tw. 
32 or/1-31 
33 Cancer specific filter and 32 
34 limit 33 to yr="2006 -Current" 
35 (Britain or British or United Kingdom or UK or GB or Wales or Welsh or Scottish or Scots or 
Scotland or England or Northern Ireland).tw. 
36 great britain/ or england/ or scotland/ or wales/ or northern ireland/ 
37 35 or 37 
38 34 and 37 
39 limit 38 to English 
40 (cost or costs or cost-effectiveness or cost-effectiveness analysis or cost effectiveness or cost 
effectiveness or CEA or cost benefit or cost benefit analysis or cost-benefit or cost-benefit 
analysis or CBA).tw. 
41 39 and 40 
 
The cancer type specific search terms which were added to the search terms given in Table 3.1 are 
detailed in Table 3.2. 
  
Table 3.2: The search strategy used to identify economic and cost studies for patients with bladder 
cancer in the UK.  
Bladder Cancer ? 
Search Term Terms Searched 
1. Urinary Bladder Neoplasms/ 
2. (bladder adj3 (cancer$ or neoplasm$ or tumor$ or tumour$ or malignan$ or 
carcinoma$ or adenoma$ or adenocarcinoma$)).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
3. 1 or 2 
Breast Cancer Adapted from Eisai ltd. (5) 
Search Term Terms Searched 
1 breast cancer.mp. or exp Breast Neoplasms/ 
2 
(cancer or tumor* or tumour* or carcinoma* or sarcoma* or neoplasm* or 
adenocarcinoma* or polyp*).mp. 
3 (breast* or mamma*).mp. 
4 2 and 3 
5 1 or 4 
Colorectal Cancer Adapted from; Merck Serono Ltd., (6) 
Search Term Terms Searched 
1 
(((Colorect* or Colon* or Rect* or Duoden* or Ile* or Jejun* or Stomach* or 
gastri* or gastro* or GI) adj3 (cancer* or tumor* or tumour* or neoplasm* or 
malignan* or carcinom*)) or CRC).mp. or exp Colorectal Neoplasms/ 
Lung Cancer Adapted from; Hinde et al. (7) 
Search Term Terms searched 
1 exp Lung Neoplasms/ 
2 exp Carcinoma, Non-Small-Cell Lung/ 
3  exp Carcinoma, Small-Cell Lung/ 
4 (lung$ adj3 (canc$ or carcinoma$ or tumo?r$ or neoplasm$)).ti,ab. 
5  1 or 2 or 3 or 4 
Ovarian Cancer Source:  National Institute for Health and Care Excellence (8) 
Search Terms Terms Searched 
1 (ovar* adj4 (cancer* or tumo*r* or malignan* or oncolog* or carcinoma* or 
neoplas* or mass* or growth* or cyst*)).ti,ab. 
2  (adenexa* adj4 mass*).ti,ab. 
3 exp OVARY CANCER/ 
4 exp OVARIAN NEOPLASMS/ 
5  1 or 2 or 3 or 4 
 
 
 
The search for bladder cancer costing studies identified 3 articles.  
The search for breast cancer costing studies identified 108 articles.  
The search for colorectal cancer costing studies returned 106 articles.  
The search for lung cancer costing studies returned 58 studies. 
The search for ovarian cancer studies returned six articles. 
Studies were not considered relevant if they did not consider the cost of treating cancer after 
diagnosis 
  
4 Appendix: Cancer Incidence Data summary 
 
4.1 Bladder cancer 
The National Collaborating Centre for Cancer (NCC-C) draft clinical guidelines for the treatment and 
diagnosis of bladder cancer contain information on the incidence of bladder cancer by stage at 
diagnosis in England and Wales in 2012 (9). There was no information presented on the incidence of 
bladder cancer by stage and age in England or Wales. As the English data is based upon a larger 
sample size, this data will be used in the model. The NCC-C draft clinical guidelines present the 
incidence of bladder cancer by age and the incidence of bladder cancer by stage separately. The 
incidence of bladder cancer by stage in England in 2012 is presented in Table 4.1a. The incidence of 
bladder cancer by age in England is presented in Table 4.1b. 
Table 4.1a: The stage specific incidence of bladder cancer in England in 2012  
Stage Percentage of cancers in England 
Unknown 65.0% 
Stage I 11.9% 
Stage II 10.2% 
Stage III 2.1% 
Stage IV 10.5% 
Source; National Collaborating Centre for Cancer (9) 
 
Table 4.1b: The age standardized incidence rate of bladder cancer in the UK  
Age group Age standardised rate per 100,000 population in England in 2012 
 Men Women Both 
under 40 0.2 0.1 0.1 
40-49 3.2 1.5 2.4 
50-59 13.6 5.5 9.5 
60-69 48.1 14.4 31.3 
70-79 127.5 34.7 81.1 
80+ 236.6 66.7 151.6 
Source; National Collaborating Centre for Cancer (9) 
To use both data sources in the model it will be necessary to assume that age and stage specific 
incidence rates are independent. This means that the stage distribution of cancers will not change 
with patient’s age.  
4.2 Breast cancer  
The data on breast cancer incidence was obtained from multiple sources, as no source had the 
incidence by stage at diagnosis for different age groups. The stage distribution of breast cancer was 
obtained from Walters et al. (10) and the age distribution of breast cancer was obtained from Cancer 
Research UK (11).  A study by Woods et al. (12) reported the age and stage distributions of breast 
cancer incidence in the UK separately.  
4.2.1 Stage distribution 
Walters et al. (10) report the stage distribution but not the age distribution of breast cancer 
incidence in the UK for breast cancers diagnosed between 2000-07. It should be noted that cancer 
sites with a missing stage will be underreported in Table 4.2a, as all cancer registries in the UK with 
over 50% missing stage information (three English regional registries) were excluded from the 
analyses.  
 
Table 4.2a: The incidence of breast cancer by stage at diagnosis in the UK from 2000-7 
TNM Stage  Number Mean Age Percentage 
All patients 140,568 63   
Missing Stage 35,517 67.7  
Stage 1 44,135 60.6 42.0% 
Stage 2 47,738 61.2 45.4% 
Stage 3 8,663 63.3 8.2% 
Stage 4 4,515 67.6 4.3% 
Source; Walters et al. (10) 
 
A study by Woods et al. (12) compared the incidence by age and stage of breast cancer incidence 
over time from 1980 -2002.  Data was collected over this time period from the West Midlands 
cancer registry and in the period of 1990-94 for the whole of the UK. The age specific incidence rates 
by stage at diagnosis are presented in Figure 2 of the paper. 
 
 
4.2.2 Age distribution 
Cancer research UK present data on the age specific incidence rates breast cancer in females in the 
UK from 2009-11 (11). Table 4.2b shows a clear pattern in that incidence is increasing with age until 
age 70 to 74, were there is a decrease in the incidence rate. This is unsurprising as the age extension 
of breast cancer screening did not start until 2011. Screening stopped for the women in this cohort 
at age 70.  
  
Table 4.2b: The incidence of breast cancer by age in the UK from 2009-11 
Age Range Female Cases Rate per 100,000 female population 
0 to 04 0 0 
05 to 09 0 0 
10 to 14 1 0 
15 to 19 4 0.2 
20 to 24 34 1.6 
25 to 29 180 8.4 
30 to 34 537 26.5 
35 to 39 1331 61.9 
40 to 44 2899 123.3 
45 to 49 4844 209.2 
50 to 54 5608 277.3 
55 to 59 4982 272.8 
60 to 64 6805 354.9 
65 to 69 6089 399.7 
70 to 74 4188 323.2 
75 to 79 4228 382.7 
80 to 84 3639 414.5 
85+ 4187 447.4 
All Ages 49557 155.2 
Source; Cancer Research UK (11) 
Woods et al. (12)   present data on the three-year rolling average incidence rate for a primary 
invasive breast cancer in the West Midlands from 1980-2002. This data is presented in Figure 3 of 
Woods et al.(12). 
  
4.3 Colorectal cancer 
There were multiple sources on the incidence of colorectal cancer across different age groups and 
stage at diagnosis groups. The stage distribution of colorectal cancer was obtained from Maringe  et 
al.(13) and the age distribution of colorectal cancer was obtained from Cancer Research UK(11).  
Both of these data sources include data collected after the NHS bowel screening programme was 
introduced in England in 2006. Data on CRC cancer incidence prior to 2006 was obtained from 
Whyte et al.(b) (14).  
4.3.1 Stage distribution of colorectal cancer incidence  
Maringe et al. (13) report the stage distribution but not the age distribution of colorectal cancer 
incidence in the UK for colorectal cancers diagnosed from 2000-07. This data was used for the stage 
distribution of colorectal cancer as it based upon the same dataset that was used to estimate the 
one year net survival. It should be noted that cancer sites with a missing stage will be underreported 
in Table 4.3a, as all cancer registries in the UK with over 50% missing stage information (Wales and 
one English regional registry) were excluded from the analyses. This data only includes two out of 
seven years in which the NHS bowel screening programme was active. This is the most recent data 
known on the stage distribution of the incidence of colorectal cancer.    
 
Table 4.3a: The stage distribution of colorectal cancer incidence in the UK from 2000-07. 
Dukes' 
stage 
Rectal Colon Colorectal 
 Observed Mean 
age 
% Observed Mean 
age 
% Observed Mean 
age 
% 
All patients 67,399 70.4 0% 142,410 72.3 0.0% 209,809 71.7 0% 
Missing 
Stage 
20,630 73.3 30.6% 39,585 74.8 27.8% 60,215 74.3 28.7% 
Stage A 9,693 69.5 14.4% 9,644 71.2 6.8% 19,337 70.3 12.9% 
Stage B 13,355 70.1 19.8% 39,588 72.4 27.8% 52,943 71.8 35.4% 
Stage C 15,802 68.2 23.4% 36,037 70.7 25.3% 51,839 69.9 34.7% 
Stage D 7,919 68.9 11.7% 17,286 70.6 12.1% 25,205 70.1 16.8% 
Source; Maringe et al. (13) 
 
4.3.2 Age distribution of colorectal cancer incidence 
Data on the age profile of colorectal cancer incidence was obtained from Cancer Research UK 
statistics on the incidence of bowel cancer across age groups. This data was only available from 
2009-11, so it reflects the age distribution of colorectal cancer when all patients have been screened 
for colorectal cancer. This data is presented in Table 4.3b.   
  
Table 4.3b: The age distribution of colorectal cancer in the UK 2009-11 
Age Range Cases 
 
Rate per 100,000 population 
 
 Male Female Male Female 
0 to 04 0 0 0.00 0.00 
05 to 09 0 1 0.00 0.10 
10 to 14 6 6 0.30 0.30 
15 to 19 11 14 0.50 0.70 
20 to 24 22 28 1.00 1.30 
25 to 29 53 55 2.50 2.60 
30 to 34 96 79 4.70 3.90 
35 to 39 119 109 5.60 5.10 
40 to 44 257 263 11.20 11.20 
45 to 49 518 462 22.90 20.00 
50 to 54 923 730 46.50 36.10 
55 to 59 1,510 1052 84.80 57.60 
60 to 64 3,066 1895 166.00 98.80 
65 to 69 3,605 2245 252.20 147.40 
70 to 74 3,789 2505 327.70 193.30 
75 to 79 3,719 2842 415.70 257.20 
80 to 84 2,960 2760 490.50 314.40 
85+ 2,280 3119 518.10 333.30 
All Ages 22,934 18166 74.50 56.90 
Source; Cancer Research UK (15)  
 
To use the stage profile of colorectal cancer incidence and the age profile of colorectal cancer 
incidence in the model, it will be necessary to assume that age and stage specific incidence rates are 
independent. This means that the stage distribution of cancers will not change with patient’s age.  
 
4.3.3 Stage and age distribution of colorectal cancer incidence  
Whyte et al.(b) (14)  obtained the data on CRC cancer incidence from English cancer registry data for 
Oxford, Northern and Yorkshire and Eastern regions from 2004-06. This data shows the incidence of 
colorectal cancer across age groups prior to the implementation of the NHS bowel screening 
programme.  Table 4.3c shows that the rate of colorectal cancer incidence is generally increasing in 
age and that the most common stage that people will present is Dukes stage C.   
  
Table 4.3c: The incidence of colorectal cancer from 2004 - 06. 
 Incidence rates per 100,000 population 
Age Range Dukes stage A  Dukes stage B  Dukes stage C  Stage D  CRC (all stages) 
0-29 0.03 0.10 0.17 0.19 0.48 
30-34 0.20 0.50 1.02 0.77 2.48 
35-39 0.67 0.90 2.04 1.51 5.11 
40-44 0.87 1.45 3.25 3.11 8.68 
45-49 2.04 5.54 7.87 6.56 22.02 
50-54 4.11 8.51 14.92 12.60 40.15 
55-59 7.69 15.77 25.49 19.76 68.70 
60-64 13.32 26.35 39.78 31.19 110.65 
65-69 20.78 44.20 60.87 46.90 172.74 
70-74 29.73 67.14 84.04 63.47 244.38 
75-79 35.38 89.36 109.04 86.18 319.95 
80-84 33.30 96.01 129.00 106.64 364.96 
85+ 22.69 76.42 135.90 129.00 364.02 
Source; Whyte et al.(b) (14) 
In the model the data from Cancer Research UK and Maringe et al. will be used to model the 
incidence of colorectal cancer. This the data in both sources covers the period in which the NHS 
bowel screening programme was operating (2006 onwards).  
4.4 Lung cancer  
The data on Lung cancer incidence was obtained from multiple sources, as no source had the 
incidence by stage at diagnosis for different age groups. The stage distribution of Lung cancer was 
obtained from Walters  et al.(16),the proportion of Lung cancers which were NSCLC or SCLC was 
obtained from a the national lung cancer audit (17) and the age profile of lung cancer incidence was 
obtained from cancer research UK(18).  
4.4.1 Stage distribution 
Walters et al. (16) report the stage distribution but not the age distribution of Lung cancer incidence 
in the UK for Lung cancers diagnosed from 2000-07. This data was used for the stage distribution of 
Lung cancer as it based upon the same dataset that was used to estimate the one year net survival. 
It should be noted that cancer sites with a missing stage will be underreported in Table 4.4a, as all 
cancer registries in the UK with over 50% missing stage information (Wales and six English regional 
registries) were excluded from the analyses. 
  
Table 4.4a: The stage distribution of Lung cancer incidence in the UK from 2004-07(16). 
 Small cell lung cancer Non-small cell lung cancer 
TNM Stage  Number  Percentage Number  Percentage 
All patients 3,250  22,993  
Stage I 96 2.95% 2,376 10.3% 
Stage II 67 2.06% 1,165 5.1% 
Stage III 529 16.28% 4,718 20.5% 
Stage IV 1,309 40.28% 7,759 33.7% 
Missing Stage 1,249 38.43% 6,975 30.3% 
Source, Walters et al. (16) 
4.4.2 The age profile of non small cell and small cell lung cancer  
Data on the age profile of non small cell  and small cell lung cancer incidence was obtained from lung 
cancer cases that first presented in 2013 (19). When calculating these rates it was assumed that 
carcinoid lung cancers were counted as lung cancers, despite these cancers not been included in the 
economic model.Therefore the percentage of NSCLC and SCLC cases do not add to 100%.  
 
Table 4.4b: The percentage of lung cancers which are non small cell or small cell lung cancer from a 
subsection of cases in England, Scotland and Wales in 2013 
  Proportion of male 
cases NSCLC 
Proportion of female 
cases NSCLC 
Proportion of male 
cases SCLC 
Proportion of female 
cases of SCLC 
0-
54 
87.3% 81.6% 12.3% 17.5% 
55-
59 
84.7% 83.6% 15.2% 16.3% 
60-
64 
84.9% 83.2% 14.9% 16.6% 
65-
69 
87.6% 84.7% 12.3% 15.1% 
70-
74 
88.3% 86.6% 11.7% 13.2% 
75-
79 
90.1% 89.1% 9.9% 10.8% 
80-
84 
92.0% 91.7% 7.9% 8.2% 
85+ 95.5% 96.7% 4.5% 3.3% 
Tot
al 
89.2% 87.7% 10.8% 12.1% 
Source, National lung cancer audit(17); NSCLC, non-small cell lung cancer; SCLC, small cell lung 
cancer 
4.4.3 The age profile of lung cancer 
The age profile of lung cancer was obtained from cancer research UK(20). This information was 
presented seperately for males and females.  
Table 4.4c: The age distribution of lung cancer in the UK 2009-11 
Age Range Male Cases Female Cases Male Rates Female Rates 
0 to 04 1 1 0 0.1 
05 to 09 0 0 0 0 
10 to 14 0 1 0 0 
15 to 19 4 5 0.2 0.3 
20 to 24 6 7 0.3 0.3 
25 to 29 13 11 0.6 0.5 
30 to 34 23 20 1.1 1 
35 to 39 58 48 2.7 2.2 
40 to 44 157 140 6.8 6 
45 to 49 353 368 15.6 15.9 
50 to 54 751 722 37.8 35.7 
55 to 59 1,553 1,294 87.3 70.8 
60 to 64 2,737 2,253 148.2 117.5 
65 to 69 3,596 2,774 251.5 182.1 
70 to 74 4,271 3,100 369.4 239.3 
75 to 79 4,146 3,118 463.5 282.2 
80 to 84 3,411 2,838 565.2 323.3 
85+ 2,563 2,570 582.3 274.6 
All Ages 23,642 19,271 76.8 60.3 
Source, Cancer Research UK (20) 
To use the stage profile of Lung cancer incidence, the age profile of non small cell lung cancer 
incidence in the model amd the age profile of lung cancer incidence it was necessary to assume that 
these rates are independent. This means that the stage distribution of cancers will not change with 
patient’s age, however the proportion of lung cancer cases that are non small cell lung cancer will 
change with a patient’s age.  
 
4.5  Ovarian cancer 
The data on ovarian cancer incidence was obtained from multiple sources, as no source had the 
incidence by stage at diagnosis for different age groups. The stage distribution of ovarian cancer was 
obtained from Maringe  et al.(21) and the age distribution of ovarian cancer was obtained from a 
report by the Trent cancer registry (22).  
4.5.1 Stage distribution 
Maringe et al. (21)  present the stage distribution of ovarian cancer incidence in the UK for cancers 
diagnosed from 2004-07. This data is calculated from the same dataset that was used to estimate 
the one year net survival. It should be noted that cancer sites with a missing stage are 
underreported in Table 4.5a, as all cancer registries in the UK with over 50% missing stage 
information (Wales and four English regional registries) were excluded from the analyses. 
 
 Table 4.5a: The stage distribution of ovarian cancer incidence in the UK from 2004-07.  
FIGO Stage Number Percentage of cases 
All patients 11909  
Stage I 2681 22.5% 
Stage II 478 4.0% 
Stage III 3127 26.3% 
Stage IV 1842 15.5% 
Missing stage 3781 31.7% 
Source, Maringe et al.(21) 
 
4.5.2 Age distribution 
Data on the age profile of ovarian cancer incidence was obtained from a 2012 Trent cancer registry 
report on the incidence, survival and mortality from ovarian cancer in England (22).  Table 4.5b 
shows that the age specific incidence rate is increasing in age for women, the incidence rate after 
age 75 is broadly similar for all age groups.   
Table 4.5b: The age distribution of ovarian cancer in England in 2009.  
Age Band Total Cases Rate * 
15-19 26 1.6 
20-24 64 3.7 
25-29 89 5.2 
30-34 95 5.9 
35-39 161 8.8 
40-44 255 12.9 
45-49 332 17.6 
50-54 441 27.1 
55-59 560 36.9 
60-64 767 48.3 
65-69 709 58.2 
70-74 732 68.2 
75-79 609 66.2 
80-84 462 63.1 
85+ 547 69.5 
Source, Trent cancer registry  (22); 
* Rate is the age specific incidence rate per 100,000 
female population 
To use the stage profile of ovarian cancer incidence and the age profile of ovarian cancer incidence 
in the model it was necessary to assume that age and stage specific incidence rates are independent. 
This means that the stage distribution of cancers does not change with patient’s age.  
  
 5 Appendix: Cancer Survival Data summary 
 
5.1 Bladder cancer 
The NCC-C draft clinical guidelines  were used as the source of survival data in the model (9). The 
NCC-C draft clinical guidelines for the diagnosis and management of bladder cancer use relative 
survival statistics to show the effect of stage of diagnosis on the probability that a patient will be 
alive after one or five years. The NCC-C draft clinical guidelines for the treatment and diagnosis of 
bladder cancer (9) present the one and five year relative survival of bladder cancer patients in 
England and Wales separately. To estimate these survival figures, data was collected from the 
National Cancer Registration Service (NCRS) in England and the Welsh Cancer Intelligence and 
Surveillance Unit (WCISU). Data from Wales is not presented, as it will not be used in the model due 
to the lower sample size of the Welsh population.  The one year and five year relative survival of all 
bladder cancer patients in England is shown Table 5.1.  
Table 5.1: The one year and five year relative survival of bladder cancer patients in England 
TNM 
Stage 
One year relative survival,  
(95% confidence interval) 
Five year relative survival,  
(95% confidence interval) 
 Men Women Men Women 
Stage I 95.3%, 
(93.8%, 96.4%) 
90.9%, 
(87.5%, 93.5%) 
78.5%, 
(72.7%, 83.3%) 
76.2%, 
(65.1%, 84.2%) 
Stage II 72.6%, 
(70.0%, 74.9%) 
58.3%, 
(53.8%, 62.5%) 
39.6%, 
(34.4%, 44.7%) 
36.8%, 
(30.9%, 42.8%) 
Stage III 63.8%, 
(57.8%, 69.2%) 
55.5%, 
(47.0%, 63.3%) 
29.4%, 
(19.9%, 39.5%) 
33.8%, 
(22.6%, 45.3%) 
Stage IV 42.2%, 
(39.6%, 44.8%) 
34.4%, 
(30.6%, 38.3%) 
11.4%, 
(7.5%, 16.2%) 
12.4%, 
(8.9%, 16.6%) 
Unknown 78.8% 
(78.1%, 79.4%) 
65.2%, 
(64.1%, 66.3%) 
61.1%, 
(59.7%, 62.5%) 
48.1%, 
(45.9%, 50.3%) 
Source; National Collaborating Centre for Cancer (9) 
The NCC-C draft clinical guidelines present the relative survival of bladder cancer by age and the 
relative survival of bladder cancer by stage separately. This data does not include a breakdown of 
the relative survival of patients across age groups and stage at diagnosis groups. This data will not be 
used in the model, as it would be necessary to make the following assumptions: 
1. Which age group was the baseline for shifting the stage distribution.  
2. Independence of stage and age effects.  
Also the results of combining the stage and age data would have to be consistent with the 
information presented in Table X.  
5.2 Breast cancer 
As part of the ICBP, Walters et al. (10) published estimates of the one and three year net-survival of 
breast cancer patients in the UK from 2000-07. Data for the UK covered England, Wales and 
Northern Ireland, but not Scotland (10). In the study all cancer registries with less than 50% of 
patients with a valid stage were excluded from the analyses. This lead to the exclusion of three out 
of the eight English cancer registries for the TNM stage analysis.  Walters et al. (10) also present the 
survival of breast cancer by SEER summary stage. The SEER summary stage could only be calculated 
if there are records for each patient’s T, N and M separate from the overall stage. The English cancer 
registries did not collect this data. Therefore, the net survival estimates using the SEER summary 
stages are based upon Northern Irish and Welsh data only.  Table 5.2a shows that patients who are 
diagnosed at an earlier stage have higher survival. For patients who are diagnosed at Stage I or II, 
age appears to have little impact on net survival. However for Stages III and IV, patients who are 
diagnosed at a younger age have higher survival. 
 
Table 5.2a: Survival of breast cancer patients in the UK from 2000-07 
TNM Stage One year net survival, (95% confidence interval) 
  Age Standardised 15-49 50-69 70-99 
All patients 94.3%,  
(94.2%, 94.4% ) 
98%, 
(97.8%, 96.1% ) 
96.9%,  
(96.8%, 97% ) 
87.9%,  
(87.6%, 88.2% ) 
Stage I 100%,  
(100%, 100% ) 
100%, 
(99.9%, 100% ) 
100%,  
(100%, 100% ) 
100%,  
(100%, 100% ) 
Stage II 99.2%,  
(99.2%, 99.3% ) 
99.2%, 
(99.1%, 99.3% ) 
99.3%,  
(99.2%, 99.4% ) 
99.1%,  
(99.0%, 99.3% ) 
Stage III 90.9%,  
(90.5%, 91.4% ) 
95.5%,  
(94.8%, 96.2% ) 
93.9%,  
(93.3%, 94.5% ) 
84.2%,  
(82.9%, 85.4% ) 
Stage IV 53%,  
(52%, 54% ) 
68.3%,  
(65.5%, 71.1% ) 
60%,  
(58.2%, 61.9% ) 
42.2%,  
(40.3%, 44.1% ) 
Missing Stage 87.3%,  
(87.1%, 87.6% ) 
96.4%,  
(96%, 96.7% ) 
93.2%, 
 (92.9%, 93.6% ) 
79.9%,  
(79.2%, 80.5% ) 
 Three year net survival, (95% confidence interval) 
All patients 87.4%,  
(87.3%, 87.6% ) 
91.1%,  
(90.8%, 91.4% ) 
91.6%,  
(91.4%, 91.8% ) 
78.6%,  
(78.1%, 79.1% ) 
Stage I 99.3%,  
(99.2%, 99.4% ) 
98.5%,  
(98.2%, 98.8% ) 
99.4%,  
(99.2%, 99.5% ) 
99.7%,  
(99.6%, 99.9% ) 
Stage II 92.4%,  
(92.2%, 92.7% ) 
92.4%,  
(92%, 92.9% ) 
93.1%,  
(92.8%, 93.5% ) 
91.2%,  
(90.4%, 92.1% ) 
Stage III 70.7%,  
(69.9%, 71.5% ) 
76.5%, 
 (74.8%, 78.1% ) 
74.6%,  
(73.3%, 76% ) 
61.9%,  
(59.9%, 63.9% ) 
Stage IV 27.9%, 
 (26.9%, 28.9% ) 
36.2%,  
(33.1%, 39.4% ) 
33.1%,  
(31.2%, 35% ) 
20.8%,  
(19.0%, 22.6% ) 
Missing Stage 77.1%,  
(76.7%, 77.5% ) 
88%,  
(87.2%, 88.7% ) 
85.7%,  
(85.2%, 86.3% ) 
66.9%,  
(66.0%, 67.9% ) 
Source; Walters et al.(10) 
Five year relative survival information was obtained from the Cancer Research UK website, this 
information is presented in Table X below. This information includes all women diagnosed with 
breast cancer in 2002-06 in the Former Anglia cancer network. 
Table 5.2b: The five year relative survival  of female breast cancer patients in the former Anglia 
cancer network in 2002-06 
Stage Relative survival 
Stage I 99.1% 
Stage II 87.6% 
Stage III 55.1% 
Stage IV 14.7% 
All Stages 85.8% 
Stage Not Known 63.7% 
Source, Cancer Research UK (20) 
 
5.3 Colorectal cancer 
The one year and three-year net-survival of colorectal cancer patients in the UK from 2000-07 was 
reported in Maringe et al.(13). In the study all cancer registries with less than 50% of patients with a 
valid stage were excluded from the analyses. In the colon cancer analysis the Welsh registry was 
excluded and in the rectal cancer analysis one English registry and the Welsh registry were excluded. 
Tables 5.3a and 5.3b show that patients who are diagnosed at an earlier stage or a younger age, 
have higher survival. Tables 5.3a and 5.3b also show that patients diagnosed with colon cancer tend 
to have a worse prognosis than a patient diagnosed with rectal cancer.  
  
Table 5.3a: The one year net survival of colorectal cancer patients in the UK from 2000-07 in 
different stage at diagnosis and age groups 
Duke’s stage One year net survival,  
(95% Confidence Interval) 
 Age standardised 15-49  50-69 70-99 
  Colon cancer 
All patients 67.4%, (67.2%, 67.6%) 80.6%, (79.9%, 81.4%) 76.5%, (76.1%, 76.8%) 61.6% (61.3%, 61.9%) 
Stage A 95.7%, (95.3%, 96.2%) 98.8%, (98%, 99.6%) 97.8%, (97.3%, 98.3%) 94.4% (93.5%, 95.2%) 
Stage B 90.1%, (89.8%, 90.4%) 96.8%, (96.2%, 97.4%) 94.4%, (94%, 94.7%) 87.6% (87.1%, 88%) 
Stage C 76.8%, (76.4%, 77.1%) 87.2%, (86%, 88.3%) 83.6%, (83.1%, 84.1%) 71.4% (70.8%, 72%) 
Stage D 34.2%, (33.7%, 34.7%) 50.8%, (48.4%, 53.2%) 43.6%, (42.6%, 44.7%) 26% (25.2%, 26.8%) 
Missing 
Stage 
42.9%, (42.6%, 43.3%) 72.4%, (70.6%, 74.1%) 58.9%, (58.1%, 59.7%) 35.3% (34.7%, 35.8%) 
Rectal Cancer 
All patients 75.2%, (75%, 75.5%) 86%, (85.2%, 86.9%) 83.2%, 
 (82.8%, 83.6%) 
67.7%, (67.2%, 68.2%) 
Stage A 95.7%, (95.4%, 96%) 99.2%, (98.9%, 99.4%) 97.5%, (97.1%, 97.9%) 93.8%, (93%, 94.6%) 
Stage B 91.5%, (91.1%, 91.8%) 98.1%, (97.8%, 98.5%) 95%, (94.5%, 95.4%) 88.2%, (87.4%, 89%) 
Stage C 87.4%, (87%, 87.8%) 94.5%, (93.4%, 95.5%) 92.1%, (91.6%, 92.6%) 81.7%, (80.8%, 82.6%) 
Stage D 43.2%, (42.5%, 43.8%) 57.9%, (55.2%, 60.7%) 52.5%, (51.2%, 53.8%) 31.7%, (30.4%, 32.9%) 
Missing 
Stage 
59.4%, (58.9%, 59.9%) 79.4%, (77.3%, 81.4%) 70.1%, (69.2%, 71.1%) 49%, (48.1%, 49.8%) 
Source; Maringe et al. (13) 
 
  
Table 5.3b: The three year net survival of colorectal cancer patients in the UK from 2000-07 in 
different stage at diagnosis and age groups 
Dukes’ stage Three year net survival, 
(95% Confidence Interval) 
 Age standardised 15-49  50-69 70-99 
Colon cancer 
All patients 54.9%,  
(54.7%, 55.1%) 
65.1%,  
(64.1%, 66.1%) 
62%,  
(61.6%, 62.5%) 
50.4%,  
(50.0%, 50.7%) 
Stage A 94.9%,  
(94.2%, 95.5%) 
96.7%,  
(95.1%, 98.3%) 
95.9%,  
(95.1%, 96.7%) 
94.2%,  
(92.9%, 95.4%) 
Stage B 84.8%,  
(84.4%, 85.2%) 
90.1%,  
(88.9%, 91.4%) 
88.1%,  
(87.5%, 88.6%) 
82.8%,  
(82.1%, 83.5%) 
Stage C 58.1%,  
(57.7%, 58.6%) 
65.8%,  
(63.9%, 67.7%) 
64.4%,  
(63.6%, 65.2%) 
53.4%,  
(52.6%, 54.2%) 
Stage D 11.6%,  
(11.3%, 12%) 
18.3%,  
(16.3%, 20.3%) 
16.0%,  
(15.1%, 16.8%) 
8.0%,  
(7.4%, 8.5%) 
Missing Stage 31.2%,  
(30.8%, 31.6%) 
58.2%,  
(56.2%, 60.2%) 
44.8%,  
(43.9%, 45.7%) 
24.6%  
(24.0%, 25.1%) 
Rectal Cancer 
All patients 59.9%, 
(59.5%, 60.2%) 
69.7%, 
 (68.3%, 71%) 
67.8%,  
(67.2%, 68.3%) 
52.5%,  
(51.9%, 53.1%) 
Stage A 94%,  
(93.5%, 94.5%) 
97.7%, 
 (97%, 98.3%) 
95.6%,  
(95%, 96.2%) 
92.3%,  
(91.1%, 93.5%) 
Stage B 84.1%,  
(83.6%, 84.6%) 
91.9%, 
 (90.9%, 93%) 
87.2%,  
(86.4%, 88%) 
81%,  
(79.8%, 82.2%) 
Stage C 67.5%,  
(66.8%, 68.2%) 
75.8%, 
 (73.4%, 78.2%) 
72.7%,  
(71.6%, 73.7%) 
61.1%,  
(59.8%, 62.5%) 
Stage D 14.4%,  
(13.9%, 15%) 
20.3%, 
 (17.9%, 22.7%) 
18.9%,  
(17.8%, 20.1%) 
9.1%,  
(8.3%, 10.0%) 
Missing Stage 40.7%,  
(40.1%, 41.2%) 
63.2%, 
 (60.6%, 65.8%) 
52.4%,  
(51.3%, 53.6%) 
29.1%,  
(28.2%, 30.0%) 
Source; Maringe et al.(13) In tables III and IV of the supplementary material 
 
 
5.4  Lung cancer  
The one year net-survival of lung cancer patients in the UK from 2004-07 was reported in Walters et 
al.(16). In the study all cancer registries with less than 50% of patients with a valid stage were 
excluded from the analyses, this lead to the exclusion six English cancer registries and the Welsh 
cancer registry. Table 5.4a shows that patients who are diagnosed at an earlier stage have a better 
chance of survival than someone who is diagnosed at a later stage and that a patient who is 
diagnosed at a younger age have a better chance of survival than someone who is diagnosed at an 
older age. 
Table 5.4a: The one year net survival of lung cancer patients in the UK from 2004-07 in different 
stage at diagnosis and age groups. 
TNM Stage One year net survival, 
(95% confidence interval) 
 Age 
standardised 
15-54 55-74 75-99 
Non small cell lung cancer 
All patients 29.6% 
(29.1%,30% ) 
41.5% 
(39.6%,43.5% ) 
32.5% 
(31.7%,33.2% ) 
22.6% 
(21.8%,23.3% ) 
Stage I 72.5% 
(71.4%,73.6% ) 
90.0% 
(88%,92% ) 
77.5% 
(75.6%,79.3% ) 
60.9% 
(58.2%,63.6% ) 
Stage II 59.8% 
(57.9%,61.7% ) 
79.9% 
(74.5%,85.2% ) 
65.3% 
(62.1%,68.5% ) 
45.5% 
(41.6%,49.4% ) 
Stage III 35.3% 
(34.3%,36.3% ) 
44.4% 
(40.2%,48.6% ) 
39.6% 
(37.9%,41.4% ) 
26.3% 
(24.6%,28.1% ) 
Stage IV 15.9% 
(15.3%,16.4% ) 
24.5% 
(22%,27.1% ) 
17.1% 
(16.1%,18% ) 
10.9% 
(9.9%,11.8% ) 
Missing Stage 20.6% 
(19.9%,21.2% ) 
42.1% 
(38%,46.1% ) 
23.7% 
(22.4%,25% ) 
16.0% 
(14.9%,17% ) 
Small cell lung cancer 
All patients 24.9%, 
( 23.7%,26.1% ) 
33.2%, 
( 33.9%,40.7% ) 
27.9%, 
( 26.2%,29.6% ) 
14.4%, 
( 12.5%,16.2% ) 
Stage I and 
II* 
55.9%*, 
( 49.6%,62.2% ) 
82.2%*, 
( 70.5%,93.8% ) 
57.3%*, 
( 48.7%,65.9% ) 
44.9%*, 
( 32.4%,57.5% ) 
Stage III 37.3%, 
( 33.9%,40.7% ) 
50.8%, 
( 40.5%,61% ) 
42.2%, 
( 37.3%,47.1% ) 
18.8%, 
( 13.1%,24.5% ) 
Stage IV 14.4%, 
( 13.1%,15.8% ) 
19.9%, 
( 15.8%,24% ) 
14.7%, 
( 12.9%,16.5% ) 
11.1%, 
( 8.7%,13.6% ) 
Missing Stage 24.2%, 
( 22.4%,26.1% ) 
38.2%, 
( 30.8%,45.6% ) 
28.0%, 
( 25.3%,30.8% ) 
13.7%, 
( 11%,16.4% ) 
Source, Walters et al. (16); 
* due to small patient numbers stage I and II small cell lung cancer were grouped in the survival 
analyses 
The clinical advisors believed that the survival figures present in Walters et al. (16) were likely to be 
lower than current survival of lung cancer patients in the UK. These figures will be used in the model 
as they are likely to be unfavorable to an early cancer detection strategy.  
 
5.5 Ovarian cancer 
The one year net-survival of ovarian cancer patients in the UK from 2004-07 was reported in 
Maringe et al. (21). In the study all cancer registries with less than 50% of patients with a valid stage 
were excluded from the analyses, this lead to the exclusion four English cancer registries and the 
Welsh cancer registry. Table 5.5a shows that patients who are diagnosed at an earlier stage has a 
better chance of survival than someone who is diagnosed at a later stage and that a patient who is 
diagnosed at a younger age has a better chance of survival than someone who is diagnosed at an 
older age. 
 
Table 5.5a: The one year net survival of ovarian cancer patients in the UK from 2004-07 in different 
stage at diagnosis and age groups. 
FIGO Stage One year net survival, 
(95% Confidence Interval) 
 Age standardised 15-49 year olds 50-69 year olds 70-99 year olds 
All patients 68.7%, 
( 68.3%, 69.1% ) 
92.8%, 
( 92.3%, 93.2% ) 
78.0%, 
( 77.3%, 78.7% ) 
48.3%, 
( 47.1%, 49.5% ) 
Stage I 97.2%, 
( 96.9%, 97.6% ) 
98.9%, 
( 98.4%, 99.3% ) 
97.4%, 
( 96.8%, 98% ) 
94.6%, 
( 92.9%, 96.4% ) 
Stage II 89.9%, 
( 88.5%, 91.3% ) 
95.9%, 
( 94%, 97.8% ) 
91.5%, 
( 89.1%, 93.9% ) 
83.7%, 
( 78.8%, 88.6% ) 
Stage III 70.3%, 
( 69.2%, 71.4% ) 
84.1%, 
( 81.1%, 87.0% ) 
76.4%, 
( 74.6%, 78.2% ) 
57.1%, 
( 54.5%, 59.6% ) 
Stage IV 52.6%, 
( 51.1%, 54.1% ) 
71.5%, 
( 65.9%, 77.1% ) 
66.3%, 
( 63.6%, 69.1% ) 
35.7%, 
( 32.8%, 69.1% ) 
Missing stage 51.0%, 
( 50.0%, 52.0% ) 
88.2%, 
( 86.0%, 90.4% ) 
67.9%, 
( 65.9%, 70% ) 
31.2%, 
( 29.3%, 33.1% ) 
Source, Maringe et al. (21) 
Five year relative survival information was obtained from the Cancer Research UK website, this 
information is presented in Table 5.5b below. This information includes all women diagnosed with 
breast cancer in 2002-06 in the Former Anglia cancer network. 
  
Table 5.5b: The five year relative survival  of ovarian cancer patients in the former Anglia cancer 
network in 2002-06 
Stage Relative survival 
Stage I 90% 
Stage II 42.8% 
Stage III 18.6% 
Stage IV 3.5% 
All Stages 39.3% 
Stage Not Known 12.5% 
Source, Cancer Research UK (20) 
 
  
6 Appendix: Fitted survival curves  
Cancer Research UK and Brenner et al. were searched for information on wether the fraction of 
cancer survivors (in the last year in which there was survival information) who had non-terminal 
cancer would vary by stage for each cancer type(20;23). There was no information to indicate that 
the fraction of cancer survivors who had non-terminal cancer patients varied by stage for any of the 
cancer types. Therefore in each cancer type, the fraction of cancer survivors who had non-terminal 
cancer was assumed to be constant. The solver function in Microsfot Excel® was used to calculate 
the fraction of patients who have non-terminal cancer by matching the modelled mortality (in a 
2012 population) to the observed mortality in 2012 (adjusted for the modelled incidence rates). 
Exponential curves were fitted to the proportion of patients who were assumed to have a terminal 
cancer using the last in which there was stage specific survival. 
6.1  Bladder cancer 
For bladder cancer one year and five year relative survival information was available by stage at 
diagnosis. When the curves were fitted to the five year survival data, the modelled moratlity was 
higher than the observed mortality even when 100% of patients who survived until five years were 
assumed to have non-terminal cancer. This is likely due to the fact that the survival data was based 
on a 2006-10 cohort of English patients. The difference between modelled and expected mortality 
could be due to improvements in the survival of bladder cancer patients between 2006 and 2012. 
Therefore, a fractional survival model was fitted using the one year survival information. The 
parameters used in the survival model are given in Table 6.1a and the fitted survival curves are 
shown in Figure 6.1a.  
Table 6.1a: The parameters used in the fractional survival model for bladder cancer  
 Stage 
 
1 year 
survival 
 
Fraction of 1 year survivors, 
who have a non-terminal 
cancer 
 
Total proportion of patients who 
have a non-terminal cancer 
(γ) 
Lambda 
(λ)  
Stage 1 94.0% 69.9% 63.9% 0.18  
Stage 2 68.5% 69.9% 46.5% 0.89  
Stage 3 61.5% 69.9% 41.7% 1.08  
Stage 4 40.0% 69.9% 27.1% 1.74  
 
 
  
Figure 6.1a: The fitted survival curve for bladder cancer by stage at diagnosis 
 
 
6.2  Breast cancer 
Five year stage specific relative survival information was available for breast cancer so the fractional 
survival model was fitted using this data. The parameters used in the survival model are given in 
Table 6.2a and the fitted survival curves are shown in Figure 6.2a.  
Table 6.2a: The parameters used in the fractional survival model for breast cancer 
 Stage 
 
5 year survival 
 
Fraction of 5 year survivors, 
who have a non-terminal 
cancer 
 
Total proportion of patients 
who have a non-terminal 
cancer 
(γ) 
Lambda 
(λ)  
Stage 1 99.1% 75.1% 74.41% 0.01  
Stage 2 87.6% 75.1% 65.8% 0.09  
Stage 3 55.1% 75.1% 41.4% 0.29  
Stage 4 14.7% 75.1% 11.0% 0.64  
 
Figure 6.2a: The fitted survival curve for breast cancer by stage at diagnosis 
  
 
6.3  Colorectal cancer 
Short term survival was presented separately for colon and rectal cancer. As there were differences 
in the relative survival of patients with colon and rectal cancer up until year three, survival curves 
were fitted to each cancer type. To enable the use of the curves in the model, an incidence weighted 
average of colon and rectal cancer was applied to combine the survival curves in the model. No data 
was available on the stage specific survival of colon or rectal cancer patients after three years. The 
fractional survival model was fitted to the three year relative survival information for clon and rectal 
cancer separately.The parameters used in the survival model are given in Tables 6.3a and 6.3b and 
the fitted survival curves are shown in Figures 6.3a and 6.3b.  
Table 6.3a The parameters used in the fractional survival model for colon cancer 
 Stage 
 
3 year survival 
 
Fraction of 3 year survivors, 
who have a non-terminal 
cancer 
 
Total proportion of patients 
who have a non-terminal 
cancer 
(γ) 
Lambda 
(λ)  
Stage A 94.9% 87.1% 82.7% 0.12 
Stage B 84.8% 87.1% 73.9% 0.29  
Stage C 58.1% 87.1% 50.6% 0.63  
Stage D 11.6% 87.1% 10.1% 1.37  
 
  
Table 6.3b: The parameters used in the fractional survival model for rectal cancer 
 Stage 
 
3 year survival 
 
Fraction of 3 year survivors, 
who have a non-terminal 
cancer 
 
Total proportion of patients 
who have a non-terminal 
cancer 
(γ) 
Lambda 
(λ)  
Stage A 94.0% 87.1% 81.9% 0.13  
Stage B 84.1% 87.1% 73.3% 0.30  
Stage C 67.5% 87.1% 58.8% 0.52  
Stage D 14.4% 87.1% 12.5% 1.29  
 
Figure 6.3a: The fitted survival curve for colon cancer by stage at diagnosis 
 
 
Figure 6.3b: The fitted survival curve for rectal cancer by stage at diagnosis 
 
 
6.4  Lung cancer 
Short term survival was presented separately for non-small cell and small cell lung cancer. As there 
were differences in the one year relative survival of patients with non-small cell and small cell lung, 
survival curves were fitted to each cancer type. The incidence of non-small cell and small cell lung 
cancer was modelled separately, so there was no need to combine the survival curves. No data was 
available on the stage specific survival of non small cell lung cancer or small cell lung cancer patients 
after one year years. The fractional survival model was fitted to the one year relative survival 
information for non-small cell and small cell lung cancer separately.The parameters used in the 
survival model are given in Tables 6.4a and 6.4b and the fitted survival curves are shown in Figures 
6.4a and 6.4b.  
Table 6.4a: The parameters used in the fractional survival model for for non small cell lung cancer 
 Stage 
 
1 year 
survival 
 
Fraction of 1 year survivors, 
who have a non-terminal cancer 
 
Total proportion of patients who 
have a non-terminal cancer 
(γ) 
Lambda 
(λ)  
Stage 1 72.5% 32%  23%  0.44  
Stage 2 59.8% 32%  19%  0.69  
Stage 3 35.3% 32%  11%  1.31  
Stage 4 15.9% 32%  5%  2.17  
 
Table 6.4b: The parameters used in the fractional survival model for small cell lung cancer 
 Stage 
 
1 year survival 
 
Fraction of 1 year 
survivors, who have a non-
terminal cancer 
 
Total proportion of patients 
who have a non-terminal 
cancer 
(γ) 
Lambda 
(λ)  
Stage 1 and 2 56% 32%  18%  0.77  
Stage 3 37% 32%  12%  1.24  
Stage 4 14% 32%  5%  2.27  
 
  
Figure 6.4a: The fitted survival curve for non-small cell lung cancer 
 
Figure 6.4b: The fitted survival curve for small cell lung cancer 
 
 
 
6.5  Ovarian cancer 
Five year stage specific relative survival information was available for ovarian cancer so the 
fractional survival model was fitted using this data. The parameters used in the survival model are 
given in Table 6.5a and the fitted survival curves are shown in Figure 6.5a.  
 
  
Table 6.5a: The parameters used in the fractional survival model for ovarian cancer 
 Stage 
 
5 year survival 
 
Fraction of 5 year survivors, 
who have a non-terminal 
cancer 
 
Total proportion of patients 
who have a non-terminal 
cancer 
(γ) 
Lambda 
(λ)  
Stage 1 90% 91%  82% 0.16  
Stage 2 43% 91% 39% 0.55  
Stage 3 19% 91% 17% 0.78  
Stage 4 4% 91% 3% 1.14  
 
 
Figure 6.5a: The fitted survival curve for ovarian cancer 
 
  
7 The National Screening Committee’s criteria for a new screening 
programme in the UK 
All 21 criteria used by the national screening committee when considering whetheror not to 
implement a new screening programme are listed below (23):  
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition, including development from latent to 
declared disease, should be adequately understood and there should be a detectable risk factor, 
disease marker, latent period or early symptomatic stage. 
3. All the cost-effective primary prevention interventions should have been implemented as far as 
practicable. 
4. If the carriers of a mutation are identified as a result of screening the natural history of people 
with this status should be understood, including the psychological implications. 
5. There should be a simple, safe, precise and validated screening test. 
6. The distribution of test values in the target population should be known and a suitable cut-off 
level defined and agreed. 
7. The test should be acceptable to the population. 
8. There should be an agreed policy on the further diagnostic investigation of individuals with a 
positive test result and on the choices available to those individuals. 
9. If the test is for mutations the criteria used to select the subset of mutations to be covered by 
screening, if all possible mutations are not being tested, should be clearly set out. 
10. There should be an effective treatment or intervention for patients identified through early 
detection, with evidence of early treatment leading to better outcomes than late treatment. 
11. There should be agreed evidence based policies covering which individuals should be offered 
treatment and the appropriate treatment to be offered. 
12. Clinical management of the condition and patient outcomes should be optimised in all health 
care providers prior to participation in a screening programme. 
13. There should be evidence from high quality Randomised Controlled Trials that the screening 
programme is effective in reducing mortality or morbidity. Where screening is aimed solely at 
providing information to allow the person being screened to make an “informed choice” (eg. Down’s 
syndrome, cystic fibrosis carrier screening), there must be evidence from high quality trials that the 
test accurately measures risk. The information that is provided about the test and its outcome must 
be of value and readily understood by the individual being screened. 
14. There should be evidence that the complete screening programme (test, diagnostic procedures, 
treatment/ intervention) is clinically, socially and ethically acceptable to health professionals and the 
public. 
15. The benefit from the screening programme should outweigh the physical and psychological harm 
(caused by the test, diagnostic procedures and treatment). 
16. The opportunity cost of the screening programme (including testing, diagnosis and treatment, 
administration, training and quality assurance) should be economically balanced in relation to 
expenditure on medical care as a whole (ie. value for money). Assessment against this criteria should 
have regard to evidence from cost benefit and/or cost effectiveness analyses and have regard to the 
effective use of available resource. 
17. All other options for managing the condition should have been considered (eg. improving 
treatment, providing other services), to ensure that no more cost effective intervention could be 
introduced or current interventions increased within the resources available. 
18. There should be a plan for managing and monitoring the screening programme and an agreed 
set of quality assurance standards. 
19. Adequate staffing and facilities for testing, diagnosis, treatment and programme management 
should be available prior to the commencement of the screening 
20. Evidence-based information, explaining the consequences of testing, investigation and 
treatment, should be made available to potential participants to assist them in making an informed 
choice. 
21. Public pressure for widening the eligibility criteria for reducing the screening interval, and for 
increasing the sensitivity of the testing process, should be anticipated. Decisions about these 
parameters should be scientifically justifiable to the public. 
22. If screening is for a mutation the programme should be acceptable to people identified as 
carriers and to other family members.  
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